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1 Abbreviations 
aCGH  array-based comparative genomic Hybridization 
ALT   alanine transaminase  
ALPPS associating liver partition and portal vein ligation for staged hepatectomy 
AOM  azoxymethane 
APC  Adenomatous Polyposis Coli 
AST   aspartate transaminase 
ATM  ataxia telangiectasia mutated 
ATR  ataxia telangiectasia and Rad3 related  
BHA  butylated hydroxyanisole 
BCL2-A1 Bcl-2-related protein A1 
BSA   bovine serum albumin  
cDNA   copy DNA  
Casp8  caspase 8 
CD  Crohn`s disease 
cl.Casp3 cleaved caspase 3 
DAMPs damage-associated molecular patterns 
DDR  DNA damage response 
dpi   days post injection  
DNA   deoxyribonucleic acid  
DNA-PK DNA-dependent protein kinase 
DSS  dextran sulfate sodium 
DX  doxorubicin 
FCS   fetal calf serum 
FFPE  formalin-fixed, paraffin-embedded 
FITC  fluorescein isothiocyanate 
gDNA  genomic DNA 
GPNMB glycoprotein nmb-like protein (“osteoactivin”) 
HBV   hepatitis B virus  
HCC   hepatocellular carcinoma  
HCV   hepatitis C virus  
H/E   Hematoxylin/Eosin staining  
HRP   horse-radish peroxidase  
IBD  inflammatory bowel disease 
IECs  intestinal epithelial cells 
IKKβ   inhibitor of nuclear factor kappa-B kinase subunit beta 
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IL   interleukin  
ILC  innate lymphoid cell 
i.p.   intraperitoneal  
JNK   c-Jun N-terminal kinase  
kDa   kilo Dalton  
LPS   lipopolysaccharide  
LTα  lymphotoxin alpha  
LTβ  lymphotoxin beta  
MAPK   mitogen-activated protein kinase  
Mcl-1  myeloid cell leukemia 1 
MDa  mega Dalton 
mdr2   multidrug resistance gene 2  
min   minute  
mRNA   messenger ribonucleic acid  
NFκB    nuclear factor kappa B  
NVH   non-viral hepatitis  
PHX  partial hepatectomy 
PBS   phosphate-buffered saline  
PBST   phosphate-buffered saline (with) Tween-20  
PCR   polymerase chain reaction  
PFGE  pulse field gel electrophoresis 
PLK1  polo-like kinase 1 
qPCR   quantitative PCR (real-time PCR)  
Rag1   recombination activating gene 1  
RIPK1  receptor-interacting serine/threonine-protein kinase 1 
RIPK3  receptor-interacting serine/threonine-protein kinase 3 
RNA   ribonucleic acid  
ROS   reactive oxygen species  
TAK1   TGFβ activated kinase  
TGFβ   transforming growth factor beta 
TINAG  tubulointerstitial nephritis antigen 
TLR   toll-like receptor  
TNFα   tumor necrosis factor alpha  
TNFR   tumor necrosis factor receptor  
UC  ulcerative colitis 
WNT   Wnt family int1  
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2 Summary 
Cancer is the second leading cause of death worldwide, accounting for 8.2 million deaths 
and an estimated 14 million newly diagnosed cases in 2012 [1]. The most common causes of 
death due to cancers are carcinoma of the lung (1.45 million/year), liver (0.75 million/year), 
stomach (0.72 million/year) and colon (0.69 million/year). The most important risk factor for 
cancer development is age and the most modifiable risk factors besides tobacco 
consumption are chronic infections and unhealthy life style. Patients with chronic diseases of 
the digestive system such as persistent infections (e.g. hepatitis due to infections with 
hepatitis B or C virus; chronic gastritis due to Helicobacter pylori infection), inflammatory 
bowel diseases (IBD) or metabolic disease (alcoholic and non-alcoholic steatohepatitis) are 
at higher risk to develop carcinoma of the liver, stomach or intestinal tract, respectively. 
However, the exact molecular, genetic and cellular mechanisms driving carcinogenesis in 
these chronically diseased organs remain elusive.  
 
1.1 Constant hepatocyte apoptosis triggers proliferation-induced DNA damage and 
genetic instability in the liver and predisposes towards hepatocarcinogenesis  
In the first part of my thesis, I investigated the molecular and genetic mechanisms of 
tumorigenesis in chronic liver disease.  
Hepatocyte cell death is a hallmark of chronic liver disease (CLD), the background on which 
most hepatocellular carcinoma (HCC) develop [2]. In my doctoral thesis, I was able to show 
that constantly increased levels of hepatocyte apoptosis in human CLD as well as in several 
independent murine HCC models correlate with subsequent HCC development. Moreover, 
hyper-regenerative human and murine livers already revealed proliferation-associated DNA 
damage and genetic instability long prior the detection of dysplastic changes. Genetic 
reduction of elevated levels of hepatocyte apoptosis resulted in reduced levels of hepatocyte 
proliferation, DNA damage, genetic instability and significantly reduced HCC development in 
vivo. 
In addition, I uncovered an oncogenic gene expression pattern in regenerating mouse livers, 
which is highly overlapping and similar to expression patterns found in murine and human 
HCC. Expression of these genes significantly correlated with patient survival and thus these 
genes are of potential interest as biomarkers for liver malignancy and tumorigenesis. 
These findings suggest that - independent of the underlying etiology - the accumulated 
amount of apoptotic liver cell death not only correlates with, but is the decisive determinant of 
liver carcinogenesis.  
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1.2. A non-apoptotic function of Caspase 8 mediates DNA damage response via 
JNK1/2  
Most interestingly, when studying mechanisms of apoptosis-driven hepatocarcinogenesis, I 
uncovered a novel DNA damage response (DDR) pathway in hepatocytes. A (dynamic) 
signaling platform comprising a non-catalytic, scaffolding function of Caspase 8, a kinase-
dependent function of receptor interacting protein kinase 1 (RIPK1) and cFLIP controls the 
activity of c-Jun N-terminal kinase (JNK) and the JNK-dependent phosphorylation of the key 
component in DNA repair, histone variant H2AX (γH2AX), independent of TNFR1 signaling. 
Hepatocyte-specific deletion of Caspase 8 or cFLIP, or genetic or pharmacological inhibition 
of RIPK1 abolished DDR and decreased DDR in mice post partial hepatectomy and 
genotoxic challenge. 
 
2. Chronic intestinal tissue damage suffices to trigger hyper-proliferation, IBD-like 
inflammation and carcinogenesis 
In the second part of my thesis, I focused on intestinal regeneration and carcinogenesis. 
Based on the observation that constant hepatocyte cell death suffices to trigger 
hepatocarcinogenesis, I asked whether the concept of apoptosis-triggered tumorigenesis is 
also transferable to other regenerative organs, in particular the intestinal tract. Enterocyte-
specific knock-out of the anti-apoptotic protein Mcl-1 (Mcl-1∆IEC mice) led to disruption of the 
epithelial barrier, severe consecutive intestinal inflammation, and intestinal carcinogenesis, 
thus recapitulating central features of inflammatory bowel diseases (IBD) 
By germ-free housing and antibiotic treatment I was able to show that the inflammatory 
reaction was triggered by a leaky intestinal barrier and the influx of microbiota. Using RAG1-/- 
intercrossings and antibody treatments of Mcl-1∆IEC mice, I identified innate lymphoid cells 
(ILCs) - and not classical B- and T-lymphocytes - as the most important immune cell type 
responsible for intestinal inflammation upon intestinal barrier disruption. Furthermore, Mcl-
1∆IEC mice morphologically and genetically recapitulated the well-described adenoma-
carcinoma sequence and finally developed invasive carcinoma harboring chromosomal 
aberrations and mutations in well-described genes of human colorectal cancer. For the first 
time, I showed that constant enterocyte cell death suffices to drive intestinal carcinogenesis 
under genotoxic-free conditions.  
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3 Zusammenfassung 
Krebserkrankungen gelten heute als die zweithäufigste Todesursache und die Ursache für 
8,2 Millionen Todesfälle und geschätzte 14 Millionen Neuerkrankungen im Jahr 2012. Die 
meisten Todesfälle, die auf Krebserkrankungen zurückzuführen sind, resultieren aus 
Krebserkrankungen der Lunge (1,45 Millionen Todesfälle/Jahr), der Leber (0,75 
Millionen/Jahr), dem Magen (0,72 Millionen/Jahr) und dem Darm (0,69 Millionen/Jahr). Der 
Hauptrisikofaktor für eine Krebsentstehung ist das Alter, gefolgt von beeinflussbaren 
Risikofaktoren wie Tabakkonsum, ein ungesunder Lebensstil und chronische Infektionen.  
Patienten mit chronischen Erkrankungen des Verdauungstrakts wie zum Beispiel 
chronischen Infektionen (HBV/HCV-induzierte Hepatitis, Helicobacter pylori-induzierte 
chronische Gastritis), chronisch entzündlichen Darmerkrankungen oder chronischen 
metabolischen Erkrankungen (alkoholische oder nichtalkoholische Steatohepatitis) weisen 
ein erhöhtes Krebsrisiko für die Leber, den Magen oder den Intestinaltrakt auf. Die genauen 
molekularen, genetischen und zellulären Mechanismen, die zur Krebsentstehung in diesen 
chronisch erkrankten Organen führen, sind bisher wenig verstanden. 
 
1.1. Konstanter Hepatozyten-Zelltod führt zu proliferations-induziertem DNA Schaden, 
genetischer Instabilität und prädisponiert die Leber für eine Krebsentstehung 
In dem ersten Teil meiner Doktorarbeit habe ich die molekularen und genetischen 
Mechanismen der Krebsentstehung in chronisch erkrankten Lebern untersucht. 
Chronische Lebererkrankungen sind gekennzeichnet durch eine erhöhte Rate an induzierten 
Tod von Hepatozyten und bilden somit den Hintergrund, auf dem am häufigsten 
Hepatozellulären Karzinome (HCC) entstehen. In der vorliegenden Doktorarbeit konnte ich 
zeigen, dass eine konstant erhöhte Rate von induziertem Zelltod von Hepatozyten in 
humanen chronischen Lebererkrankungen und in verschiedenen unabhängigen 
Mausmodellen mit der Krebsentstehung korreliert. Hyper-regenerative humane und murine 
Lebern zeigten bereits lange Zeit vor dem Nachweis von dysplastischen Veränderungen eine 
proliferations-assoziierte DNA Schädigung und genetische Instabilität. Eine durch genetische 
Manipulation reduzierte Rate von Zelltod führte im Mausmodell ebenfalls zu reduzierter 
Hepatozytenproliferation, DNA Schädigung, genetischer Instabilität und signifikant weniger 
Lebertumoren. 
Zusätzlich habe ich ein Expressionsmuster von Onkogenen in regenerativen Mauslebern 
gefunden, das sehr ähnlich zu dem Expressionsprofil dieser Gene in humanen und murinen 
HCC ist. Die Expression dieser Onkogene korrelierte signifikant mit dem Überleben der 
Patienten, weshalb diese Gene möglicherweise als Biomarker für die Malignität der Leber 
oder die Lebertumorigenese von Interesse sind.  
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1.2. Eine nicht-apoptotische Funktion von Caspase 8 vermittelt eine DNA 
Schadensantwort durch die Aktivierung von JNK  
Interessanterweise habe ich bei der Analyse der Zelltod-gesteuerten Mechanismen der 
Hepatokarzinogenese einen neuen Signalweg der DNA Schadensantwort entdeckt. Eine 
dynamische Signalplatform, bestehend aus einer katalytischen inaktiven und bindenden 
Caspase 8, einer Kinase-abhängigen Funktion von Receptor interacting protein kinase 1 
(RIPK1) und cFLIP. Dieser Komplex kontrolliert unabhängig vom TNFR Signalweg die 
Aktivität der c-Jun N-terminal kinase (JNK) und die JNK-abhängige Phosphorylierung der 
Schlüsselkomponente für die DNA Reparatur, das Histon H2AX (γH2AX) – und ähnelt dem 
Ripoptosome Komplex. Die Inhibierung des neuen Signalwegs zum Beispiel durch die 
Deletion von Caspase 8 oder cFLIP, oder die genetische oder pharmakologische Inhibierung 
von RIPK1 in Hepatozyten vermindert die Antwort auf DNA Schädigung nach partieller 
Hepatektomie oder genotoxischer Behandlung. 
 
2. Chronischer intestinaler Gewebeschaden reicht aus um eine Hyper-Regeneration, 
chronische Entzündung und Karzinogenese auszulösen 
Basierend auf der Beobachtung der Leberkarzinogenese aufgrund einer konstant erhöhten 
Rate von induziertem Zelltod in Hepatozyten, habe ich die Frage gestellt, ob das Konzept der 
Zelltod-gesteuerten Karzinogenese auch auf andere regenerative Organe, insbesondere den 
Intestinaltrakt übertragbar ist. Der Enterozyten-spezifische Knock-out des anti-apoptotischen 
Proteins Mcl-1 (Mcl-1∆IEC Mäuse) zeigte wesentliche Aspekte von chronisch entzündlichen 
Darmerkrankungen mit einer Störung der intestinalen Barriere, gefolgt von schwerer 
intestinaler Entzündung und Karzinogenese. 
Ich konnte durch keimfreie Haltung oder die Behandlung von Mcl-1∆IEC Mäuse mit Antibiotika 
zeigen, dass die Entzündungsreaktion von der Störung der intestinalen Barriere und dem 
Einströmen der Mikrobiota abhängig war. Ich konnte durch eine RAG1-/- Rückkreuzung und 
Antikörper Behandlungen zeigen, dass nicht die klassischen B- und T-Lymphozyten, sondern 
innate lymphoid cells die wichtigsten Immunzellen für die intestinale Entzündung nach 
Barriereverlust sind. 
Die Pathologie der Mcl-1∆IEC Mäuse spiegelt genetisch und morphologisch die Adenom-
Karzinom Sequenz wider, welche zu invasiven Karzinomen mit Mutationen und 
chromosomalen Aberrationen führt. Zum ersten Mal konnte so gezeigt werden, dass der 
chronisch induzierte Zelltod von intestinalen Epithelzellen alleine ausreicht, um intestinale 
Karzinogenese ohne Gabe von genotoxischen Substanzen zu induzieren. 
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4 The role of hepatocyte apoptosis in DNA damage response and 
tumorigenesis 
 
Parts of the ‘Introduction’, ‘Material and Methods’, ‘Results’ and ‘Discussion’ section are 
reproduced or adapted from the following manuscript (in preparation): 
 
 
 
“A novel RIPK1/c-FLIP/CASP8-dependent pathway mediates DNA damage response 
via JNK signaling in hepatocytes” 
 
 
Yannick Boege1, Mohsen Maleh Mir1, Akshay Ahuja2, Monika Wolf1, Mihael Vucur3, 
Friederike Böhm1, Lukas Frick1, Joachim Mertens4, Beat Müllhaupt4, Holger Moch1, Regina 
Boger5, Henning Schulze-Bergkamen5, Tobias Speicher6, Susagna Padrissa-Altés6, Sabine 
Werner6, Christiane Koppe3, Tom Lüdde3, Massimo Lopes2, Ricardo Weinlich5, Douglas 
Green5, Christopher Dillon5, Emmanuel Dejardin6, Mathias Heikenwälder1,7* and Achim 
Weber1*                
 
1 Institute of Surgical Pathology, University Hospital Zürich, Switzerland 
2 Institute of Molecular Cancer Research, University of Zürich, Switzerland  
3 University Hospital RWTH Aachen, Germany 
4 Institute of Gastroenterology and Hepatology, University Hospital Zürich, Switzerland,  
5  National Center for Tumor Diseases (NCT), University of Heidelberg, Germany 
6 Institute for Molecular Health Sciences, ETH Zürich, Switzerland 
5 St.Jude Children's Research Hospital, Memphis, U.S.A.  
6 GIGA-Research, University of Liège, Belgium 
7 Institute of Virology, Helmholtz Center Munich/TU Munich, Germany 
* These authors contributed equally to this work 
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4.1 Introduction 
4.1.1 Introduction: Global burden of cancer 
Cancer is one of the leading causes of death worldwide, accounting for 8.2 million deaths 
accompanied by estimated 14 million newly diagnosed cases in 2012 [3]. In 2014, the latest 
WHO cancer report predicts a significant increase in cancer incidence, doubling within the 
next two decades, with approximately 22 million new cases and 13 million deaths due to 
cancer to be expected per year.  
The most common causes of death due to cancer are carcinoma of the lung (1.59 million 
deaths/year), liver (0.75 million/year), stomach (0.72 million/year), colon (0.69 million/year) 
and breast (0.52 million/year) (Figure 1), but the most frequent types of cancer differ between 
men and women. In men, lung cancer was the most common cancer diagnosed in 2012 with 
1.18 million/year (16.7% of all cases in men). In women, breast cancer is the most common 
type of cancer, diagnosed in 1.7 million women in 2012 (25.2% of all new cases) [3].  
 
Figure 1: Estimated cancer incidence and 
mortality rates (both sexes) in 2011. 14 
million new cancer cases and 8.2 million 
cancer deaths are expected to rise up to 22 
million new cases within the next 2 decades. 
Figure from WHO-Cancer Fact Sheet [1]. 
 
 
 
 
 
 
 
 
Tobacco consumption is the most important modifiable risk factor for cancer development, 
causing 71% of deaths due to lung cancer and 22% of cancer deaths in total. The second 
most important risk factor for cancer is chronic infection. Persistent infection with 
Helicobacter pylori, hepatitis B, C and human papilloma virus taken together account for 
around 1.9 million cases of gastric, liver and cervix uteri cancer per year being responsible 
for estimated 20% of total cancer-related deaths (Figure 2). Around 30% of all cancer deaths 
are due to an unhealthy life style combining an metabolic syndrome, low fruit and vegetable 
intake, lack of physical activity with tobacco and alcohol consumption [3].  
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 Figure 2: Estimated Cancer Mortality Worldwide in 2012 (only men). In men, the mortality rates 
are 15% higher in more developed compared to less developed regions in men. The mortality is 8% 
higher in women compared to men due to high incidence and mortality of breast cancer. In men, the 
highest rates are in Central and Eastern Europe (173/100.000) and the lowest are in Western Africa 
(69/100000) Color code: estimated age-standardized rates (world) per 100.000. Figure from WHO-
Cancer Fact Sheet [1].  
 
4.1.2 Cancer of the digestive system 
All of the above described risk factors directly or indirectly affect the organs of the digestive 
system. Especially liver, intestine and stomach are at high risk to become affected by 
infections or inappropriate diet.  
The most prevalent risk factor for liver cancer development has been chronic hepatitis, 
mainly due to persistent infection with hepatitis B or C viruses (HBV or HCV). However, the 
most common etiology for HCC in Western countries has recently changed from viral 
infections to obesity and therefore HCC is the most rapidly increasing type of cancer in the 
U.S., with around 19.000 new cases and 17.000 deaths in 2007 [4]. A strong link between 
obesity and cancer is well established and a body mass index (BMI) >25 substantially 
increases the risk for developing cancer [5].  
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4.1.3 Chronic liver disease and liver cancer 
In the majority of cases, liver tumor development is caused by chronic liver disease (CLD), 
which substantially increases the risk for tumor development independent of their etiology. In 
most circumstances, CLD are characterized by increased hepatocyte damage and 
hepatocyte death [6]. Activation of an energy-dependent, apoptotic cell death program is a 
means of keeping liver homeostasis, resulting in the controlled elimination of damaged 
hepatocytes, thus preventing accumulation of genotoxic events [7]. Therefore, hepatocyte 
apoptosis can be considered as hallmark of CLD, independent of etiology. 
 
4.1.4 Parameters for analyzing hepatocyte cell death in patients  
The health status of the liver can be assessed non-invasively in serum of patients by 
measuring various parameters. The most important markers for CLD measured in serum are 
aminotransferases such as alanine (ALT) or aspartate aminotransferase (AST), alkaline 
phosphatase, bilirubin and bile acids. Additional markers such as miR-122 or keratin-18 are 
also used but not frequently applied in clinics.  
Aminotransferases are cytoplasmic enzymes that catalyze the transfer of amino groups. 
Whereas AST is also expressed in cardiac and skeletal muscle, ALT expression is restricted 
to hepatocytes. ALT and AST are released from dying hepatocytes into the blood stream and 
can be used as liver-specific markers to monitor acute and chronic liver dysfunction. ALT is 
the most common and established biomarker for diagnosis and monitoring of CLD and it can 
be even correlated with the progress of fibrosis and cirrhosis in HBV-positive patients and the 
liver-specific mortality in the population [8, 9].  
 
4.1.5 Cell death in chronic liver disease 
Clinical data and mouse models indicate that hepatocyte death is the key trigger of chronic 
liver disease and the main reason for the development of inflammation, fibrosis and cirrhosis 
(Figure 3) [10]. The phenotypical outcome of hepatocyte death largely depends on the 
different forms of cell death with respect to the inflammatory reaction or regeneration rate. 
Different forms of cell death have been described during the last years based on their 
characterization on molecular level, but the three most prevalent forms in the liver are 
apoptosis, necrosis and necroptosis [11, 12]. 
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 Figure 3: Cell death in chronic liver 
disease. In chronic liver disease, apoptosis, 
necroptosis, and necrosis lead to 
compensatory hepatocyte proliferation, HSC 
activation, inflammatory cell recruitment and 
activation. The long term outcomes 
potentially are fibrosis, chronic hepatitis, 
cirrhosis and HCC development. Figure from 
Luedde et al [10]. 
 
 
 
 
 
 
 
 
4.1.6 Apoptosis 
Programmed cell death is an active process and plays an important role to maintain liver 
tissue homeostasis. Apoptosis is a self-protective function of hepatocytes for the clearance of 
hepatotropic viruses, pathogens and to remove aberrant hepatocytes to prevent the 
malignant transformation. Hepatocytes express high levels of death receptors and are highly 
susceptible to death receptor induced cell death (Figure 4) and death receptor mediated 
apoptosis is a common feature of chronic and acute liver diseases [13]. Apoptosis is tightly 
controlled and can be actively induced by extrinsic or intrinsic signaling pathways and finally 
leads to the activation of effector caspase and subsequently to cellular shrinkage, nuclear 
fragmentation, DNA laddering and formation of apoptotic bodies (Figure 4).  
 
4.1.7 Extrinsic apoptosis 
The extrinsic apoptosis pathway is triggered via activation of cell surface bound death 
receptors through binding of their cognate ligands. All death receptors belong to the tumor 
necrosis factor receptor superfamily (TNFRSF) and for hepatocytes the expression of the 
following receptors is known: TNFR1, TNFR2, Fas/CD95, TRAILR and TWEAK [14]. Their 
ligands (FasL/CD95L, TNFα, and TRAIL) are mainly expressed by cells of the immune 
system and are crucial for the elimination of virally infected, transformed, or damaged 
hepatocytes. The ligand binding to the receptor first leads to trimerization and is followed by 
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the recruitment of several adaptor protein to form the so-called death-inducing signaling 
complex (DISC) (Figure 4A). First, the TNFR-associated death domain (TRADD) protein is 
recruited to the cytoplasmic death domain of the death receptor and second the Fas-
associated protein with death domain (FADD) binds to TRADD. The association of TRADD 
and FADD leads to the induction of apoptosis via the recruitment and cleavage of pro-
Caspase 8, whereas binding of TNF-associated factor 2 (TRAF2) to TRADD initiates NFκB 
or JNK signaling pathways [15] (Figure 4D). TNFR complex IIb, also called necrosome, is 
formed under some cellular conditions such as presence of RIPK3 or reduced Caspase 8 
activity in which RIPK3 is recruited to RIPK1 allowing mutual phosphorylation and 
subsequent activation of necroptosis executer protein MLKL (Figure 4B). 
 
Figure 4: Activation of TNFR can lead to apoptosis, necroptosis or cell survival. Binding of TNFα 
to TNFR1 lead to its trimerization and recruitment of TNFR-associated death domain (TRADD), TNFR-
associated factor 2 (TRAF-2) and receptor-interacting protein 1 (RIPK1) and further binding partners 
to form the death-inducing signaling complex (DISC), also called TNFR complex I. This complex may 
activate NF-κB and mediate cell survival by inducing a number of anti-apoptotic molecules (Bcl-xL, 
cIAPs, cFLIP, A20) and therefore inhibiting apoptosis. After internalization of the DISC, FADD and 
Caspase 8 are recruited and form the pro-apoptotic TNFR complex IIa or the pro-necroptotic complex 
IIb (also called necrosome). The complex IIa inhibits RIPK1 and RIPK3 and allows the release of 
Caspase 8 inhibitory protein cFLIP and subsequent Caspase 8 homodimerization and activation, 
finally leading to the activation of executioner Caspase 3.  
The cytosolic FADD-RIPK1-RIPK3-cFLIP-Caspase 8 complex, also defined as ripoptosome complex, 
is formed independent of death receptor activation upon cellular stress and eventually leads apoptosis 
induction or inflammasome activation. Figure from Vanden Berghe et al [16].  
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4.1.8 Apoptosome-dependent apoptosis (type 2)  
The activated Caspases 8 and 10 trigger a proteolytic cascade, leading to activation of 
effector caspases (Caspase 3, 6, and 7) and finally cleavage and degradation of cellular 
proteins resulting in cell death  (Figure 4B).  
There are two different signaling pathways described for the activation of effector pathways, 
defined as “type 1 death receptor signaling” and “type 2 death receptor signaling”. Whereas 
type 1 signaling, the direct cleavage of effector caspases through initiator caspases, is 
mainly taking place in lymphocytes, type 2 signaling occurs in hepatocytes via formation of 
the cytoplasmic apoptosome [14]. The assembly of the apoptosome complex depends on 
Cytochrome c released from the mitochondria and dATP to the binding of the cytosolic 
protein Apaf1, which serves as central scaffold protein [17]. The assembled apoptosome is a 
heptameric complex of around 1.4 MDa with a seven-fold symmetry structure and a 
Cytochrome c/Apaf1 ratio of 1:1. Next, the inactive pro-Caspase 9 is recruited as monomer 
or dimer to the apoptosome complex and activated by auto-cleavage, but the exact 
mechanisms how the apoptsome serves as platform for autocleavage of pro-Caspase 9 is 
still poorly understood [17]. Activated Caspase 9 itself leads activation of the caspase 
cascade by cleavage and therefore activation of the downstream effector caspases 3, 6 [17]. 
 
4.1.9 Intrinsic apoptosis 
Whereas the extrinsic apoptotic pathway is activated by death receptors on the plasma 
membrane, the intrinsic apoptotic pathway is initiated by cytochrome c release upon 
disruption of the outer mitochondrial membrane caused by pro-apoptotic stimuli such as DNA 
damage, endoplasmic reticulum (ER) stress or the activated pro-apoptotic Bcl-2 family 
members BAX or BAK [18, 19]. Anti-apoptotic proteins of the Bcl-2 family (Bcl-2, Mcl-1, Bcl-
x) prevent the mitochondrial outer membrane permeabilization (MOMP) by binding and 
neutralization of pro-apoptotic family members [19]. Upon disruption of the outer 
mitochondrial membrane the released cytochrome c triggers the formation of the 
apoptosome and the execution of cell death. 
 
4.1.10 Necrosis  
Chronic liver diseases do not only show signs of programmed and tightly controlled cell 
death, but also others forms of cell death are observed, for example in alcoholic livers and 
non-alcoholic fatty liver disease [20]. Necrosis is defined as an acute form of accidental cell 
death as a consequence of an extreme cytotoxic stimulus, e.g. physicochemical stress, such 
as heat, osmotic shock or mechanical stress, which does not share features of apoptosis and 
autophagy [11, 21]. Necrosis is morphologically characterized by a gain in cell volume 
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(oncosis), swelling of organelles, plasma membrane rupture and subsequent uncontrolled 
loss of intracellular contents [11]. 
 
4.1.11 Necroptosis 
For a long time, necrosis has been considered as an accidental and uncontrolled form of cell 
death, but pathways regulating the execution of necrosis have been described in the last few 
years and consequently the term “necroptosis” was defined [22]. Necroptosis is mainly 
mediated by TNFRSF members or Toll-like receptors (TLR) in a RIPK1-dependent manner 
(Figure 4C). RIPK1 in the DISC remains inactive through ubiquitination and serves as a 
scaffold protein and consequently contributes to the survival-promoting effects by mediating 
TNF-dependent activation of the pro-survival pathways NFκB and MAP kinase. The RIPK1-
specific deubiquitinating enzyme CYLD leads to the de-ubiquitination and to the activation of 
the RIPK1 kinase activity and the recruitment and binding of RIPK1 to RIPK3 and MLKL to 
form the necrosome complex. The necrosome complex mediates the activation of RIPK3 and 
MLKL, two crucial downstream mediators of necroptosis, and finally leads to membrane 
permeabilization to induce necrotic cell death (Figure 4C) [11, 22].   
 
4.1.12 Cell death and inflammatory response 
Apoptosis was considered as none or low-inflammatory process in the liver due to the rapid 
clearance of apoptotic bodies by engulfment through phagocytic cells, i.e. macrophages or 
granulocytes [11]. But recent studies described the release of intracellular cytokines (e.g. IL1, 
TNFα) during apoptotic processes as an important mechanism to alert the immune system of 
tissue damage and to initiate the tissue healing. The cytokine and chemokine secretion 
under non-infectious conditions has been defined as “sterile inflammation” [23, 24]. 
In contrast, necrosis and necroptosis are described as highly immune stimulatory events. 
The uncontrolled release of cellular contents triggers a strong inflammatory response in solid 
tissues, while the inflammatory reaction itself further promotes cell death, constituting a feed-
forward loop [22, 25]. The uncontrolled release of immunogenic molecules called ‘‘damage-
associated molecular patterns’’ (DAMPs) and include HMGB1, IL-1a, uric acid, DNA 
fragments, mitochondrial content and ATP (Figure 5).  
It was recently shown that Caspase 8 and FADD suppress a RIPK1 and RIPK3-dependent 
necroptotic cell death and inflammatory response in murine keratinocytes and murine 
intestinal epithelial cells. Both, necroptotic cell death as well as subsequent inflammation 
could be rescued by additional pharmacological inhibition of RIPK1 or genetic deletion of 
RIPK3 [25]. Stimulation of TNFR1 by TNF triggered necroptotic cell death and chronic ilitis 
with TNFα being mainly MyD88-dependent produced as response to bacterial infection [25]. 
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 Figure 5: Inflammatory cell death and release of DAMPs. A) and B) Pathogen triggered necroptotic 
cell death via TLRs when Caspase 8 is inhibited or genetically ablated. Additionally, stimulation of 
TLRs by PAMPs can provoke inflammatory responses in infected cell  C) Necroptotic cell death is 
highly immune stimulatory due to the widebroad and unspecific release of DAMPs, e.g. HMBG1, IL1, 
TNFα and ATP. Figure from Kaczmarek et al [25]. 
 
4.1.13 Cell death and liver regeneration 
Apoptosis contributes to tissue homeostasis in solid and regenerative organs and is needed 
for the removal of damaged hepatocytes in the liver and to keep the equilibrium between loss 
and replacement of hepatocytes [10]. Most of the hepatocytes rest in G0 phase and the 
proliferation and turn-over rate of hepatocytes under normal physiological conditions is very 
low (about 0.05% of hepatocytes) as reflected by almost undetectable aminotransferase 
levels. The liver has an unique ability to control regeneration processes and quickly adjust 
liver tissue regeneration in response to massive hepatocyte death or loss of liver mass [10], 
as seen in acute liver failure due to toxin or poison uptake or surgical resection of liver mass. 
But also under non-acute conditions, the constant uptake of food-derived toxins, alcohol 
consumption or a persistent hepatic inflammation with hepatotropic virus may lead to 
persistently increased hepatocyte death, as known from patients suffering from chronic HBV 
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or HCV infection or life-style related chronic liver diseases such as NAFLD, ASH or NASH. In 
these chronically diseased livers, increased levels of hepatocyte apoptosis and liver tissue 
regeneration and the promoted development of liver fibrosis, cirrhosis and 
hepatocarcinogenesis is well known [10].  
 
4.1.14 Liver cancer and hepatocellular carcinoma 
Tumors of the liver are classified by the World Health Organization (WHO) due to their origin 
into epithelial or non-epithelial tumors. Malignant tumors derived from hepatocytes are 
named hepatocellular carcinoma (HCC) (Figure 6) and account for 75% of all liver cancers, 
whereas benign tumors are called hepatocellular adenoma. Cholangiocarcinoma, tumors 
derived from bile ducts account for approximately 6% of primary liver cancers [4, 26].  
 
Figure 6: Macroscopic appearance of HCC. HCC are 
visible macroscopically as clear and distinct nodular 
structures in in the liver. Figure from Flejou et al. [27]. 
 
 
 
 
 
HCC is the most frequent and clinically significant primary neoplasia, and is almost always 
lethal. Only 5-9% of patients survive for five years or more from the time point of diagnosis. 
The incidence of HCC has doubled in the US and Europe in the past four decades. In line, 
the most common etiology for HCC in industrialized countries has recently switched from 
viral infections to obesity, making HCC the most rapidly increasing type of cancer in the U.S., 
with 19,160 new cases and 16,780 deaths in 2007 [4, 26].  
HCC have various epidemiologic features including variations among (I) geographic regions, 
(II) racial and ethnic groups, (III) gender and (IV) environmental risk factors. In almost all 
populations worldwide males are more likely to be affected by HCC than females (Figure 7) 
[28]. The male:female ratio persists around 2:1 to 4:1 and is declared to the exposure of risk 
factors.  
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 Figure 7: Liver cancer incidence worldwide, only males. For men, the average lifetime risk of 
getting liver or bile duct cancer is approximately 1 in 100, for women 1 in 250. Liver cancer mainly 
occurs in less developed regions where 83% of the estimated 782,000 new cancer cases worldwide 
occurred in 2012 [1, 29]. 
 
4.1.15 HCC treatments: diagnosis, resection and transplantation 
Non-invasive imaging tests like computer tomography (CT) or magnetic resonance imaging 
(MRI) made it possible to detect early lesions with more than 2 cm in diameter in the liver 
because the radiologic changes are related to increased vascularity in the hepatocellular 
carcinoma and can be detected easily. Additional liver needle biopsies are necessary to 
validate the tumor finding in case of unclarity. The choice of treatment depends on the 
cancer stage and different curative or palliative treatments available, but the treatment finally 
depends on the tumor stage at the day of diagnosis [28]. According to the so-called Milan 
criteria, patients suffering from an early-stage HCC with less than 5 cm in diameter or up to 3 
lesions each less than 3 cm in diameter, with preserved liver function normally undergo 
surgical transplantation and show a 5-year survival rate of up to 75% [30]. Since the Milan 
criteria were implemented the numbers of liver transplantation in HCC patients have 
increased worldwide and currently in Europe around 27% of all patients with solid organ 
transplantation suffer from HCC [31]. To assess the need for liver transplantation for patients 
suffering from liver dysfunction due to HCC, the Child-Pugh classification or model for end-
stage liver disease (MELD) criteria are used to predict the potential survival of the patient 
and set the priorities for transplantations. 
Systemic therapy with the sorafenib (Nexavar®), a small molecule that inhibits cell 
proliferation and angiogenesis by inhibiting RAF1 and VEGF, is currently the best option for 
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advanced HCC. Monotherapy with sorafenib significantly prolonged overall survival of 
patients and the 1-year survival rates were 44% with sorafenib versus 33% with placebo and 
also the median time to progression was prolonged to 7.6 versus 2.8 months [32]. A 
combination therapy of sorafenib plus doxorubicin showed a significantly longer survival of 
patients (13.7 months) compared to placebo plus doxorubicin treated patients (6.5 months) 
[33]. 
 
4.1.16 Genetic alterations in hepatocellular carcinoma 
Various genetic alterations mount up during the process of hepatocarcinogenesis and 
progressively provoke the malignant transformation of hepatocytes by altering expression of 
genes controlling cell cycles and cell proliferation [34, 35]. Genetic alterations also decrease 
the genomic integrity for example by inactivating the machinery of sensing and repairing 
DNA damage or the correct chromosomal segregation during mitosis, which can lead to 
aneuploidia.  
Malignant hepatocytes in HCC accumulate a large number of chromosomal rearrangements 
leading to highly complex karyotypes. About 40% of all HCC reveal an aneuploid genome 
and numerical chromosomal abnormalities [34]. Malignant tumors are in general highly 
aneuploid, containing an uncommon number of chromosomes. The chromosomal regions 
involved frequently in structural rearrangements are located on chromosomes 1, 7 and 8 [36] 
and exhibit structural alterations such as translocations, deletions and amplifications. The 
first chromosomal abnormality detected in human tumors was the Philadelphia chromosome. 
This chromosomal aberration is generated by reciprocal translocation involving the ABL 
oncogene, a tyrosine kinase on chromosome 9. The ABL gene locus is linked close to the 
BCR (breakpoint cluster region) on chromosome 22, leading to the expression of the BCR-
ABL gene product [37]. However, chromosomal alterations provide important evidence to the 
genetic changes in cancer. The chromosomal alterations in human solid tumors such as 
carcinoma are heterogeneous and complex. Therefore, the comprehensive knowledge of a 
broad field of genetic alterations in tumor subtypes and the study of the correlation between 
these alterations and the different clinical and histological parameters allow to refine the 
tumor classification and the understanding of the multi-step carcinogenesis process [34] [38]. 
 
4.1.17 The role of oncogenes and tumor suppressor genes in tumorigenesis 
Hepatocarcinogenesis is tightly linked to chronic liver damage but hardly occurs in healthy 
liver. One possible driver of carcinogenesis and chromosomal aberrations in hepatocytes is 
the high proliferation rate occurring in chronic liver damage – also named compensatory 
proliferation. Multiple genetic mutations can activate oncogenes or disrupt/inactivate tumor 
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suppressor genes [39]. Mutations or aberrant expression of oncogenes, as well as activation 
of oncogenic pathways found the basis for the malignant transformation of healthy 
hepatocytes. Oncogene expression patterns of tumors can differ between various types of 
cancer and also within the same subclass of cancer. Therefore, expression analysis of 
oncogenes is a tool to classify tumor subtypes in humans. In human liver cancer, increased 
expression levels of the ras subfamily, namely H-ras, N-ras and K-ras, have been reported 
[40]. The RAS proteins are GTPases involved in cell signal transduction and activating 
mutations lead to the permanently activation of cell growth and cell division. The oncogenic 
activation links (I) enhanced cell proliferation, (II) resistance to apoptosis and (III) the self-
sufficiency in growth signals to the uncoupling of cell growth from extrinsic regulatory signals, 
finally leading to limitless replication and carcinogenesis [41]. Tumor suppressor genes, or in 
fact the proteins these genes encode, mediate various functions including the repression of 
cell cycle promoting genes, sensing of DNA damage and apoptosis.  
 
4.1.18 Hallmarks of cancer 
During the multi-step process of hepatocarcinogenesis numerous genetic and cellular 
alterations select for proliferative and survival advantages of malignant cells [39]. The 
complexity of cellular and genetic alterations allowing cancer cells to survive, proliferate and 
disseminate was summarized for the first time in the year 2000 by Douglas Hanahan and 
Robert Weinberg as the six hallmarks of cancer, namely (I) self-sufficiency in growth signals, 
(II) evading growth suppressors, (III) resisting cell death, (IV) replicative immortality, (V) 
inducing angiogenesis and (VI) tissue invasion and metastasis [41]. In addition, inflammation 
was added as the seventh hallmark of cancer, but inflammation was actually already 
described by Rudolph Virchow in the year 1863, uncovering the tumor promoting effects of 
the inflammatory micro-environment [42]. 
Remarkable progress in cancer research has been achieved in the last years and new 
observations and conclusions deepened the understanding of cancer biology leading to 
additional hallmarks of cancer. (VIII) Evading immune destruction, but also (IX) 
reprogramming of energy metabolism and (X) genome instability & mutations have been 
added to the classical hallmarks of cancer (Figure 8) [43]. The hallmarks summarize the 
enabling and emerging characteristics of cancer, but to understand the complex progress of 
carcinogenesis, one has also to consider the tumor micro-environment, cancer stem or 
progenitor cells and overlapping signaling networks as important determinants. Furthermore, 
cell type specific reactions for example due to the differentiation status or tissue environment 
may lead to different cellular outcome. 
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 Figure 8: Hallmarks of cancer.  The initially described acquired capabilities defining the hallmarks of 
cancer I) self-sufficiency in growth signals, II) evading growth suppressors, III) resisting cell death, IV) 
replicative immortality, V) inducing angiogenesis and VI) tissue invasion and metastasis have be 
complemented. The emerging hallmarks VII) reprogramming energy metabolism and VIII) evading 
immune destruction as well as the enabling characteristics IX) tumor-promoting inflammation and X) 
genome instability and mutation have been added. Figure adapted from Hanahan and Weinberg [43]. 
 
4.1.19 Mouse models for cell death and hepatocarcinogenesis 
The relevance of constant hepatocyte cell loss in driving chronic liver regeneration and 
hepatocarcinogenesis is very well described in different mouse models for spontaneous 
development of HCC (Table 1) [44]. Increased hepatocyte apoptosis in non-transformed 
hepatocytes could be observed in TAK1∆hep, Mcl-1 ∆hep as well as Bcl-xl ∆hep knock-out mice 
and a causal link to HCC development in relation to hepatocyte apoptosis is already shown 
[45-48].  
The hepatocyte-specific deletion of TAK1 leads to apoptotic and necrotic hepatocyte death, 
accompanied by enhanced liver cell proliferation and HCC development at 4 months of age. 
Of note, the additional Caspase 8 knock-out prevented hepatocyte apoptosis and 
subsequently led to reduced liver regeneration and abrogated tumor development. Whereas 
the additional knock-out of RIPK3 prevented necrotic cell death, it leads to increased rates of 
 
25 
 
apoptotic and proliferative hepatocytes resulting in a higher tumor burden. The TAK1∆hep 
mouse model demonstrated that hepatocyte apoptosis-driven liver regeneration and not 
necroptotic hepatocyte cell death promotes hepatocarcinogenesis [49]. 
The hepatocyte-specific knock-out of the anti-apoptotic Bcl-2 family members Bcl-xl and Mcl-
1 lead to spontaneous induction of hepatocyte apoptosis, accompanied by compensatory 
hyper-proliferation to restore liver mass and function. Over time, the hyper-apoptotic and 
hyper-proliferative environment in Bcl-xl∆hep and Mcl-1∆hep mice leads to spontaneous liver 
tumor formation, with an incidence of 27% in Bcl-xl∆hep and 50% in Mcl-1∆hep mice at 12 
months and 88% in Bcl-xl ∆hep and 100% in Mcl-1∆hep mice at 18 months. Interestingly, the 
additional knock-out of the pro-apoptotic counter-player Bak in Mcl-1∆hep mice rebalanced 
hepatocyte apoptosis to a physiological level and finally completely abolished tumorigenesis 
in Mcl-1∆hep mice, showing that tumor development is not a functional consequence of the 
knock-out of Mcl-1 but rather due to the apoptotic rate in hepatocytes [45]. The following 
table is adapted from Ringelhan et al. and Weber et al. and shows some of the currently 
used genetic mouse models to study HCC development in vivo [44, 50]. 
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Table 1: Frequently used HCC mouse models. Several mouse models have been established in the 
past 30 years to study liver tumorigenesis. Some of the most frequently used are listed below. Due to 
space limitations not all HCC models are listed. Table adapted from Weber et al [44] 
Models Phenotype Known mechanism 
Transgenic models 
AlbLTαβ Chronic inflammation, fibrosis, dysplasia, HCC at 12 months 
Chronic hepatitis, cell damage, apoptosis, 
compensatory hepatocyte proliferation, genomic 
instability 
Alb-c-myc 
Dysplasia, preneoplastic foci, 
adenoma, HCC at 12–15 
months 
Apoptosis induction, enhanced proliferation, genomic 
instability 
c-myc/TGFα 
Dysplastic and apoptotic 
changes in hepatocytes multiple 
focal lesions, HCC at 8 months  
Acceleration of neoplastic development compared to 
single transgenic models 
Knockout models 
Mcl-1Δhep 
Apoptoses, architectural 
disarray, fibrosis, dysplastic 
nodules and 50% HCC 
incidence at 12 months 
Spontaneous hepatocyte apoptosis leading to chronic 
liver damage and compensatory proliferation 
Mdr2-/- 
Cholastasis, inflammation,  
100% HCC incidence at 10 
months, metastasis 
Mice are unable to secrete phospholipids into bile 
leading to liver disease 
NEMOΔhep 
Steatohepatitis, liver fibrosis, 
dysplasia, 100% HCC incidence 
at 11 months 
Increased apoptotic hepatocyte death and subsequent 
compensatory proliferation 
TAK1Δhep 
Steatohepatitis, liver fibrosis, 
biliary cirrhosis, 100% HCC 
incidence at 4 months 
TAK1 deficiency leads to Caspase 3- mediated 
apoptosis accompanied by enhanced liver cell 
proliferation 
Dietary models / chemically-induced models 
Choline-deficient 
high fat diet 
Recapitulated key features of 
human metabolic syndrome, 
NASH and HCC, 30% HCC 
incidence at 12 months,  – 
NKT cell secreted LIGHT mediated steatosis, activated 
CD8(+) T cells and NKT cell triggered liver damage 
Choline-deficient 
diet 
Steatosis, HCC at 11–12 
months 
Formation of oval cells due to oxidative DNA damage 
and chromosomal instability finally leading to 
generation of hepatocytes 
DEN wild-type 
 
Acute hepatitis, hepatocyte 
proliferation, HCC at 8–10 
months  
 
Chemically-induced DNA damage leading to genetic 
mutations 
 
Transgenic models / viral genes 
HBV X protein 
Cytoplasmic vacuolations, 
neoplastic lesions, HCC at 13 
months 
Transcriptional transactivation of viral genes leading to 
altered host gene expression and carcinoma 
HCV core Steatosis, HCC at 16 mo 
Core protein acts as transcriptional activator affecting 
the proliferative ability of hepatocytes, ROS production, 
transcriptional activation of TNF and IL1 
SV40 T-Ag 
Hyperplastic hepatocytes, 
dysplasia, HCC at 3 months, 
lung metastasis 
SV40 T-Ag-mediated immortalisation, cell 
transformation, aberrant DNA replication 
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4.2 Scientific Questions 
As described above, hepatocyte apoptosis seems to be the main driver of 
hepatocarcinogenesis in chronically diseased human livers and in different mouse models, 
but the exact molecular mechanisms driving malignant hepatocyte transformation and 
hepatocarcinogenesis are still poorly understood. 
 
In my doctoral thesis, I aim to understand the molecular mechanisms driving tumor 
development in chronically diseased livers. More precisely, I aim to answer the following 
questions: 
 
- Is the Mcl-1∆hep mouse a suitable model to study human hepatocarcinogenesis? 
 
- Are the central mechanisms found in the Mcl-1∆hep mouse model applicable to human 
hepatocarcinogenesis? 
 
- What are the molecular mechanisms driving the malignant transformation of 
hepatocytes in a hyper-apoptotic and hyper-proliferative environment? 
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4.3 Results  
4.3.1 Increased hepatocyte apoptosis and regeneration correlate with DNA damage 
and genetic instability in human chronic liver diseases  
Hepatocyte apoptosis is a hallmark of human chronic liver diseases (CLD) independent of 
the underlying etiology [6, 10]. Increased levels of hepatocyte apoptosis in CLD correlate 
with increased levels of proliferating hepatocytes reflecting regeneration. In addition, 
positivity for the DNA damage marker γH2AX has been described in livers of HBV- and HCV-
infected patients, with a sequentially increase in γH2AX positivity from normal to chronic 
hepatitis, liver cirrhosis, dysplastic nodules and HCC [51, 52].  
In the herewith presented doctoral thesis, I observed DNA damage response by γH2AX 
immunohistochemistry (Figure 9) and immunofluorescence (Figure 10A) in liver tissue from 
patients independent of etiology. The analyzed etiologies included viral hepatitis (HBV, 
HCV), autoimmune hepatitis (AIH) and a metabolic disorder, precisely nonalcoholic 
steatohepatitis (NASH) (Figure 9).  
Figure 9: Increased levels of hepatocyte apoptosis, constant regeneration and DNA damage 
response in chronically diseased human livers and HCC. Human CLD of different etiology 
including chronic viral hepatitis (HBV, HCV), metabolic (NASH) and autoimmune (AIH) diseases show 
increased levels of hepatocyte apoptosis (cl.Casp3), proliferation (Ki67) and signs of DNA damage 
(γH2AX). Scale bars: 100 µm. 
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Furthermore, I have been able to validate the activation of DNA damage response (DDR) on 
protein level with immunoblotting for pCHK2 and pCHK1 (Figure 10B), indicating the 
activation of the two major pathways for single strand and double strand repair (ATR- and 
ATM-mediated pathways), as well as increased mRNA expression levels of genes of the 
DNA repair machinery (e.g. Rad51, Exo1, Ddit3) in liver tissue specimen from HBV, HCV 
and NASH patients (Figure 10C).  
 
Figure 10: Activation of DNA damage response pathways in CLD tissue. A) Representative 
immunofluorescence staining demonstrated typical dotted γH2AX foci in the nucleus, indicating DNA 
damage response.  B) Western blots of CLD tissues (liver needle biopsies) revealed activation of 
proteins associated with DNA repair. C) Increased mRNA expression levels of genes associated with 
DNA repair in CLD tissue and markers of malignancy analyzed by qPCR. *p < 0.05; **p < 0.01; ***p < 
0.001.  
 
The DDR in highly proliferative tissue is considered to reflect replicative stress associated 
DNA damage, e.g. a stalled or collapsed replication fork and subsequent single or double 
strand breaks. Therefore, I next addressed the question whether hyper-proliferation in 
regenerative livers induces genetic instability at chromosomal fragile sites, which are well-
known to be susceptible for spontaneous breakage during replication-associated DNA stress 
and were described to reflect genetic instability in pre-cancerous lesions [53]. I analyzed 
gDNA from micro-dissected liver tissue of different areas of the same liver needle biopsy by 
TaqMan copy number assay (Figure 11A) and fragment length analysis (Figure 11B). 
Interestingly, I could detect significant levels of genetic instability by both methods in 
chronically diseased livers compared to control patients.  
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 Figure 11: Genetic instability in CLD tissue. A) Increased rates of allelic imbalances (AI) reflecting 
genetic instability were detected in CLD tissues by TaqMan copy number assay at chromosomal 
fragile sites. Each square represents one area of microdissected liver tissue and lines indicating 
different distinct areas of the same liver (red: AI; black: no AI). B) AI was also detected in CLD tissues 
by fragment length analysis for the loci DS31263 and DS31289 (indicated by arrow heads). A) and B) 
Representative samples are shown and n=20 control, n=30 HBV, n=22 HCV, n=20 NASH, n=8 AIH, 
and n=31 HCC and n=6 corresponding non-tumor tissue samples have been analyzed. Statistics 
calculated by Pearson's Chi-square test compared to control tissue. Chromosomal fragile sites were 
selected and analyzed according to Gorgoulis et al. [53]. 
 
DDR activation and genetic instability were described to correlate with the dysplastic 
character of pre-cancerous lesions in skin, lung and colon and contribute to tumor 
progression [53, 54]. In addition, I have been able to detect a shift of gene expression 
towards a malignant character of chronically diseased HBV, HCV and NASH livers by 
detecting the significant overexpression of liver malignancy markers Afp, Epcam, Glypican3 
and CD44 as well as tumor marker Glypican3 on RNA level.  
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4.3.2 Increased hepatocyte apoptosis correlates with HCC development in human 
CLD 
Based on the above presented data, I concluded that chronically diseased livers - as 
reflected by elevated serum transaminase levels (Figure 12) - already possess a pre-
cancerous character of early tumor progression and are of high risk for promoting the 
malignant transformation towards liver tumor development.  
 
Figure 12: Elevated serum ALT levels detected in human 
CLD of various etiologies indicating liver damage 
hepatocyte death. Serum of n=8 normal , n=4 HBV, n=8 HCV, 
n=4 NASH and n=4 AIH patients was analyzed. 
 
 
 
 
Therefore, I hypothesized that constant hepatocyte death in combination with compensatory 
proliferation would trigger the malignant transformation of chronically diseased livers and the 
constant accumulation of genetic and cellular changes over time would significantly 
contribute to liver tumor development. 
To test this hypothesis, I sought for an association between serum transaminase levels and 
HCC development in a retrospective analysis of patients with HCC versus tumor-free 
patients and we designed a retrospective cohort study with chronically HCV-infected patients 
with the defined endpoint HCC diagnosis (Clinic for Gastroenterology and Hepatology/USZ, 
Prof. Dr. Beat Müllhaupt/ Dr. Joachim Mertens). We compared HCC patients to HCV-positive 
control patients without HCC development with similar liver function over the years according 
to their MELD score. 
Interestingly, HCC and non-HCC patients did not differ with respect to their serum albumin or 
bilirubin levels confirming the same liver function, but HCC patients displayed significantly 
higher ALT and AST levels in the years preceding HCC diagnosis (Figure 13). This finding 
confirmed the hypothesis that apoptosis-driven hepatocyte death and liver damage 
significantly contribute to liver tumorigenesis and might be the first and crucial step for tumor 
initiation and development in chronically diseased livers.  
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 Figure 13: Retrospective cohort study with the defined endpoint of HCC diagnosis.  ALT levels 
in patients with chronic HCV infection and HCC development compared to matched HCV patients 
without HCC development. n=19 patients were grouped to control patients without HCC development 
with the same liver function according to the MELD score (based on serum bilirubin, serum creatinine, 
and the international normalized ratio for prothrombin time (INR). Equal level of serum albumin 
confirms the same liver function between both groups, whereas patients with HCC development 
showed significantly elevated ALT levels prior first diagnosis of HCC. Left panel: time course 6 years 
prior to HCC diagnosis; right panel: mean of values over time.   
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4.3.3 HCC from Mcl-1∆hep mice reveal morphology similar to human HCC 
If hepatocyte apoptosis is the first step in driving liver tumorigenesis and if there is a causal 
link between hepatocyte cell death and HCC development, I hypothesized that the reduction 
or ablation of hepatocyte apoptosis in the liver would finally reduce tumorigenesis.  
To address this question I analyzed the impact of hepatocyte apoptosis on tumor 
development in Mcl-1∆hep mice, as it was shown that this mouse model can be used to 
analyzed spontaneous liver tumorigenesis in constantly regenerating livers [48, 55]. The 
hepatocyte-specific deletion of Mcl-1 leads to spontaneous apoptosis of hepatocytes 
accompanied by compensatory hyper-proliferation, reflecting liver regeneration. Finally, 
around 50% of knock-out mice develop spontaneously HCC after 12 months of age [48]. 
To determine to which extend the Mcl-1∆hep mouse model mimics human 
hepatocarcinogenesis, liver tumors and non-neoplastic livers of Mcl-1∆hep mice were analyzed 
on morphological, immunohistochemical and gene expression level. 
Figure 14: Histology of HCC derived from Mcl-1∆hep mice. Histological analysis of HCC derived 
from Mcl-1∆hep mice revealed a histologically and morphologically spectrum of growth patterns found in 
human HCC. Solid, thick trabecular and pseudoglandular growth patterns, HCC with cytoplasmic 
inclusions and clear cell and fatty change and combined HCC-CCC could be observed in livers of 12 
month-old Mcl-1∆hep mice. Upper scale bars = 500 µm, lower scale bar = 500 µm. 
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Liver tumors developing in Mcl-1∆hep mice revealed a broad morphological spectrum 
displaying all major growth patterns and cytological features found in human HCC [56]: solid, 
(thick) trabecular, and pseudoglandular growth patterns, clear cell and fatty change, HCC 
with cytoplasmic inclusions, and also a combined HCC-CCC (hepatocellular-
cholangiocellular) carcinoma (Figure 14). Thus, liver tumors developing in Mcl-1∆hep mice are 
morphologically heterogeneous and recapitulate the spectrum of human HCC. 
 
4.3.4 HCC from Mcl-1∆hep mice show deregulated oncogene and tumor suppressor 
gene expression 
Furthermore, I screened the mRNA expression of approximately 95 well-known oncogenes 
and tumor-suppressor genes, which are known to be relevant for human tumor development 
or described to be deregulated in human or murine HCC [46, 57, 58]. In my analysis,14 
HCC-relevant oncogenes and tumor suppressor genes including e.g. H-Ras, Net1, Tp53, 
and Mdm2 were significantly deregulated in tumors, and also in corresponding non-tumor 
tissue of Mcl-1∆hep mice compared to wild-type mice (Figure 15). The deregulated expression 
of oncogenes and tumor suppressor genes described to be relevant for human 
hepatocarcinogenesis demonstrated the close relation between human 
hepatocarcinogenesis and the Mcl-1∆hep mice on expression level. 
 
Figure 15: Oncogene expression in HCC and corresponding non-tumor tissue of Mcl-1∆hep 
mice. mRNA expression analysis of HCC and corresponding non-tumor tissue (NT) of 95 oncogenes 
and tumor suppressor genes performed by qPCR and compared to wild-type controls. Genes were 
significantly up- and down-regulated in tumor as well as non-tumor tissue. Only significantly 
deregulated genes are shown for space reasons. Asterisk indicates genes that were significantly up-
regulated after multiple comparison (one-way ANOVA, bonferroni-correctd *p<0.05, **p<0.01, 
***p<0.001). 
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Next, I performed a 16-gene expression profiling developed by Cairo et al. to analyze gene 
expression according to the proliferation and differentiation status initially described for 
human livers and hepatoblastoma [59]. HCC revealed two signatures, one being indicative of 
a more aggressive proliferative and less differentiated phenotype, similar to aggressive 
tumors from c-myctg/+/p53-/- mice, and the other indicative of a less proliferative and more 
differentiated phenotype, similar to differentiate hepatocytes from control livers. This analysis 
reflected the heterogeneous character of HCC developed in Mcl-1∆hep mice in contratst to 
several other models (e.g. c-myctg/+/p53-/- mice) in which only particular HCC subtypes 
develop (Figure 16). 
 
Figure 16: 16-gene profiling 
analysis of HCC from Mcl-1∆hep 
mice. mRNA analysis by qPCR 
comparing HCC derived from Mcl-
1∆hep mice to aggressive liver 
tumors from c-myctg/+/p53-/- mice 
[59] and hepatocytes from wild-type 
livers. Genes above the line 
indicate a proliferative phenotype 
and genes below the line represent 
a less proliferative, but more 
differentiated phenotype. color code 
= log2 ratio. 
 
 
 
4.3.5 Gene expression analysis in regenerating livers of Mcl-1∆hep mice uncovered 
novel tumor-associated genes 
In order to investigate the molecular mechanisms driving tumor initiation during chronic liver 
regeneration in Mcl-1∆hep mice, I performed an unbiased mRNA microarray analysis on liver 
tissue of two-month-old wild-type, homozygous and hemizygous Mcl-1∆hep mice (Figure 17A). 
The expression of genes found deregulated in mRNA microarray analysis was validated by 
quantitative RT-PCR. KEGG pathway database analysis revealed that genes which were up-
regulated at least two-fold were broadly assigned to variable cellular functions including 
apoptosis, cell cycle regulation, differentiation, metabolism and DNA damage response 
(Figure 17B).  
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 Figure 17: RNA microarray analysis of regenerating livers from Mcl-1∆hep mice. A) RNA 
microarray was performed with RNA isolated from highly regenerative two month-old Mcl-1∆hep mice, 
AlbCre-negative littermates as control mice as wells as hemizygous AlbCre-Mcl-1flox/wt mice with liver 
damage. B) KEGG pathway analysis revealed an heterogenous expression pattern of pathways (e.g. 
cell cycle, DNA damage response, angiogenesis), reflecting tissue damage and regeneration. 
 
I performed Gene Set Enrichment Analysis (GSEA) [60] to determine whether livers of Mcl-
1∆hep mice differ from livers of wild-type mice with respect to several gene sets of interest. 
Whereas no significant differences were found with respect to a gene set of normal liver, 
livers of Mcl-1∆hep mice were significantly enriched for genes related to apoptosis, 
proliferation and DNA replication (Figure 18) 
confirming previous morphological and 
functional data. Furthermore, livers of Mcl-1∆hep 
mice also displayed a significant enrichment for 
genes related to wounding, viral infection and 
alcoholic hepatitis, and despite representing 
non-neoplastic tissue also to human HCC. RNA 
microarray datasets performed with RNA from 
human liver tissue derived from public availably 
databases.  
 
 
Figure 18: GSEA of RNA microarray data. GSEA 
to compare all differentially deregulated genes from 
Mcl-1∆hep mice with human gene sets for cellular 
processes, stress response and normal as well as 
diseased livers, including HCC. NES= normalized 
enrichment score.  
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4.3.6 Uncovered tumor-associated genes are significantly deregulated in other 
mouse models of HCC 
The genes with the strongest up-regulation at two months of age, especially the top five 
upregulated genes (Gpnmb, Tinag1, Plk1, Tpx2 and Bcl2a1b), are indicative for mitotic and 
regenerative processes in the liver. Because of the overlapping gene expression pattern of 
livers derived from Mcl-1∆hep mice pattern with human HCC found by GSEA, I decided to 
analyse the gene expression of the newly uncovered genes in tumor and corresponding non-
tumor and control livers of 12-month-old Mcl-1∆hep mice and could also find a significant over-
expression (Figure 19). Therefore I concluded that the expression of these genes is not only 
related to liver regeneration and tumor initiation but rather also involved in tumor progression. 
But further experimental approaches would be required to analyze whether these genes 
causally drive tumorigenesis or are only upregulated as secondary/side-effect. 
 
Figure 19: Validation of target gene 
expression in 12 month-old mice. Top 
five upregulated genes uncovered in two 
month-old mice are also significantly 
upregulated in tumor and non-tumor tissue 
of 12 month-old Mcl-1∆hep mice. *p<0.05, 
**p<0.01, ***p<0.001.  
 
 
 
Next, I asked whether this gene expression of the newly uncovered target genes is specific 
for Mcl-1∆hep mice and therefore analyzed liver tumors derived from c-myc transgenic mice 
(an oncogene-driven model), LTαβ transgenic mice (inflammation-driven) and the TAK1∆hep 
mouse model. In brief, the genes of interest were significantly overexpressed in all analyzed 
mouse models for spontaneous HCC development (Figure 20) but not in chemically, in 
particular DEN-induced HCC (data not shown), making a similar pathomechanism of 
spontaneous hepatocarcinogenesis during chronic liver tissue damage and regeneration 
likely, at least described by this gene expression profile. 
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Figure 20: Increased expression of 
target gene in HCC derived from 
further mouse models. Top five 
upregulated genes were also detected 
by qPCR to be significantly 
deregulated in HCC of an 
inflammatory mouse model 
(Alb37LTαβ), an oncogene-driven 
mouse model (c-myctg/+) and the 
TAK1∆hep mouse model. n=4 to 8 HCC 
were analyzed. *p<0.05, **p<0.01, 
***p<0.001. 
 
 
 
4.3.7 Uncovered tumor-associated genes are significantly deregulated in human HCC 
and relevant for human hepatocarcinogenesis 
Next, to test whether the tumorigenic gene expression profile initially uncovered in livers of 
Mcl-1∆hep mice reveals further similarities with human HCC, expression of genes showing the 
strongest up-regulation in livers of Mcl-1∆hep compared to wild-type mice was analyzed in 
human HCC of different etiology. Indeed, significantly up-regulated mRNA levels of TINAG, 
PLK1, and TPX2 were found by qPCR in HCC independent of etiology (Figure 21A). 
Expression of Gpnmb was not detectable with different primer sets in human livers tissue 
and excluded for further analysis. Finally, overexpression of TINAG1, PLK1, and TPX2 was 
confirmed by data mining in several published HCC expression data sets by cand.doc. Lukas 
Frick (Figure 21B).  
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 Figure 21: RNA expression analysis of target genes in human tumor and non-tumor liver 
tissue. A) Expression analysis by qPCR in naïve human liver tissues of CLD and HCC of diverse 
etiologies revealed elevated expression by tendency in non-tumorous liver tissue of CLD. Expression 
levels of Plk1, Tpx2, and Tinag, respectively, were significantly upregulated on HCC, independent of 
etiology. B) Overexpression of Plk1, Tpx2, and Tinag in human HCC could be confirmed in public 
available microarray expression datasets representative shown for a cohort pf primary HCC from 
patients treated with surgical resection or liver transplantation and without chemotherapy [61]. 
Asterisks indicate genes that were significantly up-regulated after multiple comparison, one-way 
ANOVA, bonferroni-corrected *p<0.05, **p<0.01, ***p<0.001. 
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As next step, I analyzed together with the help of Dr. Juliane Friemel the protein expression 
of target genes. Enhanced expression of TINAG, PLK1, TPX2, and BCL2A1 was 
demonstrated in primary HCC (independent of the underlying etiology) by 
immunohistochemistry (Figure 22A). In addition, significant overexpression of TINAG, TPX2, 
and BCL2A1 was observed by quantifying tissue microarray containing human HCC (Figure 
22B and C).  
Figure 22: Elevated protein expression of target genes in human HCC. A) B) and C) Semi-
quantitative immunohistochemical analysis using tissue microarrays (TMA) containing HCC 
(duplicates of n=95 HCC specimen) as well as non-tumorous liver tissue (duplicates of n=58). Analysis 
revealed statistically significant higher protein levels of TPX2, TINAG, and BCL2A1B in HCC, 
compared to non-HCC liver tissue. PLK1 was not quantified due to inconsistent staining pattern.   
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Finally, we correlated the protein expression with the patient survival and were able to 
observe a significant correlation for TPX2 and TINAG (Figure 23), but not for BCL2A1. A 
strong expression of TPX2, a kinase involved in mitosis, that is required for AuroraKA 
activation and mediates chromosome segregation [62], significantly correlated with a short 
survival and poor outcome of patients. In contrast, the overexpression of poorly described 
extracellular matrix protein TINAG [63] in HCC significantly correlated with a prolonged 
survival of patients, compared to low or medium TINAG expression in HCC  
 
 
Figure 23: TPX2 and TINAG protein expression correlated with clinical prognosis. Strong 
expression TPX2 with a poor prognosis, whereas a strong expression of TINAG correlated with a good 
prognosis and prolonged survival, compared to patients with negative or low expression. Kaplan-Meier 
survival curved were generate based on semi-quantitative immunohistochemical analysis of TMA, .p-
values were calculated by the log-rank test. 
 
In summary, I uncovered novel genes which were poorly (Plk1, Tpx2) or not yet described 
(Bcl21ab, Tinag, Gpnmb) to be involved in human hepatocarcinogenesis. These genes were 
initially discovered to be deregulated in highly regenerative livers of 2 month-old Mcl-1∆hep 
mice and are apparently associated with early tumor initiation, tumor progression as well as 
survival of patients and thus are potentially of interest as therapeutically targets or as 
biomarkers for liver malignancy and tumor development. 
Thus, tumors developing in Mcl-1∆hep mice are not only highly similar to human HCC on 
morphological and immunohistochemical level, but livers of Mcl-1∆hep mice also reveal a gene 
expression pattern highly overlapping with other mouse models for liver tumorigenesis and 
human HCC. These findings are indicative of a common underlying pathophysiological 
mechanism and suggest that the Mcl-1∆hep model recapitulates central features of human 
hepatocarcinogenesis and represents a very useful tool to study human 
hepatocarcinogenesis. 
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4.3.8 Risk of HCC correlates with apoptotic hepatocyte death in Mcl-1∆hep mice  
As mentioned above, I hypothesized that hepatocyte cell death is the main stimulus of 
tumorigenesis and the amount of hepatocyte cell death over-time directly influences tumor 
development. Therefore, I decided to first correlate basic clinical parameters before 
analyzing the regenerating livers on molecular level. 
At two months of age, Mcl-1∆hep mice showed moderate to severe hepatocyte death rates 
when applying a standard human scoring system for disease activity [64], and a statistically 
significant positive correlation between the percentage of hepatocyte apoptosis and ALT 
levels (Figure 24A-C), confirming that apoptotic hepatocyte death is the major source of 
increased serum transaminase levels in this model.  
Figure 24: Elevated hepatocyte cell death and signs of DDR in livers Mcl-1∆hep mice. A) 
Hepatocyte apoptosis (black arrow) and signs of DNA damage (γH2AX) in livers of Mcl-1∆hep mice 
(scale bar, upper panel: 50 µm) and B) grading of disease activity in livers of Mcl-1∆hep mice. C) ALT 
levels reflecting liver damage significantly correlate with the rate of apoptotic hepatocytes in livers of 
Mcl-1∆hep mice. D) Significantly increased numbers of hepatocytes per high power field (HPF) positive 
for γH2AX in livers of Mcl-1∆hep mice significantly correlate with D) ALT levels measured non-invasively 
and reflecting liver damage. A) - E) Livers of 2 month-old Mcl-1∆hep or wild-type mice. 
 
 
 
43 
 
Similar to human CLD, livers of 2-month-old Mcl-1∆hep mice not only revealed increased 
levels of proliferating hepatocytes [55], but also a substantial number of γH2AX-positive 
hepatocytes when compared to age-matched wild-type mice (Figure 24D). Notably, the 
number of γH2AX-positive hepatocytes positively correlated with ALT levels indicating an 
association between the amount of hepatocyte apoptosis and DNA damage (Figure 24E).  
 
Next, we asked whether a correlation between the level of hepatocyte apoptosis and HCC 
development also does exist. To this aim, Mcl-1∆hep and wild-type mice were prospectively 
monitored over time for serum transaminase levels, before they were killed at 12 months of 
age. Similar to what was reported before [48], 50% of Mcl-1∆hep developed liver tumors after 
one year. Remarkably, Mcl-1∆hep mice with HCC had constantly higher serum ALT (and also 
AST, not shown) levels compared to Mcl-1∆hep mice without HCC (Figure 25A). ALT levels 
were statistically significantly elevated at the age of 2 months (Figure 25B), i.e. the time-point 
when I also observed elevated numbers of regenerating hepatocytes, which is long before 
tumors or dysplastic changes were observable (Figure 25C). Thus, the association between 
elevated transaminase levels indicative of hepatocyte apoptosis and HCC development, 
which was observed in human patients, could be recapitulated in an in vivo model of 
hepatocarcinogenesis. 
 
 
Figure 25: The risk of HCC development correlates with levels of apoptotic cell death in Mcl-
1∆hep mice. A) Time course of transaminase levels shown for ALT revealing constantly elevated ALT 
levels throughout life in Mcl-1∆hep mice which developed an HCC at 12 months compared to tumor-free 
Mcl-1∆hep mice. B) ALT levels were significantly different at the age of 2 months. C) Macroscopy of 
livers of 12-month-old wild-type and Mcl-1∆hep mice (with and without HCC development). 
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4.3.9 Inhibition of TNFR1 signaling reduces apoptosis, proliferation and tumor 
development in Mcl-1∆hep mice 
Based on the strong link between hepatocyte death and HCC development in Mcl-1∆hep mice 
and the idea that constant hepatocyte apoptosis is the first and crucial step in a cascade 
leading to liver tumorigenesis, I hypothesized that the reduction or ablation of hepatocyte 
apoptosis in the liver would finally reduce tumorigenesis. Therefore, I took advantage of mice 
which systemically lack the pro-apoptotic TNFR signaling pathway and intercrossed TNFR1-/- 
mice to Mcl-1∆hep mice (Mcl-1∆hep/TNFR1-/- mice) aiming to reduce the extrinsic apoptotic 
signaling pathway via TNFR1.  
 
Figure 26: Expression of death receptors and ligands in Mcl-1∆hep/TNFR1-/- mice. Increased 
expression of A) death receptors (Tnfr1, Fas, Trailr) and B) ligands (Tnfα, Trail, Fasl) in livers of 2-
month-old Mcl-1∆hep compared to Mcl-1∆hep/TNFR1-/- and wild-type mice. Statistics analyzed by one-
way ANOVA, *p<0.05, **p<0.01, ***p<0.001. 
 
TNFα-induced cell death via TNFR1 is known to be one of the most important pathways 
causing hepatocyte apoptosis in a wide range of chronic and acute liver diseases [65, 66]. 
Mcl-1∆hep mice showed enhanced expression of death receptors (Tnfr1, Fas, Trailr) and 
associated ligands (Tnfα, Trail, Fasl) (Figure 26). Interestingly no activation of the 
downstream pro-survival pathway NFκB was observed (Figure 27). 
 
Figure 27: NFκB signaling in Mcl-1∆hep mice. RelA staining shows no obvious RelA translocation, 
indicating NFκB signaling in livers of Mcl-1∆hep. Scale bar = 50 µm. 
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Two-month-old Mcl-1∆hep/TNFR1-/- mice revealed a lower amount of serum transaminases 
(statistically significant for AST) and an increased liver to body weight ratio compared to age-
matched Mcl-1∆hep mice (Figure 28A and B).  
Liver histology and protein blotting revealed that Mcl-1∆hep/TNFR1-/- mice had not only 
significantly lower levels of apoptotic hepatocytes, but also of proliferating hepatocytes 
compared to Mcl-1∆hep mice (Figure 28C, Figure 29). Therefore, I concluded that TNFR1 
signaling is crucial for hepatocyte cell death and significantly influences tumor development 
in Mcl-1∆hep mice. 
 
 
Figure 28: Reduced liver damage, hepatocyte apoptosis and proliferation in Mcl-1∆hep/TNFR1-/- 
mice. A) Transaminase (AST, ALT) and B) liver/body weight ratio in Mcl-1∆hep, Mcl-1∆hep/TNFR1-/- and 
wild-type mice at 2 months of age. C) Immunohistochemistry and quantification for cleaved Caspase 3 
and Ki67 showing significantly reduced hepatocyte apoptosis and proliferation in Mcl-1∆hep/TNFR1-/- 
mice compared to Mcl-1∆hep mice at 2 months of age. Upper scale bar = 100 µm, lower scale bar = 200 
µm.  
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 Figure 29: Western blotting confirmed reduced proliferation and apoptosis in livers Mcl-
1∆hep/TNFR1-/- mice compared to age-matched Mcl-1∆hep mice. Activated Caspase 8 blotting 
indicates Caspase 8 dependent cell death in Mcl-1∆hep, abolished in Mcl-1∆hep/TNFR1-/- mice. 
To analyze the inflammatory reaction in Mcl-1∆hep and Mcl-1∆hep/TNFR1-/- mice I isolated 
intrahepatic immune cells and flow cytometry analysis (together with Dr. Monika Wolf) 
revealed a mild increase in CD11+/Ly6G+ immune cells in livers of Mcl-1∆hep mice, indicating a 
contribution of granulocytes and/or neutrophils in the clearance of apoptotic hepatocytes. No 
alteration in numbers of other immune cells, i.e. CD45+/CD4+, CD45+/CD8+, or CD11b+/Ly6C+ 
cells, could be found in Mcl-1∆hep mice (Figure 30). The increase of CD45+/Ly6G+ cells was 
reduced to wild-type levels in livers of Mcl-1∆hep/TNFR1-/- mice (Figure 30). 
 
Figure 30: Analysis of intrahepatic immune cells by flow cytometry. No significant changes could 
be observed in intrahepatic immune cell, but the amount of Ly6G-positive granulocytes has been 
elevated two fold in Mcl-1∆hep compared to wild-type and Mcl-1∆hep/TNFR1-/- mice (n=3 mice per group, 
2 months of age). 
 
Remarkably, significantly deregulated potential oncogenes which I initially found in in livers of 
2-month-old Mcl-1∆hep mice and HCC were also deregulated in livers of Mcl-1∆hep/TNFR1-/- 
mice, indicating that the malignant character in regenerative livers of Mcl-1∆hep mice is 
restored in Mcl-1∆hep/TNFR1-/- mice (Figure 31). 
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 Figure 31: Reduced oncogenic gene expression in Mcl-1∆hep/TNFR1-/- mice. Previously described 
by microarray analysis uncovered target genes, reflecting the malignant character of livers on RNA 
level, were signifcatnly reduced in Mcl-1∆hep by TNFR1 deficiency. (n=3 mice per group, 2 months of 
age). 
 
More important, analysis of the tumor incidence at the age of 1 year revealed a statistically 
significant reduction of the tumor incidence in Mcl-1∆hep/TNFR1-/- mice compared to Mcl-1∆hep 
mice (16% versus 50%, p<0.05, Figure 32). Of note, Mcl-1∆hep/TNFR1-/- mice which 
developed liver tumors at 1 year have had significantly higher transaminase levels at 2 
months of age (Figure 32), again showing the same association between high transaminase 
levels - indicating high apoptotic activity - early in life and tumor development which we 
already have observed in Mcl-1∆hep mice. 
 
Figure 32: Tumor incidence in 12-month-old mice. Significantly reduced tumor development after 
12 months in Mcl-1∆hep/TNFR1-/- mice, compared to Mcl-1∆hep mice. H/E and Collagen IV stainings 
demonstrate invasive tumor growth, Tumor borders are marked by asterisks. Tumor development 
correlated with ALT levels at 2 months (retrospectively analyzed). Scale bar = 100 µm *p < 0.05; **p < 
0.01; ***p < 0.001.  
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In summary, these results indicate that the depletion of the pro-apoptotic TNFR signaling in 
regenerative livers derived from Mcl-1∆hep mice reduces hepatocyte death, liver damage and 
as consequence the malignant character and finally tumorigenesis. 
 
4.3.10 Inhibition of TNFR1 signaling and Caspase 8 reduces the DNA damage 
response and genetic instability in Mcl-1∆hep and TAK1∆hep mice  
Next, I wanted to address whether apoptosis contributes to tumor initiation and progression 
in hepatocarcinogenesis in general or whether the findings are only specific for the Mcl-1∆hep 
model. Therefore, I took advantage of the TAK1∆hep mouse model [49] in which the 
hepatocyte-specific knock-out of TAK1 causes hepatocyte apoptosis and necrosis and mice 
show an early onset of tumorigenesis at around 35 weeks of age. As published by Vucur et 
al, the additional knock-out of Caspase 8 prevented hepatocyte apoptosis, liver damage and 
tumorigenesis, whereas the additional knock-out of RIPK3 prevented necroptosis, but leads 
to high levels of hepatocyte apoptosis and proliferation resulting in increased tumor burden 
[49]. 
In line with my results from the Mcl-1∆hep model, I expected to find a correlation between 
hepatocyte apoptosis, DNA damage and genetic instability in TAK1∆hep mice and 
intercrossings. 
 
 
Figure 33: DNA damage response in Mcl-1∆hep and TAK1∆hep mice. Western blotting revealed 
activation of DNA damage reponse pathways. Reduced levels of activated DNA damage proteins (e.g. 
phosphorylated p53) were detected in livers of Mcl-1∆hep/TNFR1-/- mice compared to Mcl-1∆hep and in 
livers of TAK1/Casp8∆hep mice compared to TAK1∆hep. B) GSEA of RNA microarrays revealing 
statistically significant enrichment of gene associated with DNA replication, DNA damage response 
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and DNA repair. NES = normalized enrichment score. C) Heat map showing reduced expression of 
DNA damage and DNA repair-associated genes by qPCR in livers of Mcl-1∆hep/TNFR1-/- mice and 
TAK1/Casp8∆hep mice compared to single knock-out mice. *p < 0.05; **p < 0.01; ***p < 0.001. A) – C) 
Mcl-1∆hep mice analyzed at 2 months and TAK1∆hep at 6 weeks of age.  
 
First, I analyzed the activation of the DDR pathways on protein and RNA level in highly 
regenerative livers of two-month-old Mcl-1∆hep and 6-week-old TAK1∆hep mice and 
intercrossings. I observed a strong activation of the DDR pathways by immune blotting in 
livers from Mcl-1∆hep, TAK1∆hep and TAK1∆hep/RIP-/- mice, but not in Mcl-1∆hep/TNFR1-/- and 
TAK1/Casp8∆hep mice (Figure 33A). This finding could be confirmed by qPCR for genes 
involved in DNA repair and by GSEA, suggesting a persistent activation of DNA damage 
response pathways in regenerating livers of Mcl-1∆hep and TAK1∆hep mice (Figure 33B,C). 
 
To analyze the DNA damage response in hepatocyte specific, we performed together with 
Dr. Akshay Ahuja (Institute of Molecular Cancer Research, Prof. Massimo Lopes) single cell 
flow cytometry analyses for the intracellular DNA damage markers γH2AX and RPA, a 
protein that binds to single-stranded DNA during DNA repair. Therefore we isolated primary 
hepatocytes from TAK1∆hep mice and TAK1/Casp8∆hep mice and interestingly, a substantial 
amount (~15%) of hepatocytes from TAK1∆hep mice showed signs of DNA damage, whereas 
DNA damage was completely reduced in TAK1/Casp8∆hep mice and not detectable in wild-
type mice (Figure 34). This confirmed the above mentioned findings that livers from 
TAK1/Casp8∆hep are not only completely rescued from apoptotic cell death and hyper-
regeneration but also from DDR.  
 
 
Figure 34: Intracellular analysis of DNA repair by flow cytometry. Isolated primary hepatocytes 
were analyzed by flow cytometry for γH2AX and RPA showing reduced DNA damage in 
TAK1/Casp8∆hep mice compared to TAK1∆hep. 2-4 mice per genotype analyzed at the age of 6 weeks,; 
average percentage of γH2AX+/RPA+ cells indicated. 
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Next, addressed the question whether livers from Mcl-1∆hep and TAK1∆hep mice showed 
genetic instability as described before in human chronically diseased livers and how the 
knock-out of TNFR1 or Caspase 8 would influence genetic instability. I performed Taqman 
copy number assay by qPCR for the same chromosomal fragile sites as previously analysed 
in human tissue and I could detect allelic imbalance in liver tissue from Mcl-1∆hep, TAK1∆hep 
and TAK1∆hep/RIPK3-/- mice (Figure 35). Interestingly, allelic imbalance was significantly 
reduced in Mcl-1∆hep/TNFR1-/- compared to Mcl-1∆hep mice and in TAK1/Casp8∆hep compared 
to TAK1∆hep mice. Conclusively, the pro-apoptotic TNFR1 as well as Caspase 8 signaling 
significantly contributes to genetic instability in regenerative murine livers. 
 
 
Figure 35: Genetic instability in regenerating livers of Mcl-1∆hep and TAK1∆hep mice. Statistically 
lower rate of allelic imbalances (AI) in Mcl-1∆hep/TNFR1-/- mice and TAK1/Casp8∆hep compared to Mcl-
1∆hep and TAK1∆hep mice, respectively. Each square represents one area of microdissected liver tissue 
and lines indicating different areas of the same liver. AI analyzed by Taqman copy number assay, red 
= AI; black= no AI. A) - C): *p < 0.05; **p < 0.01; ***p < 0.001. Mcl-1∆hep mice and intercrossings 
analyzed at 2 months; TAK1∆hep mice and intercrossings analyzed at 6 weeks of age.  
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4.3.11 Proliferation triggers DNA damage in regenerative livers of Mcl-1∆hep and 
TAK1∆hep mice  
As described before, I detected DDR on RNA and protein level as well as increased DNA 
damage by immunohistochemical staining for γH2AX in hepatocytes. To gain insight into the 
source of DNA damage in hyper-apoptotic and hyper-proliferative livers, I next addressed the 
question whether DNA damage derived from apoptotic, proliferative or unaffected/senescent 
hepatocytes. Therefore, I analyzed γH2AX co-stainings with cleaved Caspase 3 (cl.Casp3) 
as apoptosis marker and Ki67 as proliferation marker. 
First, co-staining for γH2AX and cl.Casp3 revealed hepatocytes double-positive for γH2AX 
and cl.Casp3, whereas γH2AX signals in nuclei resulted from fragmentation during the 
apoptotic process. I also detected a substantial amount of hepatocytes positive for γH2AX 
but negative for cl.Casp3. γH2AX single positivity illustrated non-apoptotic hepatocytes 
carrying DNA damage. Immunofluorescence (IF) staining for γH2AX revealed the typical 
nuclear staining pattern in the nucleus (Figure 36). 
 
Figure 36: DNA damage in Mcl-1∆hep and TAK1∆hep mice. Immunohistochemical co-staining for 
γH2AX (brown, indicated by black arrow haeds) and cleaved Caspase 3 (red, indicated by red arrow 
haeds) revealed single and double positive hepatocytes, indicating non apoptotic hepatocytes carrying 
DNA damage in regenerating livers of 6 weeks old mice. Scale bar = 100 µm. 
 
Second, I analyzed IF co-stainings for γH2AX and Ki67 on livers of Mcl-1∆hep and TAK1∆hep 
mice and found a substantial proportion of γH2AX and Ki67 double positive hepatocytes 
(about 10% and 15%, respectively) (Figure 37). Remarkably, the percentage of γH2AX-
double positive hepatocytes was significantly reduced in Mcl-1∆hep/TNFR1-/- mice compared 
to Mcl-1∆hep mice, and also in TAK1∆hep/Casp8∆hep mice compared to TAK1∆hep mice, but not in 
TAK1∆hep/RIP3-/- mice.  
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 Figure 37: Proliferation-associated DDR in Mcl-1∆hep, TAK1∆hep and TAK1∆hep/RIP3-/- mice. IF co-
staining for γH2AX and Ki67 and quantification revealed statistically reduced numbers and rate of 
Ki67-single positive and Ki67/γH2AX-double positive hepatocytes in Mcl-1∆hep/TNFR1-/- mice und 
TAK1/Casp8∆hep compared to Mcl-1∆hep and TAK1∆hep mice, respectively. Arrow heads indicate positive 
nuclei. Statistics shown for Ki67/γH2AX double-positivity. * compared to wild-type, § compared to Mcl-
1∆hep and # compared to TAK1∆hep mice. Mcl-1∆hep mice were analyzed at 2 months and TAK1∆hep at 6 
weeks of age. 
 
Of note, I found only a very low proportion (approximately 1-3%) of γH2AX single positive 
hepatocytes in murine livers (Figure 37B). In summary, γH2AX-staining strongly correlated 
with Ki67-positivity of hepatocytes pointing to hyper-proliferation as the main source of DNA 
damage in Mcl-1∆hep and TAK1∆hep mice.  
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4.3.12 DNA damage in livers of Mcl-1∆hep and TAK1∆hep mice is independent of 
oxidative stress 
The accumulation of reactive oxygen species (ROS) in proliferative cells is well known [67] 
and also ROS as trigger of DNA damage is very well described [68]. Furthermore, ROS as 
driver of steatohepatitis and liver damage has been described recently in NEMO∆hep mice and 
could be prevented by feeding mice with the antioxidant butylated hydroxyanisole (BHA) [69]. 
Livers of Mcl-1∆hep and TAK1∆hep mice showed signs of oxidative stress within hepatocytes as 
characterized by 8-OHdG staining (Figure 38A). Therefore, I wanted to gain insight into the 
contribution of oxidative stress in DNA damage under proliferative conditions and decided to 
analyze Mcl-1∆hep and TAK1∆hep mice which were kept for four weeks on diets supplemented 
with the antioxidants BHA or vitamin E. Antioxidant feeding resulted in a reduction of 8-
OHdG-positive hepatocytes in both genotypes (Figure 38A), indicative of reduced oxidative 
stress in murine livers. 
 
Figure 38: Antioxidant treatment of mice does not reduce proliferation-associated DDR. A) 
Livers of Mcl-1∆hep and TAK1∆hep mice on normal chow but not on antioxidant diets showed 8-OHdG 
positive hepatocytes, indicating oxidative stress. B) and C) Livers of mice kept for four weeks on 
antioxidant diet, Mcl-1∆hep on a Vitamin E supplemented and TAK1∆hep on a BHA supplemented diet 
showed no reduction of hepatocytes proliferation or γH2AX positivity. Arrow heads indicate positive 
nuclei.  
 
As next step, I analyzed the liver sections for γH2AX and Ki67 co-staining and found no 
obvious reduction in hepatocyte proliferation in antioxidant-fed mice versus control mice on 
normal diet. In addition, the rate of proliferating hepatocytes positive for γH2AX was also not 
altered compared to knock-out mice on normal diet (Figure 38B).  
I concluded that ROS does not contribute to hepatocyte proliferation in Mcl-1∆hep and 
 
54 
 
TAK1∆hep mice and even more important that oxidative stress is not crucial for hepatocyte-
specific DNA damage. Therefore, I concluded that proliferation is the main source of DNA 
damage in livers of Mcl-1∆hep and TAK1∆hep mice, most probably due to replicative stress 
trigged DNA damage, e.g. replication fork stalling and collapse and subsequent DNA strand 
breaks [70, 71]. 
 
4.3.13 Proliferation-associated replicative stress causes DNA damage in murine and 
human regenerating livers, independent of apoptosis 
DDR activation in HCC and corresponding non-tumor tissue has been described in human 
hepatitis B and C infected livers [51], as wells as activation of DDR in hyper-proliferative 
livers of mice upon partial hepatectomy. But in this study, partial hepatectomy was performed 
in 9-month-old mdr2-/- mice at a time-point when livers are strongly inflamed and show pre-
neoplastic lesion [72]. 
To address the question whether proliferation per se - independent of apoptosis - is able to 
trigger DNA damage in hepatocytes of regenerating wild-type livers, we performed partial 
hepatectomy in collaboration with the laboratory of 
Prof. Sabine Werner (ETH Zürich) and I analyzed 
livers for DNA damage response in respect to 
hepatocyte proliferation. 
Indeed, DDR was detectable by immunoblotting, 
immunohistochemical and IF staining for γH2AX in 
livers of wild-type mice correlating with proliferative 
activity peaking at 48 hours post PHX, whereas no 
sign of apoptosis could be detected (Figure 39). 
 
 
 
 
Figure 39: Proliferation-driven DDR in a non-
apoptotic environment of acute regenerating wild-
type livers. A) Western blotting and B) IHC staining for 
γH2AX revealed DDR-positive hepatocytes. C) 
Quantification confirmed significantly elevated numbers 
of γH2AX-positive hepatocytes at proliferative peak at 
48h post PHX. Wild-type mice at the age of 2 months 
were analyzed at indicated time-points post 2/3 PHX. 
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Hyper-proliferation-induced DNA damage in hepatocytes was confirmed by γH2AX and BrdU 
co-stainings following BrdU incorporation in mice after PHX. Almost 75% of all BrdU-positive 
hepatoctyes in regenerating livers showed γH2AX signals and only very few γH2AX single 
positive cells could be detected (Figure 40). This pointed out that almost exclusively actively 
replicating hepatocytes show DNA damage response.  
 
 
Figure 40: Proliferation-associated DDR in 
actively replicating cells confirmed by BrdU 
incorporation. A) and B) BrdU incorporation 
combined with γH2AX staining demonstrated 
proliferation-associated DNA damage in replicating 
hepatocytes. Arrow heads indicate positive nuclei. *p 
< 0.05; **p < 0.01; ***p < 0.001. *comparing Ki67-
single positive cells, #comparing double-positive cells 
of untreated and operated wild-type mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further investigate whether hyper-proliferative hepatocytes indeed show DNA strand 
breaks and γH2AX is a robust marker for DNA damage in proliferating hepatocytes, and does 
not only occur during replication independent of DNA damage, pulse field electrophoresis 
(PFGE) was performed and clearly demonstrated DNA strand breaks in hepatocytes of PHX 
mice (Figure 43). 
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Next, I wanted to find out whether this finding of proliferation-induced DDR in artificially 
increased proliferation rates of hepatocytes in PHX mice is also transferable to human liver 
regeneration. Therefore, I analyzed liver specimen from patients who underwent two-step 
hepatectomy called ALPPS (associating liver partition and portal vein ligation for staged 
hepatectomy). ALPPS is usually performed in patients with extensive tumors in the liver, e.g. 
colorectal metastasis to avoid postoperative liver failure due to insufficient functional liver 
mass. Precisely, during the first step to stimulate liver hypertrophy of the left lobe, the left and 
right liver lobe is split and the right portal vein is ligated. After 2 weeks, the right liver lobe 
carrying the initial tumor is resected [73].  
I analyzed γH2AX-Ki67 co-stainings of liver needle biopsies of the right and left liver lobes of 
step1 and step2 of ALPPS patients and I could detect a strong correlation of γH2AX and Ki67 
positivity in liver sections derived from the left lobe (Figure 40). 
 
Figure 41: Proliferation-associated DDR in acute regenerating human livers. A) and B) IF co-
staining for γH2AX and Ki67 and quantification demonstrated a substantial amount of γH2AX-positive 
and proliferating hepatocytes. in the acute regenerating left liver lobe. Liver biopsies of each liver lobe 
of n=6 patients prior to and after (right) portal vein ligation and liver transsection (PVL/LT) were 
analyzed. Arrow heads indicate positive nuclei. *p < 0.05; **p < 0.01; ***p < 0.001. *comparing Ki67-
single positive cells, #comparing double-positive cells. 
 
 
  
*** 
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4.3.14 Impaired DDR of proliferation-induced DNA damage in Caspase 8-deficient 
hepatocytes 
As described above, TAK1/Casp8∆hep mice were completely lacking DDR at 6 weeks of age 
and Mcl-1∆hep/TNFR1-/- mice show reduced DDR whereas livers from Mcl-11∆hep, TAK1∆hep 
and TAK1∆hep/RIP3-/- were strongly positive. Comparing different genotypes also uncovered 
different rates of hepatocyte proliferation, potentially leading fo fals-positive conclusion about 
proliferation-induced DDR in analyzed murine livers. Therefore, to address the question 
whether Caspase 8 or further proteins directly contribute to DDR or whether the proliferation 
rate of hepatocytes in the different genotypes is responsible for proliferation-associated DDR. 
 
 
Figure 42: Hyperproliferation-induced DDR is significantly impaired in Casp8∆hep mice. A) and B) 
IF staining for Ki67 and γH2AX and quantification revealed a significant reduction γH2AX-positive 
proliferating hepatocytes in Casp8∆hep mice, compared to wild-type and RIPK3-/- and TNFR1-/- mice. 
n=3-6 mice analyzed 48h post PHX. Arrow heads indicate positive nuclei. *p < 0.05; **p < 0.01; ***p < 
0.001. *comparing Ki67-single positive cells, #comparing double-positive cells.   
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I analyzed livers of Casp8∆hep mice for DNA damage and DDR 48h post PHX. By PFGE 
quantification, DNA strand breaks were detectable in livers of Casp8∆hep mice to a similar 
level as in wild-type mice (Figure 43). Additionally, Ki67 staining revealed slightly reduced 
hepatocyte proliferation in Caspase 8 deficient livers (~40%), compared to wild-type livers 
(~50%) (Figure 42B). Most strikingly, γH2AX/Ki67 co-staining revealed significantly less than 
10% of γH2AX-positive proliferating hepatocytes in Casp8∆hep mice compared to 30% in wild-
type mice (Figure 42A). In summary, these findings indicated the presence of DNA strand 
breaks in Caspase 8-deficient hepatocytes under proliferative conditions, but an impaired 
DDR. 
 
 
Figure 43: DNA strand breaks (DSB) detectable 48h 
post PHX. A) and B) PFGE analysis revealed DSB in 
livers derived from wild-type mice 48h post PHX compared 
to untreated mice. The amount of DSBs (black arrow) was 
increased in hepatocytes from Caspase 8 deficient livers. 
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4.3.15 Impaired DDR in Casp8∆hep livers upon chemical induction of DNA strand 
breaks 
I next asked whether Caspase 8 is directly or indirectly involved in DDR upon induction of 
DNA strand breaks - independent of apoptotic or proliferating stimuli. Therefore, I decide to 
treat mice with the genotoxic agent doxorubicin (DX) which leads to the intercalation of 
doxorubicin into the DNA, blockage of DNA topoisomerases, disaggregation of the enzyme-
DNA complex and subsequently to DNA double strand breaks in hepatocytes [74, 75].  
Wild-type mice treated with doxorubicin showed a strong DDR 12h post treatment in 
hepatocytes reflected by almost 100% positivity for γH2AX (Figure 44A). Strikingly, Caspase 
8-deficient hepatocytes were negative for γH2AX 12h after chemical induction of DNA strand 
breaks (Figure 44A and B), whereas γH2AX-positivity could be detected in Kupffer cells. 
 
 
Figure 44: Caspase 8 is crucial for DDR in hepatocytes. A) Hepatocytes of Casp8∆hep mice are 
negative for γH2AX following doxorubicin (DX)-induced DNA damag, but B) and C) demonstrate DNA 
strand breaks by PFGE. No significant difference in γH2AX staining between untreated and pan-
caspase inhibitor (QVD-OPH)-treated wild-type mice. 
 
 
Of note, doxorubicin at this concentration was not hepatotoxic and no apoptotic hepatocytes 
or elevated aminotransferase levels 12h post injection could be observed (Figure 45). In 
addition doxorubicin-induced DDR could be detected in several other organs of wild-type and 
Casp8∆hep mice (Figure 46). 
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 Figure 45: DX treatment does not lead to hepatocyte cell death 12h post treatment. A) Liver 
sections of treated mice were analyzed by cleaved Caspase 3 staining and B) aminotransferase levels 
determined. 
Next, I addressed the question whether Caspase 8 is directly involved in the execution of 
DNA strand breaks upon doxorubicin treatment or in the recognition of DNA strand breaks 
and the subsequent activation of the DNA repair machinery. 
Indeed, livers of wild-type as well as Casp8∆hep mice showed DNA strand breaks in PFGE 
and interestingly the amount of DNA strand breaks in Caspase 8-deficient livers as analyzed 
by semi-densitometric quantification were higher compared to wild-type mice (Figure 43). 
This indicated the inducation of DSBs but impaired DDR in Caspase 8-deficient hepatocytes. 
Eventually, DNA strand breaks in wild-type hepatocytes were already repaired whereas 
Caspase 8-deficient cells still carried the doxorubicin-induced and unrepaired DNA strand 
breaks post doxorubicin treatment. γH2AX is phosphorylated by the key mediators ATM, ATR 
and DNA-PK for the induction of the DNA repair machinery, thus my results clearly showed 
that DNA strand breaks were induced in Caspase 8-deficient hepatocytes, but not 
recognized and apparently not repaired by the cell intrinsic DNA repair machinery in the 
same time-frame as seen in wild-type hepatocytes. 
 
Figure 46: DX-induced DDR in 
other organs. Upon DX-
treatment, γH2AX positive cells 
(black-arrow heads) were 
detectable in heart, lung and kidney 
of wild-type and Casp8∆hep mice 
12h post injection. 
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4.3.16 Catalytic activity of Caspase 8 is not required for sensing of DNA damage 
Caspase 8 is originally described as an initiator caspase for apoptotic cell death in response 
to activated death-inducing TNF family receptors. Caspase 8 is initially produced as an 
inactive monomeric pro-caspase that requires dimerization and cleavage into a large and a 
small catalytic active subunit for activation. 
Assembly into dimers or multi-protein complexes, e.g. death-inducing signaling complex 
(DISC) or ripoptosome, is facilitated by various adapter proteins that bind to specific regions 
in the pro-domain of the pro-Caspase 8. The inactive DISC is bound to the intracellular 
domain and upon death receptor activation the Casp8/RIPK1/RIP3/FADD complex leads to 
the induction of apoptosis in the cytoplasm [76] . 
Binding of cFLIP to Caspase 8 in this complex blocks Caspase 8 activity and leads to the 
activation of RIP3 and subsequent necroptosis – the latter complex is also described as 
necrosome [16]. However, the Casp8/RIPK1/RIP3/FADD complex can also be formed 
independent of death receptors signaling upon cellular stress and can lead to the induction of 
both, apoptosis or necroptosis and is referred as ripoptosome [77]. 
Based on this knowledge on Caspase 8 and its function as a scaffolding protein in a multimer 
complex as well as catalytic protein, I first investigated the role of the catalytic subunit in 
doxorubicin-induced DNA damage. Therefore, I treated wild-type mice 1h before doxorubicin 
injection with the pan-caspase inhibitor QVD-OPH to block the catalytic activity of the small 
Caspase 8 subunit and I analyzed liver tissue 12h post treatment. In a second experiment, I 
also pre-treated mice with 
QVD-OPH and repeated the 
treatment 24h post doxorubicin 
injection and collected liver 
tissue after 48h. The 
quantification of γH2AX positive 
hepatocytes revealed almost 
100% positivity and I could not 
detect a difference to 
doxorubicin-treated wild-type 
mice (Figure 47).  
 
Figure 47: Catalytic activity is not involved in DDR in hepatocytes. Blocking the catalytic subunit 
of caspases with pan-caspase inhibitor QVD-OPH in wild-type mice does not influence DDR upon DX- 
treatment. Arrow heads indicate positive nuclei. 
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Of note, the pan-caspase inhibitor QVD-OPH does not prevent cleavage of Caspase 8 but 
directly blocks the catalytic domain of all caspases. Pre-treatment of wild-type mice with 
QVD-OPH successfully rescued LPS/D-Gal induced hepatocyte apoptosis (data not shown). 
 
In conclusion, the catalytic active small subunit of Caspase 8 did not contribute to DDR in 
hepatocytes, pointing towards a potential role of Caspase 8 as catalytic-inactive protein in 
DDR. Therefore, I aimed at gaining insight into the role of the binding partners of Caspase 8 
and focused on the ripoptosome complex with RIPK1 as central kinase.  
 
4.3.17 TNFR and NFκB signaling do not contribute to the initiation of DDR 
The formation of the pro-apoptotic TNFR signaling complex comprising Caspase 8 and 
RIPK1 and the activation of Caspase 8 largely depends on active TNFR signaling. Thus, I 
next addressed the question whether TNFR signaling is required for DDR.  
In addition, the pro-survival NFκB pathway has been linked to DDR. Upon genotoxic stress 
and DDR activation, ATM-dependent phosphorylation and translocation of NEMO into the 
cytoplasm has been shown to stimulate cell survival via NF-κB -dependent expression of 
pro-survival genes [78, 79]. ATM-dependent activation of IKKβ and nuclear translocation of 
activated IKKβ was shown to be essential for prolonged ATM activation in the late phase of 
DNA repair in cells treated with alkylating agents [80]. Based on these results, I addressed 
the question whether IKKβ is required for the initiation of DNA repair and besides is essential 
for the prolongation of DNA repair in hepatocytes. 
 
 
Figure 48: TNFR1 and NFκB 
signaling does not contribute to 
DDR upon DX treatment. 
Genetically inhibited TNFR1 or NFκB 
signaling by challenging TNFR1-/- and 
IKKβ∆hep mice, with DX does not 
influence DDR. γH2AX staining 
revealed no difference in the staining 
pattern of hepatocytes 12h post 
treatment. Arrow heads indicate 
positive nuclei. 
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Interestingly, treatment of IKKβ∆hep and TNFR1/2-/- mice with doxorubicin had no effect on 
γH2AX positivity at 12h and 48h post treatment as already seen in treated wild-type mice 
(Figure 48, Figure 51). Therefore, I concluded that IKKβ and the TNFR complex or signaling 
via TNFR and IKKβ are not required for the initiation of DDR. 
 
4.3.18 RIPK1 is a direct binding partner of Caspase 8 and contributes to the initiation 
of DDR 
Next, I focused on RIPK1 in doxorubicin-induced DNA damage to uncover its potential role in 
DNA damage. RIPK1 knock-out mice are embryonic lethal and conditional knock-out mice 
were not available. Thus, I used the Necrostatin1 (Nec1), regarded RIPK1-specific inhibitor 
which binds and stabilizes RIPK1 in an inactive conformation and therefore protects the 
phosphorylation site from activation [81].  
I pre-treated wild-type mice with Nec1 before doxorubicin injection and repeated the 
treatment after 24h, respectively. Interestingly, treatment with Nec1 abolished γH2AX 
positivity of hepatocytes in wild-type mice at 12h as well as 48h post doxorubicin injection 
(Figure 49, Figure 51), whereas DSB were observed by PFGE (Figure 50). γH2AX negativity 
indicated that DNA strand break are not recognized because the γH2AX phosphorylation 
certainly did not occur in the presence of inhibited RIPK1. 
 
 
Figure 49: Pharmacological inhibition of RIPK1 
abrogates DDR in hepatocytes. Livers of wild-typemice, 
pre-treated with Nec-1, are negative for γH2AX 12h post 
DX treatment, compared to inhibitor-free and DX treated 
wild-type mice. Arrow heads indicate positive nuclei. 
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 Figure 50: DSB in livers of QVD-OPH or Nec-1 
treated and DX challenged wild-type mice. A) 
and B) Inhibitor pre-treatment has no impact on 
the induction of DSB (black arrow haed) in wild-
type livers. Livers from lethally irradiated wild-
type mice (IR, 20 Gray) were used as positive 
controls. 
 
 
 
At the later time-point 48h post doxorubicin 
treatment, wild-type hepatocytes showed a 
decrease in γH2AX positivity and about 75% 
of hepatocytes were found γH2AX positive 
indicating the gradually fading of the DNA 
repair process (Figure 51). In contrast, 
Caspase 8 deficient hepatocytes and Nec1-
treated mice showed an onset of γH2AX 
positivity 48h post treatment and a maximum of around 30% of hepatocytes were found to be 
positive for γH2AX. This suggests a delayed DDR in Caspase 8-deficient and RIPK1 inhibited 
hepatocytes and later time-points have to be analyzed in vivo and further experiments are 
planned. 
 
In summary, the results obtained from the Nec1 experiments and the known function of 
Caspase 8 and RIPK1 as direct binding partners led me hypothesize that these proteins 
contribute to DNA repair as a complex and not as monomers. 
 
 
 
 
65 
 
 Figure 51: Quantification of γH2AX-positive hepatocytes of DX-treated Casp8∆hep or inhibitor 
treated mice. Liver sections were analyzed 12h and 48h post DX treatment and the amount γH2AX-
positive hepatocytes calculated. Nuclei carrying >5 γH2AX-positive foci were counted as positive, 
negative and nuclei with 0-5 γH2AX-positive foci were counted negative for DDR. The percentage of 
γH2AX-positive hepatocytes was calculated related to all counted hepatocytes and percentage plotted 
at the y-axis. Wild-type mice were pre-treated 1h prior the experiment with QVD-OPH or Nec1. 
Inhibitor treatment was repeated after 24h for the analysis of the 48h time-point. n=3 of Casp8∆hep 
mice were analyzed at 12h and 48h, n=6-8 mice were used all other conditions. 
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4.3.19 RIPK1 kinase activity and cFLIP but not RIPK3 are required for DDR 
Next, I investigated whether other potential binding partners of Caspase 8 or molecules that 
are related to Caspase 8 and RIPK1 might contribute similarly to DDR.  
As described above, pro-Caspase 8 is part of the TNFR signaling complex IIa and IIb, mainly 
consisting of the binding partner RIPK1, FADD and cFLIP. It has been previously reported 
that the RIPK1 is required for the DDR in vitro, and that in vitro knock-down of RIPK1 in 
different lung cancer cell lines leads to a decreased and delayed response of the DNA repair 
proteins [82]. Pharmacological inhibition of RIPK1 by Nec1 in doxorubicin-treated wild-type 
mice resulted in a significantly decreased rate of γH2AX-positive hepatocytes compared to 
mice without necrostatin treatment. However, Nec1 inhibits RIPK1 scaffolding as well as 
kinase activity at the same time [81] and I took advantage of kinase-dead knock-in mice, 
carrying the intact full length but kinase inactivated RIPK1 (RIPK1KI-DK mice). Indeed, 
RIPK1KI-DK mice showed significantly reduced DDR 12h post treatment (Figure 52), clearly 
indicating the kinase activity and not the scaffolding function of RIPK1 as crucial for DDR.  
 
 
Figure 52: Genetic inactivation of RIPK1 kinase domain and cFLIP, but not RIPK3 abrogates 
DDR. RIPK1 kinase activity and cFLIP full length protein are required for DDR in hepatocytes upon 
DX-induced DSB and genetic inhibited or deficient hepatocytes are negative for γH2AX. DX-treated 
RIPK3-/- mice showed a typical dotted pattern of γH2AX-positive as seen in wild-type hepatocytes and 
RIPK3 is apparently not involved in DDR. Arrow heads indicate positive nuclei. 
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In the cellular context, the kinase function of RIPK1 is only activated in the presence of 
inactivated Caspase 8 and as described above, the catalytic activity is not essential for DDR. 
Caspase 8 is mainly inhibited by its master regulator and inhibiting binding partner cFLIP. 
Therefore, I decided to treat mice with a hepatocyte-specific knock-out of cFLIP (cFLIP∆hep 
mice) and I observed again significantly impaired DDR 12h post injection (Figure 52).  
Furthermore, I challenged mice devoid of RIPK3-/-, the essential binding factor of the 
necrosome to discriminate between the pro-apoptotic TNFR signaling complex IIa, the 
ripoptosome (both complexes devoid of RIPK3) and TNFR signaling complex IIb, called 
necrosome. RIPK3-/- mice showed clear evidence for DDR 12h post treatment and no 
difference was detectable compared treated wild-type mice (Figure 52, Figure 53).  
 
 
Figure 53 DDR in DX-treated mice under all genetic and pharmacological conditions. 
Quantification of γH2AX IF staining on livers sections of mice post DX-induction of DSBs. Nuclei 
carrying >5 γH2AX-positive foci were counted as positive and nuclei with 0-5 γH2AX-positive foci were 
counted negative for DDR. The percentage of γH2AX-positive hepatocytes was calculated related to 
all counted hepatocytes and percentage plotted at the y-axis. n= 3 Casp8∆hep, n=6 QVD-OPH or Nec 
treated wild-type mice, n=5 of RIPK1KI-DK mice, n=5 RIPK3-/-, n=4 Casp8/RIPK3-/-, n=3 cFLIP∆hep and 
n=6 TNFR1/2-/- mice were analyzed. 
 
In summary, I uncovered central molecules of the ripoptosome and TNFR signaling complex 
IIa, comprising of Caspase 8, RIPK1 and cFLIP [77, 83], to be involved in DDR, potentially 
executing a function as dynamic signaling platform in response to genotoxic stress. Based on 
the previous observation that DDR is taking place independent of TNFR signaling but TNFR 
complex IIa and IIb formation depends on TNFR activation, I hypothesized that most likely 
the ripoptosome complex is crucial to mediate DDR upon DSB.  
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4.3.20 JNK as downstream mediator of Caspase 8 and RIPK1-dependent DDR in 
hepatocytes 
Next, I sought to identify the signaling pathways involved in the downstream signaling of the 
newly identified DDR mechanism. To this aim, livers of doxorubicin-treated mice were 
stained for the downstream signaling candidates pCHK2 and pCHK1, indicating activated 
ATM or ATR signaling, respectively.  
Due to the RIPK1 kinase dependent DDR, I decided to also analyze the activity of JNK, 
because studies provided evidence that JNK might be regulated by RIPK1 [82, 84] In 
addition, JNK activity has been linked recently to DDR and H2AX described as substrate for 
JNK in vitro [85, 86]. Therefore I decided to analyze the nuclear translocation of the JNK-
target c-Jun  (cJun) as indirect marker of JNK activity.  
No substantial number of pCHK2, pCHK1, or pcJUN-positive hepatocytes was found in livers 
of untreated wild-type mice under steady-state conditions. After doxorubicin treatment of 
wild-type mice, no pCHK2- or pCHK1-positive hepatocytes were found indicating inactive 
ATM and ATR signaling upon doxorubicin-induced DNA strand breaks. Strikingly, livers of 
wild-type mice revealed pcJUN positivity in hepatocytes upon doxorubicin treatment, 
whereas Caspase 8 and cFLIP deficient and RIPK1 inhibited hepatocytes were negative for 
pcJUN as well as for pCHK2 and pCHk1 (Figure 54).  
 
 
Figure 54: DNA damage signaling in livers of DX-treated mice. Stainings for downstream kinases 
pCHK1 (indicative for ATR signaling), pCHK2 (indicative for ATM signaling) and pcJUN (indicative for 
JNK signaling) demonstrated exclusively activated JNK signaling 12h post DX-induced DNA damage 
in wild-type mice. JNK signaling was abolished in Caspase 8, cFLIP and RIPK1 kinase inhibited 
mouse livers.  
QVD-OPH treatment did not abrogate pcJUN staining and JNK signaling appeared to be 
downstream of the non-catalytic, full length Caspase 8. As expected, pcJUN-positive 
hepatocytes were detectable after doxorubicin treatment in RIP3-/- mice and TNFR1/2-/- mice, 
indicating that JNK activity upon doxorubicin treatment is exclusively downstream of 
Caspase 8 or downstream of a conceivable Caspase 8/RIPK1/cFLIP signaling complex. 
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Next, I addressed the question whether JNK directly phosphorylates H2AX at Ser139 and 
subsequently induces DDR and I analyzed IF double-stainings for phosphorylated JNK as 
well as γH2AX. Stainings revealed a strong co-localization of activated JNK and γH2AX 
(Figure 55), clearly indicating JNK as responsible kinase for the induction of DDR in 
hepatocytes upon DNA damage. 
 
Figure 55 Activated JNK co-localizes with γH2AX during DDR. IF co-staining for pJNK and γH2AX 
revealed a strong co-localization in wild-type livers 12h post induction of DSB. Activation of pJNK and 
γH2AX was abolished in Caspase 8, cFLIP and RIPK1 inhibited mouse livers. 
 
Next, to finally prove whether JNK is indeed mediating DDR, I decided to treat mice that lack 
both c-JUN N-terminal kinases 1 and 2 specifically in hepatocytes (JNK1/2∆hep mice) with 
doxorubicin and analyzed for DDR. Indeed, in line with my hypothesis, JNK1/2∆hep mice 
showed impaired DDR and significant less γH2AX-positive hepatocytes, compared to Cre-
negative control littermates (Figure 56). 
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 Figure 56: DDR is abolished in JNK deficient hepatocytes Livers of DX-challenged JNK1/2∆hep 
mice are negative for DDR marker γH”AX 12h post treatment. Arrow heads indicate positive nuclei. 
 
Taken together, these data suggested that JNK activation and JNK-dependent 
phosphorylation of H2AX at Ser139 is downstream of the RIPK1/Caspase 8/cFLIP signaling 
platform. This signaling platform comprising a non-catalytic, scaffolding function of Caspase 
8 and its master repressor cFLIP and a kinase-dependent function of RIPK1 but not RIPK3 
and TNFR1, potentially illustrates the ripoptosome complex and represents a hithero 
unknown ATM- and ATR-independent DDR pathway.  
Here, I could show that signaling via the Casp8/RIPK1/cFLIP-JNK axis is essential to initiate 
DNA repair in response to DSBs in murine hepatocytes.  
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4.3.21 JNK mediated DDR is detectable in regenerative human livers  
Finally, I addressed the question whether the concept of JNK-mediated DDR is transferable 
from the doxorubicin mouse model to the human liver.  
Indeed, pJNK/γH2AX staining revealed a strong co-localization in hepatocytes in constantly 
regenerating livers of CLD patients (HBV, HCV, NASH and AIH) as well as in acute 
regenerating livers of patient after two-step hepatectomy (ALPPS) (Figure 57). 
 
 
Figure 57: Co-localization of pJNK and γH2AX in tissue of regenerating human liver tissue. IF 
co-staining for pJNK and γH2AX revealed a strong co-localization in chronically (HBV,HCV,NASH, 
AIH) and acute (post PVL/LT) regenerating livers, but not in control livers. Arrow heads indicate 
positive nuclei. 
 
In summary, starting from human CLD and using several genetic and experimental in vivo 
approaches (knock-out mouse models, PHX and doxorubicin challenge), I uncovered a novel 
DNA repair mechanism in hepatocytes. I could show a crucial non-apoptotic function of 
Caspase 8 as part of a complex comprising Caspase 8/RIPK1/cFLIP, indicative of signaling 
platform called ripoptosome, mediating DNA repair of DSB via JNK signaling. 
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4.3.22 Caspase 8 is required for DDR in U2OS cells  
Based on the previously described results, I next addressed the question whether Caspase 8 
is required for the initiation of DDR in general or whether the mechanism is hepatocyte-
specific effect. Therefore, I decided to perform in vitro experiments using a U2OS cell, an 
osteosarcoma cell line expressing wild-type p53 which is a well-established cell line to study 
DNA repair in vitro [87].  
Strikingly, doxorubicin-induced DSB led to the activation of γH2AX and JNK 15min post 
doxorubicin challenge, but not for ATM or ATR activation. At the same time, pre-treatment 
with a JNK inhibitor (SP600125) or Caspase 8 knock-down showed significantly decreased 
levels of γH2AX (Figure 58, red boxes) as well as JNK activation, compared to treated control 
cells. Of note: preliminary time course experiments showed a delayed activation of ATM and 
pCHK2 signaling 4h post doxorubicin treatment pointing towards a Caspase 8/JNK-
dependent early phase-DDR mechanism in combination with ATM/pCHK2 responsible for 
late-phase response. Additionally, very long exposure revealed a weak ATM activation in 
Caspase 8-knock-down or SP600125 treated control cells, indicating a causal relationship 
and a cross-link between Caspase 8/JNK and ATM/pCHK2 signaling pathways (Figure 58). 
However, further in vitro experiments have to be performed to understand this relationship.  
 
In summary, I could show that the Caspase 8/JNK-mediated DDR is not only limited to 
hepatocytes and potentially presents a common mechanism for the repair of DSB. 
 
Figure 58: Impaired JNK signaling and DDR in Casp8 knock-down cells. Lentiviral knock-down of 
Caspase 8 in U2OS cells reduced pJNK and γHAX signals 15min post DX-treatment (1mM). 
Pharmacological inhibition of JNK (JNKi, SP600125) but not inhibition of ATM (ATMi, Ku-55933) of 
control cells prevented an increase in γH2AX upon DX treatment. Irradiated control cells (10Gray, 2h 
prior to the experiments) were used as positive controls. 
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4.3.23 Caspase 8 does not contribute to irradiation-induced DDR 
Based on the previously described results about the control of ATM by Caspase 8/RIPK1 in 
DDR, I next addressed the question whether Caspase 8/RIPK1 contribute to DDR in general. 
ATM as “guardian of the genome” [88] is mainly activated upon detection of DSB and is also 
cross-activated via ATR in single strand breaks (SSB) repair, but not in irradiation (IR)-
induced DNA damage. IR induced DNA damage lesions, e.g. inter-strand crosslinks, 
pyrimidine dimers, are repaired by non-homologous end joining (NHEJ) mediated by DNA-
PK. In contrast, DSB are repaired by ATM-mediated homologous recombination (HR) [88], 
showing a high degree of redundancy and collaboration between ATM and ATR mediated 
repair of SSB. 
I analyzed livers of wild-type as well as Casp8∆hep mice 30min post irradiation with 1Gy. 
Interestingly, quantification of γH2AX staining of Casp8∆hep mice showed no difference in the 
numbers of γH2AX positive hepatocytes compared to wild-type mice (Figure 59).  
 
 
Figure 59: IR induced DNA damage in wild-type and 
Caspase 8-deficient hepatocytes. Analysis of γH2AX 
stainings of whole body irradiated (1Gy) mice revealed 
positive hepatocytes in Casp8∆hep and wild-type mice. 
n=3 Casp8∆hep and n=6 wild-type mice were analyzed 
30min post irradiation. 
 
 
 
 
 
 
In conclusion, Caspase 8-deficiency did not affect DDR in hepatocytes upon IR with 1Gy. IR-
induced DNA damage mainly leads to base damage (base loss and change, base 
oxidization, pyrimidine dimers, DNA cross links) and DNA-protein cross-links which are 
repaired by mismatch or nucleotides excision signaling pathways (e.g. mediated by DNA-PK) 
and only low level of double strand breaks are induced and repaired by homologous 
recombination  
Finally, this finding suggested that exclusively DSB are repaired by the Caspase 
8/cFLIP/RIPK1-JNK axis. 
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4.4 Discussion 
In this study, I uncovered a novel and unexpected role of the cell death executer molecules 
Caspase 8, cFLIP and RIPK1 in maintaining genetic integrity by controlling JNK activation 
and JNK-dependent repair of DSBs. Precisely, I described a doubled-edged function of 
Caspase 8 in hepatocytes by driving apoptosis-dependent hyper-proliferation and 
tumorigenesis on one hand and by mediating DDR and activation of JNK representing an 
anti-tumorigenic mechanism for Caspase 8 on the other hand.  
The involvement of Caspase 8` binding partners and the TNFR-independent function 
suggest the ripoptosome complex as responsible multi-protein complex. Most probably, the 
catalytic inactive pro-form of Caspase 8 serves as a binding partner for cFLIP and especially 
RIPK1, in contrast to its catalytic function which promotes tumor development by creating a 
hyper-proliferative and genotoxic environment in regenerating livers [49]. RIPK1 requires 
Caspase 8 as scaffold partner to stabilize its kinase active conformation [89].  
This finding indicates a novel pro-survial function of the ripoptosome complex as dynamic 
signaling platform, controlling cell fate in response to cellular stress (Figure 60). 
 
4.4.1 Hepatocyte apoptosis in regenerative livers of CLD patients and murine livers 
correlates with DDR, genetic instability and tumor development 
It is well known that increased levels of apoptosis are a hallmark of many liver diseases 
including viral hepatitis and a protective mechanism to eliminate potentially damaged 
hepatocytes [6, 7, 90, 91]. Recently, it was shown in mouse models that HCC development 
occurs in an environment of chronically increased levels of hepatocyte apoptosis [45, 48, 49], 
and in humans with chronic HBV infection it has been shown that ALT levels – reflecting 
(apoptotic) hepatocyte death - are independent predictors of risk for HCC development [92].  
Here, I provide arguments, in human as well as in mice, that chronically increased levels of 
hepatocyte apoptosis are not only associated with liver tumor development, but might be a 
major, potentially most relevant determinant of HCC development: 1) Mcl-1∆hep mice which 
developed liver tumors at 1 year had higher transaminase levels early in their life reflecting 
higher levels of hepatocyte apoptosis, compared to Mcl-1∆hep mice without tumor 
development. 2) Genetically reducing levels of hepatocyte apoptosis in Mcl-1∆hep/TNFR1-/- 
mice resulted in reduced tumor incidence, similarly as also reported for Mcl-1∆hep mice with 
reduced apoptosis due to additional BAK deficiency [45], or shown for TAK1∆hep mice with 
ablation of apoptosis due to additional Caspase 8 deficiency [49]. 3) As observed in Mcl-1∆hep 
mice, also Mcl-1∆hep/TNFR1-/- mice revealed a strong correlation between transaminase 
levels early in their life and later tumor development. 4) Retrospective analyses of a patient 
cohort with chronic HCV infection revealed that patients who developed HCC during the 
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course of their disease had higher transaminase levels compared to case-control matched 
pairs respectively. Taken together, these findings strongly suggest that the accumulated 
amount of liver cells apoptosis quantitatively determines the risk of HCC development.  
Interestingly, it has been explained just recently in a mathematical approach that the number 
of stem cell divisions is more likely the reason for 2/3 of all cancer types due to stochastic 
(replicative) factors versus environmental and inherited factors, counting only for 1/3 of 
cancer types [93]. By plotting the lifetime incidence of various cancers against the estimated 
number of normal stem cell divisions in the corresponding tissues over a lifetime, they found 
a strong correlation especially in regenerative organs. HCC in HCV-infected patients showed 
the fifth highest correlation and colorectal cancer in FAP patients the highest correlation [93]. 
Therefore, they concluded that the majority of cancer is due to "bad luck," meaning random 
mutations arising during DNA replication in normal, noncancerous stem cells [93]. In my own 
study, showing HCC development in patients with elevated aminotransferase levels 
(apoptotic cell death) in the cohort of HCV-infected patients (MELD study) as well as several 
mouse models including intercossings, I could show experimentally that is possible to 
manipulate the previous defined stochastic event called “bad luck”. Since hepatocyte 
apoptosis is driving compensatory hyper-proliferation (reflecting liver regeneration) and 
proliferation-associated DNA damage, I concluded that hepatocyte apoptosis is the major, 
potentially most relevant determinant of HCC development. 
 
4.4.2 Mcl-1∆hep mice – a suitable model to study hepatocarcinogenesis  
To study to the impact of hepatocyte apoptosis in regenerative livers and 
hepatocarcinogenesis in more detail, I took advantage of the Mcl-1∆hep mouse model. Mcl-
1∆hep mice were published to develop HCC with a 50% incidence after 12 months of age and 
100% after 18 months of age [48]  
Interestingly, Mcl-1 could be seen as tumor-suppressing protein in the liver only by inhibiting 
hepatocyte apoptosis. It has been show that the genetic deletion of the pro-apoptotic counter 
player Bak in Mcl-1 deficient hepatocytes completely rescued liver tumorigenesis [45]. This 
finding also implicates that Mcl-1 has no anti-carcinogenic function besides preventing 
hepatocyte apoptosis which eventually lead to liver tumor development due to increased 
rates of hepatocyte cell death and hyper-regeneration. Based on this observation, one could 
define Mcl-1 as tissue-specific or environmental tumor suppressor. 
Furthermore, the additional knock-out of the tumor suppressor and anti-apoptotic protein p53 
does not only accelerated tumor development in Mcl-1∆hep mice, Mcl-1∆hep/p53-/- mice also 
showed embryonic lethality due to liver failure and some animals that did survive to 
adulthood showed increased hepatocyte apoptosis, severe liver damage and 100% tumor 
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burden [94].  
Taken together, the analysis of the Mcl-1∆hep mouse model suggests that chronically 
increased apoptosis in hepatocytes is carcinogenic and inhibition of apoptosis may suppress 
liver carcinogenesis in CLD [94]. Therefore, I concluded that the Mcl-1∆hep mouse model is a 
suitable model to study apoptosis-dependent liver damage and hepatocarcinogenesis. 
Indeed, by analyzing the expression of well-known oncogenes in murine HCC, I found a 
significant deregulation of oncogenes and tumor suppressor genes again indicating the close 
relationship to the molecular mechanisms of human hepatocarcinogenesis. Also the 
morphological analysis of murine HCC demonstrated a broad and heterogeneous spectrum 
of growth patterns of HCC published by the WHO for liver tumors. But exactly this 
heterogeneous pattern of murine HCC potentially reflects not unique but rather more likely 
diverse molecular and cellular mechanisms of tumor development. Therefore, one could 
potentially oversee crucial molecular and cellular events which are essential for the 
development specific HCC subtypes and are not detectable because RNA or proteins from 
different HCC are analyzed in the same experimental approach and the results are discarded 
due to missing statistical significance. It is known that human HCC subtypes pass different 
molecular events, e.g. mutations of β-catenin has been described in 32%, TP53 in 21%, 
AXIN1 in 15.2%, CDKN2A homozygous deletions in 8% and APC  in 1.6% of human HCC. 
Interestingly, TP53 alterations were usually exclusive from CTNNB1 mutations (P=0.0001), 
but not from AXIN1 and APC mutations [35, 95]. These data demonstrate the limitation of 
pooled analyses of heterogeneous tumors, which overall are not statistically significant but 
are for the individuum potentially biological relevant. 
Nevertheless, especially the fact of statistical significant gene expression in a pool of 
biological heterogeneous murine HCC elucidated the value of the Mcl-1∆hep mice for studying 
human hepatocarcinogenesis. By performing RNA microarray analysis I uncovered genes in 
regenerating liver of two months-old Mcl-1∆hep mice and validated the expression in HCC of 
several other mouse models as well as human HCC and finally could significantly correlate 
the protein expression with patients` survival. The novel regeneration and tumor-associated 
genes were already described (Plk1, Tpx2) or are not yet described (Bcl21ab, Tinag, 
Gpnmb) during human HCC development. In conclusion, Mcl-1∆hep mice resemble 
fundamental and common features of human hepatocarcinogenesis - independent of HCC 
subtypes or etiologies - and further studies have to show whether the uncovered tumor-
associated genes are of interest as therapeutically targets or as biomarkers for liver 
malignancy and tumor development. 
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4.4.3 DDR and genetic instability in regenerative murine and human livers 
In deep analysis of the hyper-apoptotic and regenerative livers of patients with chronic liver 
diseases as well as several mouse models led me to two additional remarkable observations. 
First, I found of a significant number of γH2AX-positive hepatocytes indicative of DNA 
damage response. Second, I detected significant levels of allelic imbalances at chromosomal 
fragile sites by Taqman copy number assay and fragment length analysis, indicating a 
substantial level of genetic instability in hepatocytes of regenerating livers. Of note, both DNA 
damage response as well as genetic instability was detectable in hepatocytes already prior to 
any dysplastic changes or morphological findings indicative of neoplastic transformation. 
The obvious question whether DDR and genetic instability were detected as coincidence with 
a) DNA fragmentation in apoptotic cells or appeared in b) proliferative or c) 
senescent/quiescent hepatocytes could be answered by γH2AX/cl.Casp3 and Ki67 
γH2AX/Ki67 co-stainings. Finally, as experimental proof by analyzing livers of wild-type mice 
at proliferation peak 48h post PHX, I was able to show for the first time that regenerating 
livers independent of apoptosis indeed show proliferation-associated DNA strand breaks and 
DDR.  
The most likely causes of proliferation or precisely replication-associated DNA damage are 
due to inhibited DNA polymerases (e.g. lack of nucleotides, unwinded DNA), disruptive 
secondary structure in GC rich regions to G-quadruplex structures, stalled replication forks, 
torsional stress and subsequent physical breakage at common fragile sites [96]. 
Chromosomal instability especially at chromosomal fragile sites as a result of replication 
stress is well-known to promote tumorigenesis [97]. Especially the loss of WWOX and FHIT, 
which I analyzed in my study and are located in regions of chromosomal fragile sites, were 
just recently linked to cancer in breast, prostate, ovarian, and lung [97-99]. 
The thigh correlation of hepatocyte apoptosis and susequent proliferation with later tumor 
development in several mouse models (Mcl-1∆hep and TAK1∆hep mice and intercrossings) 
supported the initial hypothesis. More important, by inducing hepatocyte proliferation in a 
model of acute regeneration (PHX mice), I demonstrated that hyper-regeneration by itself 
indeed is able to trigger DNA damage and induced DDR. This was confirmed by showing 
widespread DDR in human livers, notably restricted to the regenerating part of the liver, while 
lacking in non-regenerating parts.  
 
4.4.4 Non-apoptotic functions of Caspase 8  
By studying mice with a hepatocyte-specific Caspase 8-deficiency, I made a remarkable, at 
first glance counter-intuitive observation. Since Caspase 8-deficiency had been shown to 
abolish HCC development in TAK1∆hep mice [49], it was surprising to discover that Caspase 
 
78 
 
8-deficient hepatocytes revealed significantly reduced γH2AX-positive hepatocytes after 
exposure to cellular stress induced by either partial hepatectomy or doxorubicin treatment, 
which at the same time led to widespread γH2AX-positivity in wild-type hepatocytes. The 
simultaneous detection of DNA strand breaks, directly visualized by PFGE, in Caspase 8-
deficient hepatocytes revealed that whereas DNA damage occurred, DNA damage response 
obviously was impaired in Caspase 8-deficient hepatocytes. Finding that pre-treatment with 
the pan-caspase inhibitor and blocking of the catalytic activity of Caspase 8 did not affect 
γH2AX signals in hepatocytes after doxorubicin exposure suggested that DDR was not 
dependent on Caspase 8 catalytic activity, but rather a non-apoptotic and potentially 
scaffolding function.  
Interestingly, the non-apoptotic functions of Caspase 8 are largely unknown and a big 
“mystery”, currently of high interest. Whereas the Caspase 8-dependent inhibition of 
RIPK1/RIPK3-mediated necroptotic cell death has been described [100, 101], first studies 
described just recently a role of Caspase 8 in controlling Nlrp3 inflammasome activation 
[102, 103] or IRF3 activation and IFNγ expression upon viral infection [104]. Strikingly, this 
non-apoptotic function of Caspase 8 in controlling innate immune signaling occurs 
independent of signaling mediated through TNFα, IL-1β or TLR receptors and independent 
of NF-κB signaling (Figure 60) [105]. However, a role of Caspase 8 in DDR, either sensing of 
DNA damage or transducing DNA repair, is not yet described. 
 
4.4.5 Role of the Caspase 8-dependent ripoptosome complex in DDR 
Inactive and non-catalytic proteins of Caspase 8 are always bound at least to one binding 
partner under normal physiological conditions, e.g. its main repressor and pseudo-caspase 
cFLIP [106]. But Caspase 8 has also been shown to be an essential part of the multimeric 
ripoptosome complex, which is formed under cellular stress conditions, e.g. viral infection, 
pharmacological Caspase 8 blockage or in response to (genotoxic) stress-induced depletion 
of XIAP, cIAP1 and cIAP2 for maintaining cellular homeostasis (Figure 60) [77]. Based on 
this, I aimed to gain insights into the role of further molecules of the ripoptosome complex 
and/or related to non-apoptotic functions of Caspase 8. 
First, I have been able to phenocopy my results from genetically Caspase 8-deficient mice to 
pharmacological inhibited, Nec1 treated wild-type mice. Second, I could show that DDR is 
taking place in hepatocytes independent of TNFR1 and NF-κB signaling, but dependent on 
the presence of cFLIP. Since the kinase activity of RIPK1 seemed to be crucial, but not 
RIPK3, the composition of proteins involved in DDR potentially corresponds to the 
ripoptosome complex and is here named “RIPairosome” (Figure 61).  
In conclusion, not only assembly of the ripoptosome complex in response to genotoxic stress 
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[77], but additionally the downstream mediation of DDR represents the next layer of 
complexity of the non-apoptotic functions of Capase8-dependent ripoptosome complex in 
controlling cell survival and cell fate.  
In the past, RIPK1 was shown to control cell fate in response to extensive genotoxic stress, 
but the study focused on the induction of apoptosis or necroptosis and NF-κB signaling [84], 
Potentially, the DDR phenotype has been overseen since Caspase inhibitors against the 
catalytic subunit instead of Caspase 8 knock-out cells have been used. But additionally, a 
RIPK1-dependent DDR has been published in a paper dealing with glycolysis [82].  
 
 
 
Figure 60: The ripoptosome – a central and dynamic signaling platform controls intracellular 
stress response. The ripoptosome complex, comprising RIPK1, FADD, cFLIP and Pro-Caspase 8 is 
highly similar to the TNFR signaling complex II, but the ripoptosome assembly is triggered 
independent of TNFR signaling upon intracellular stress. The ripoptosome controls intracellular stress 
response and determines cell fate by the induction of apoptosis, necroptosis, inflammasome or IRF3 
activation or as describe in my doctoral thesis to DNA damage response. The regulation of the 
ripoptosome is highly dynamic and depends on the of the cellular context, posttranslational 
modifications (phosphorylation or ubiquitination of RIPK1, overexpression or degradation of cIAP or 
cFLIP isoforms). Figure adapted from Boege et al, unpublished. 
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Due to technical limitations for Western blotting, the hepatocyte specific knock-out of 
Caspase 8 in a full organ and technical difficulties with the subcellular fractionation of 
isolated hepatocytes, I had to characterize the DNA damage signaling pathways in single 
hepatocytes by IHC. Finding no evidence for ATM or ATR signaling following doxorubicin 
treatment by analysis of pCHK1 and pCHK2 stainings, but an obviously impaired pcJUN 
response in vivo as well in vitro in Caspase 8-knock-down U2OS cells, revealed JNK 
signaling as responsible pathway in DDR of the newly discovered signaling complex.  
The first major breakthrough confirming the existence of a nuclear-cytoplasmic signal 
transduction described first an ATM- and NEMO-dependent and second an ATM-IKKβ-
dependent nucleus-to-cytoplasm signaling responsible for NF-κB activation and cell survival 
[78, 80]. In contrast, the ripoptosome-dependent and NF-κB signaling independent DDR in 
my own experiments could be explain due to difference in detailed experimental set-ups 
(time- and dose-dependent effects) and also cell-type specific mechanisms. In above 
mentioned studies, DNA damage has been mainly induced by irradiation or etopoiside-
treatment exclusively in vitro in several cancer cell lines [78, 80] and described an ATM-
dependent but also time-dependent DNA repair exclusively [80]. Whereas I could exclude 
ATM-mediated DNA repair downstream of Capsase8, I could clearly show a convincing co-
localization of pJNK and γH2AX in hepatocytes. Interestingly and in line with the published 
studies, I observed activated ATM signaling in U2OS cell, but this phenotype seemed to be 
dose and time dependent (4-12h post DX 
challenge) whereas the JNK-dependent 
phenotype occurred early between 15min 
and 30min post treatment.  
Furthermore, irradiation experiments with 
Casp8∆hep showed the exclusivity of the 
novel discovered Caspase 8/cFLIP/RIPK1-
JNK axis for the repair of DSB in cells. 
 
 
Figure 61 Caspase 8 dependent DDR in 
hepatocytes. A complex comprising a catalytic 
inactive Caspase 8, cFLIP, FADD and RIPK1 
mediated activation JNK signaling. Activation of 
JNK depends on the kinase function of RIPK1 
and is here named “RIPairosome”. Figure from 
Boege et al, unpublished. 
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Further work has to be done to uncover the exact molecular mechanisms mediating a) the 
activation of the ripoptosome complex in response to genotoxic stimuli and b) the 
ripoptosome dependent activation of JNK. In addition, I hypothesize that Caspase 8, by 
mediating DDR in response to DSB, potentially controls the amount of mutations and genetic 
aberrations and therefore potentially inhibits the malignant transformation of hepatocytes and 
thereby inhibiting liver tumorigenesis. Caspase 8-dependent hepatocyte apoptosis triggering 
hepatocarcinogenesis has been shown in several HCC mouse models [49, 107] and the 
activated, catalytic Caspase 8 protein could be regarded as environmental oncogene in the 
liver. 
In contrast, the catalytic-inactive full length Caspase 8 protein as part of the multimeric 
ripoptosome could be potentially seen as tumor suppressor for liver tumorigenesis. To 
answer this question exactly, several experimental approaches are needed to distinguish 
between apoptotic and non-apoptotic and pro-tumorigenic functions, e.g. by using genetically 
modified mice carrying a catalytic-inactivated, uncleavable Caspase 8 for different genetic or 
experimental models of HCC development.  
In addition, the hallmarks of cancer proposed by Hanahan and Weinberg described “Genome 
Instability and Mutation” as enabling hallmark [41, 43]. So called “caretakers” are required for 
the DNA-maintenance machinery – similar to Caspase 8 and the ripoptosome complex - and 
these caretakers genes act very much like tumor suppressor genes and their functions can 
be lost during tumor progression [43]. The loss of these caretakers is gained by inactivating 
mutations or via epigenetic repression. Interestingly, the epigenetic silencing of Caspase 8 in 
human HCC has been already shown in two studies [108, 109]. But only HCC and HCC cell 
lines have been analyzed and it would beof high interest to analyze chronically diseased 
livers in respect to the loss of Caspase 8, (proliferation-induced) DNA damage, JNK 
activation and DDR to better understand the contribution of Caspase 8 to 
hepatocarcinogenesis 
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5 The role of enterocyte apoptosis in intestinal carcinogenesis 
5.1 Introduction:  
5.1.1 Intestinal carcinogenesis 
As introduced before, the four most common causes of cancer-related death worldwide (lung, 
liver, stomach, and bowel) account for nearly half (46%) of all cancer deaths (Figure 1) [3] 
Intestinal, in particular colorectal cancer (CRC) is a common and frequently lethal disease. 
CRC is among the most frequently diagnosed cancers in the Western world with around 1.36 
million new cases and estimated 700.000 deaths per year and affects men and women almost 
at equal ratios ( 
Figure 62) [3].  
Both, environmental as well as inherited factors influence tumorigenesis in this organ with 
environmental factors becoming more important in recent years. These environmental risk 
factors (also called modifiable risk factors) became more important during the last few years, 
compared to risk factors that cannot be individually controlled, such as age and genetic 
predisposition. Due to industrialization of developing countries and adaption to a Western life 
style - i.e. in particular increased intake of energy-dense food with high fat and sugar content, 
red meat and low intake of dietary fibers, leading to overweight or obesity and physical 
inactivity – tumor growth in the digestive system is promoted. In particular in countries with a 
high-income economy that have recently changed from a relatively low-income economy, 
such Eastern European countries, incidence rates have at least doubled since the mid-1970s 
[110].  
 
 
Figure 62: Estimated cancer mortality rates in both sexes in 2011. 
Colorectal cancer is the third most common cancer worldwide 
accounting for 1.36 million deaths per year.. Almost 55% of the cases 
occur in more developed regions, especially in Australia/New Zealand 
and Europe. Figure from WHO-Cancer Fact Sheet [1]. 
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5.1.2 The Vogelstein scheme 
The molecular events driving intestinal and in particular colorectal carcinogenesis are far 
better characterized than for most other solid tumors. Specific genetic changes that drive the 
transformation from a normal intestinal epithelial cell to an invasive cancer cell are thought to 
confer a selective growth advantage, resulting in preferential proliferation of the cell 
containing a mutation. A lot of our understanding was obtained by the pioneer work of 
Vogelstein and co-workers and the definition of the adenoma-carcinoma sequence (Figure 
63) [111].  
 
 
Figure 63: Histopathology of colorectal cancer according of the adenoma-carcinoma sequence 
known as Vogelstein scheme. Aberrant crypt foci (ACF) are the earliest microscopically detectable 
colorectal neoplastic lesions. ACF composed of dysplastic cells are prone to become a polyp, a 
benign tumor. Polyps may progress to adenomatous (dysplastic) polyps and finally invasive-growing 
carcinoma. Figure from Fodde et al. [112]. 
 
Their early model describing genetic changes in genes including APC, β-Catenin, K-ras, and 
p53 has been refined later. It is now expanded by data from whole tumor genome 
sequencing efforts including those from the The Cancer Genome Atlas Network giving a 
comprehensive molecular characterization of human colon and rectal cancer [113]. The 
majority of intestinal cancers progress through an adenoma-carcinoma sequence. 
Remarkably, there is a strong correlation between the histopathological changes in the 
intestinal mucosa (normal epithelium  dysplastic changes / adenoma  intramucosal  
invasive carcinoma) with the occurrence of genetic changes described in the Vogelstein 
model [111]. 
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5.1.3 Inflammatory bowel disease 
For a long time, it is known and well documented that patients suffering from inflammatory 
bowel disease (IBD), i.e. Crohn’s disease (CD) and ulcerative colitis (UC) are at higher risk to 
develop intestinal, in particular colorectal carcinoma [114]. Of note, the risk for tumor 
development in IBD patients depends on the extent, duration, and inflammatory activity of the 
disease. The pathophysiology of IBD obviously goes along with an abnormal immune 
response of both, the adaptive and innate immune system. Histopathologically, IBD is 
characterized by the persistent side by side occurrence of intestinal mucosal damage and 
inflammation on the one side, and persistent reparation and regeneration on the other side. 
Thus, the intestinal tract of patients with IBD reveals chronically increased cell death and 
proliferation of intestinal epithelial cells which are required to keep intestinal homeostasis.  
 
5.1.4 Homeostasis of intestinal epithelium 
The intestinal epithelium constitutes a specialized single cell layer with absorptive and 
secretory functions in the interface between the body and the external environment. In the 
epithelium, enterocytes are responsible for the absorption of nutrients, ions, vitamins, and 
water [115-117].  
Paneth cells, goblet cells, and enteroendocrine cells comprise the secretory lineage of the 
intestinal epithelium, playing an important role in the intestinal defense against potentially 
harmful bacteria and the coordination of intestinal functions by hormone secretion. In close 
contact with the epithelium lies the lamina propria, a loose connective tissue in which 
mesenchymal cells and mucosal immune cells are located (Figure 64) [117, 118].  
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Figure 64: The intestinal epithelium. A single layer of intestinal epithelial cells (IECs)generates a 
physical barrier that separates the microbiota in the intestinal lumen from the underlying lamina 
propria. In addition to differentiated enterocytes and goblet cells, progenitor IECs differentiate into both 
enteroendocrine cells, which secrete enteric hormones, and Paneth cells at the base of the small 
intestinal crypts [119]. Figure from Abreu et al. [119]. 
 
In the large and small intestine, differentiated enterocytes are constantly removed and 
replaced by new cells originating from undifferentiated adult intestinal stem cells, which are 
localized in the third or fourth position counted from the base of the crypt [120]. These new 
cells migrate from the base of the crypt to the apical zone of the intestine undergoing 
maturation. In the apical zone, these cells survive for about 4-5 days before being shed into 
the gut lumen. In this single epithelial layer, a tightly regulated equilibrium between cellular 
proliferation and cell death must be kept in order to maintain the intestinal barrier [117, 121]. 
Importantly, if cell death in the epithelium is not strictly regulated, it might result in a barrier 
defect with subsequent microbial invasion and inflammation. Previous studies have shown 
that epithelial cell proliferation and turnover are accelerated in IBD, with elevated levels of 
programmed cell death being observed in patients with both CD and UC [117].  
 
5.1.5 Cell death in inflammatory bowel disease 
In the normal, healthy intestinal epithelium, apoptosis is needed for tissue homeostasis. 
Apart from Paneth cells and stem cells, all cells migrate from the base of the crypt to the 
villus tip where they are shed into the lumen. Cells always undergo apoptosis before 
shedding and apoptotic bodies are never found in the epithelial monolayer. Interestingly, 
morphological changes typical of apoptosis are not apparent until the nucleus of the 
shedding cell has moved above the nuclei of adjacent cells, suggesting that shedding leads 
to apoptosis [122]. Furthermore, treatment of mice with a broad-spectrum caspase inhibitor 
blocked almost all shedding events, indicating that Caspase 3 cleavage is critical for cell 
shedding to occur as revealed by cleaved Caspase 3 staining within the cytoplasm of 
shedding cells[122]. In addition to cell shedding, rare apoptotic events were observed in the 
stem cell niche and are believed to contribute to stem cell homeostasis [123]. 
Under non-physiological conditions, as seen in patients suffering from acute or chronic IBD, 
high levels of apoptosis have been observed in the intestinal epithelium. Colonic epithelium 
specimen from patients with UC show higher rates of apoptosis than controls and apoptotic 
cells are also found in crypts of active UC, suggesting that loss of epithelial cells occurs 
mainly due to apoptosis in the affected intestine and also in adjacent unaffected areas [52]. 
In line, apoptotic features in UC patients are significantly more prevalent  than in controls but 
similar to those observed in infectious colitis patients [117, 124, 125]. 
 
86 
 
In CD, the number of apoptotic enterocytes was found to be higher in inflamed compared to 
non-inflamed areas and normal intestine, with no significant difference found between 
unaffected and normal mucosa, suggesting that a high rate of enterocyte apoptosis in the 
intestinal epithelium of CD is associated with intestinal inflammation, being exclusively 
increased in inflamed areas [126]. 
Several animal studies describe the central role of apoptosis in the disease mechanisms of 
IBD. For example, knock-out mice for XBP1 (an endoplasmic reticulum (ER) stress-related 
transcription factor), develop spontaneous enteritis, associated with Paneth cell dysfunction 
and subsequent apoptotic cell death. Interestingly, an association between UC and CD with 
XBP1 variants was identified in humans and replicated as susceptibility genetic factors [127]. 
In addition, enterocyte-specific inactivation of NFκB signaling was shown to cause apoptosis 
of colonic epithelial cells with subsequent impaired expression of antimicrobial peptides and 
translocation of bacteria into the mucosa [128].  
The first study showed the role of Caspase 8 in the regulation of necroptosis in the intestinal 
epithelium. Mice with a conditional deletion of Caspase 8 in the intestinal epithelium 
spontaneously developed terminal ileitis. These mice showed a loss of Paneth cells, 
indicating a dysregulated antimicrobial immune cell function of the intestinal epithelium. In 
addition, epithelial cell death was induced by TNFα and was associated with increased 
expression of RIP3. More importantly, the authors identified high levels of RIP3 in human 
Paneth cells and increased necroptosis in the terminal ileum of patients with CD, suggesting 
a potential role of necroptosis in the pathogenesis of this disease [117, 129].  
These findings were confirmed independently in a second study with conditional knockout 
mice for FADD in intestinal epithelial cells. These mice spontaneously develop epithelial cell 
necrosis with loss of Paneth cells and bowel inflammation. Inhibition of necroptotic cell death 
ameliorated intestinal inflammation and tumorigenesis [130]. 
In addition, a recent study showed a significantly increased expression of the necroptosis 
executer proteins RIP3 and MLKL, accompanied by a reduction of Caspase 8 expression in 
biopsy samples from children suffering from IBD. Necroptosis is strongly associated with 
intestinal inflammation in IBD and contributes to strengthen the inflammatory process [129, 
131]. 
 
5.1.6 The microbiota promotes intestinal tumorigenesis 
Studies with genetically modified mouse models for spontaneous intestinal tumorigenesis 
have unraveled a fundamental role of the microbiota in tumor promotion. Conditional NEMO 
knock-out mice or APC transgenic mice showed enhanced intestinal inflammation as well as 
increased intestinal permeability most probably due to enterocyte apoptosis. Subsequently, 
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this caused a leaky intestinal barrier, leading to the penetration of microbial products or 
microbes into the affected mucosal tissue but not into adjacent normal tissue. Germ-free 
housing of mice significantly reduced the inflammatory response as characterized by IL-23 
and IL-17 expression as well as reduced the number of apoptotic enterocytes resulting in a 
reduced tumor burden under germ-free conditions or antibiotic treatment [132, 133]. This 
indicates a crucial role of the microbiota for the induction of enterocyte apoptosis under 
inflammatory conditions and a causal relationship between the microbiota and tumorigenesis.  
In addition, the tumor promoting effects of the microbiota have been shown in a mouse 
model for spontaneous intestinal tumorigenesis being accompanied only by mild 
inflammation. Mice carrying the mutated APC gene were kept under germ-free conditions 
and the decreased number of tumors was correlated with a reduced expression of TNFα, IL-
1β and IL-23 in colonic tumors [134]. Taken together, the tumor promoting effects of the 
microbiota could be causally linked to intestinal tumorigenesis in mouse models for IBD and 
the specific IL-23-dependent inflammation pattern was linked to the metastatic spread and 
overall patient survival [135]. 
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5.2 Scientific Questions 
 
As described above, enterocyte cell death seems to be the main driver of intestinal 
inflammation in patients suffering from IBD and promotes intestinal tumorigenesis.  
 
In the second project of my doctoral thesis, I aimed at understanding the role of enterocyte 
cell death in intestinal tissue homeostasis and identifying the molecular mechanisms driving 
intestinal tumor development in chronically inflamed and regenerating intestinal tissue. More 
precisely, I aimed to answer the following questions: 
 
- Is it possible to transfer the concept of cell death driven tumorigenesis from to the 
liver to the intestine? 
 
- Is Mcl-1 required for enterocytes and intestinal tissue homeostasis? 
 
- Do Mcl-1 knock-out mice recapitulate the hallmarks of the Vogelstein scheme? 
 
- Does enterocyte apoptosis lead to an inflammatory and regenerative response? 
 
- Which immune cell type mediates intestinal inflammation in conditional Mcl-1 knock-
out mice? 
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5.3 Results 
5.3.1 Generation of enterocyte-specific Mcl-1 knock-out mice (Mcl-1∆IEC mice) 
To generate conditional Mcl-1 knock-out mice, I intercrossed mice carrying the Mcl-1 loxp 
sites allele with mice expressing the Cre-recombinase under the enterocyte-specific villin 
promotor. Mice homozygous for the Mcl-1 flox allele and positive for the Cre-recombinase 
(further denoted as Mcl-1∆IEC mice) were used as knock-out mice and compared in all 
experiments to Cre-negative littermates serving as age- and gender-matched wild-type 
controls. I confirmed the conditional knock-out of Mcl-1 in the intestinal epithelium with a 
specific set of PCR primers for the recombined genetic Mcl-1 locus (Figure 65). For breeding, 
male mice heterozygous for the Mcl-1 loxP allele were used as breeding males. 
Homozygous mice – independent of the presence of Cre recombinase - are in contrast to 
homozygous female mice infertile and therefore not suitable for breeding. 
 
Figure 65: Genotyping PCR for the enterocyte-specific recombination of the Mcl-1 locus. Snap-
frozen tissue of indicated organs has been digested with Proteinase K and gDNA was used for PCR 
reactions. Genotyping PCR primer for the Cre recombinase and the Mcl-1 gene were used as well as 
a pair of primers specific for the recombined, deleted Mcl-1 locus (“del Mcl-1”). 
 
5.3.2 Phenotypically characterization of Mcl-1∆IEC mice 
Mcl-1∆IEC mice were monitored over time by measuring body weight every 4 weeks and Mcl-
1∆IEC mice showed a reduced body weight compared to age- and gender-matched controls 
with some mice which had to be euthanized when the criteria for abortion were reached 
(Figure: 66 and Figure 67).  
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Figure: 66 Monitoring of body weight. Body weight of Mcl-1∆IEC mice were monitored over time and 
compared to gender-matched Cre-negative littermates. Mcl-1 knock-out females (n=39) as well as 
males (n=41) showed significantly reduced body weight.  
 
Figure 67: Monitoring of survival. Mcl-1∆IEC 
mice showed significantly reduced survival 
compared to Cre-negative control littermates. 
 
 
In addition, I collected stool for the analysis 
of fecal calprotectin by ELISA. Calprotectin, 
a protein consisting of a S100A8/S100A9 
dimer, strongly correlates with intestinal 
inflammation as it is released from activated monocytes and granulocytes and therefore it is 
widely used as a reliable marker for diagnostic purposes in patients suffering from IBD and 
monitoring disease activity [136]. In addition, some Mcl-1∆IEC mice started to develop diarrhea 
and indeed, I could find enrichment of calprotectin in stool samples of Mcl-1∆IEC mice and an 
enhanced expression of S100A8 and S100A9 on mRNA level in colonic tissue (Figure 68).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: Calprotectin is enriched in Mcl-1∆IEC 
mice. The amount of Calprotectin was assessed by 
ELISA in feces of mice at indicated time-points or 
the expression of the S100A8 and S100A9 
analyzed by qPCR on colonic tissue. 
  
 
91 
 
Due to the spontaneous loss of body weight, I decided to sacrifice and analyze Mcl-1∆IEC 
mice already at young age and collected tissue from 4 weeks-old animals for a detailed 
morphological analysis. First, a patchy pattern of affected and unaffected mucosal tissue 
(Figure 72) could be observed throughout the whole intestinal tract, characterized by 
increased apoptosis of intestinal epithelial cells (IECs) and epithelial damage accompanied 
by increased IEC proliferation and a strong inflammatory reaction (Figure 69, Figure 70).  
 
 
Figure 69: Histology of colonic tissue of mice at the age of eight weeks. Histological analysis 
revealed enterocyte apoptosis (yellow arrows) as well as enterocyte mitosis (black arrow). Intestinal 
tissue damage and loss of the regular intestinal architecture could be observed throughout the 
intestinal tract. Scale bar = 200 µm. 
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 Figure 70: High levels of enterocyte apoptosis and proliferation. Immunohistochemical stainings 
revealed high levels of enterocyte apoptosis and proliferation in colonic tissue of 8 weeks old mice, 
indicating strong intestinal tissue damage and compensatory hyper-proliferation. Scale bar = 500 µm. 
 
In addition, we observed a loss of differentiated enteroendocrine cells. Paneth cells in the 
small intestine as well as mucin-secreting Goblet cells in the colon were lost in affected areas 
of Mcl-1∆IEC mice (Figure 71). These observations already indicate that the anti-apoptotic 
protein Mcl-1 is a crucial pro-survival factor of enterocytes and needed for intestinal tissue 
homeostasis. 
 
 
Figure 71: Loss of Goblet cells Mcl-1∆IEC mice. Differentiated Goblet cells are lost in affected and 
highly regenerative colons of Mcl-1 deficient mice. Scale bar = 250 µm. 
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 Interestingly, the distribution of affected and hyper-apoptotic areas throughout the intestinal 
tract differed substantially between individual animals, being suggestive of an uneven 
deletion of the Mcl-1 protein. Therefore, we decided to perform a PCR analysis for the 
recombined genomic locus of the Mcl-1 flox allele on affected and unaffected intestinal tissue 
(Figure 72), isolated by laser micro dissection of scrapings from FFPE cuttings. Indeed, 
apoptotic areas showed a signal for the recombined genomic locus whereas gDNA from 
unaffected and healthy tissue showed no PCR product, indicating no genomic recombination 
in these regions. This is consistent with previous reports showing a patchy expression 
pattern of the Cre-recombinase in the Villin-Cre mouse line we used [129, 137, 138]. 
Whereas in the original publication the Villin-Cre mouse strain was shown to have an active 
Cre-recombinase throughout the intestinal tract by using a lacZ reporter system, the genomic 
locus of the Mcl-1 gene might play a crucial role in the recombination of DNA [139].  
 
 
Figure 72: Patchy distribution of Mcl-1 knock-out lesions in Mcl-1∆IEC mice. Affected and 
unaffected areas of interest were defined on histological sections and gDNA was isolated by 
scrapings. Unaffected lesions of Mcl-1∆IEC mice (3,6) showed no genetic deletion of Mcl-1 gene, 
compared to moderate (4) or severe affected lesions (2,7,8) of the same animal.  
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5.3.3 Tumor development 
As the knock-out of Mcl-1 caused a strong phenotype and Mcl-1∆IEC mice had to be 
monitored thoroughly over time, we decided to analyze the health of the animals on a weekly 
basis and mice with a loss of body weight were euthanized. We collected tissue of mice at 2, 
4, 6 and 12 months of age and also performed colonoscopy to monitor potential tumor 
development in the colon in vivo (Figure 73). 
 
 
Figure 73: Endoscopy and macroscopy of Mcl-1∆IEC mice. Animals were monitored by endoscopic 
examination at various time-points of age and representative images of a fibrotic colon at 4.5 months 
of age and polyps in 12 month-old Mcl-1∆IEC mice. Macroscopically visible tumors were found in the 
colon as well as in the small intestine of Mcl-1 deficient mice.   
Because mice at the age of four weeks already showed hyperplastic intestinal lesions, the 
entire intestinal tract of Mcl-1∆IEC mice was thoroughly examined for tumor lesions. Based on 
H&E morphology, tumors were quantified and categorized according to well-established 
criteria [140] including the following categories: (1) hyperplasia; (2) adenoma - 
subcategories: adenoma with low grade dysplasia (LGD), adenoma with high grade 
dysplasia (HGD), and (3) carcinoma, subcategories: intramucosal carcinoma, and carcinoma 
with invasion beyond muscularis mucosae. In addition, regional lymph nodes and distant 
organs, in particular lung and liver, were monitored for metastases. Mcl-1∆IEC mice (n=30) 
with carcinoma at the age of 9 months and older were analyzed but no metastases were 
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found.  
Remarkably, Mcl-1∆IEC mice developed adenoma as well as carcinoma with an invasive 
growth pattern. Low grade adenoma were observed in Mcl-1∆IEC mice at the age of 6 months 
and high grade adenoma and carcinoma in Mcl-1∆IEC mice with weight loss at the age of 9 
months. At 12 months of age, adenoma could be observed in approximately 80% of Mcl-1∆IEC 
mice, including 25% carcinoma (Figure 74). At 18 months of age, adenoma were found only 
in 50% of Mcl-1∆IEC mice, including 30% carcinoma, but due to the reduced survival of Mcl-
1∆IEC mice and the following bias, this percentage has to be considered carefully. 
Histological analyses revealed a spectrum of pathological changes including hyperplastic 
lesions, intraepithelial neoplasia (adenomas with LGD and HGD), and also invasive 
carcinoma in the small intestine as well as in the colon. Carcinoma of the colon were 
macroscopically visible and could be detected by colonoscopy.  
 
 
 
 
 
Figure 74: Tumor quality by histological analysis. The whole 
intestinal tract were analyzed thoroughly and the most affected 
region of scored for each individual animals. 
 
 
 
 
 
 
 
 
 
I could confirm the invasiveness of carcinoma with an immunohistochemical staining for the 
epithelium-specific marker cytokeratin (CK) which showed CK-positive cells within the 
muscularis propria (Figure 75). Whereas these cells were negative for αSMA, a marker for 
smooth muscle cells and defining the muscularis propria, the CK-positive cells showed a 
typical crypt-like growth pattern within the muscularis propria indicating an epithelial origin of 
these invasively growing cells. 
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 Figure 75: Invasive tumor growth in Mcl-1∆IEC mice. Ileum (upper row) and duodenum (lower row) 
sections of Mcl-1∆IEC mice at the age of 18 months and 12 months, respectively, showing invasive 
growth of tumors into the muscularis propria. Tumor cells stained positive for the epithelium-specific 
marker cytokeratin (CK) but negative for alpha-smooth muscle actin (αSMA). 
 
Interestingly, immunohistochemical characterization revealed nuclear localization of β-
catenin suggesting activated Wnt/β-catenin signaling in invasive carcinoma indicating 
parallels to human intestinal carcinogenesis (Figure 76). In summary, tumors derived from 
Mcl-1∆IEC mice revealed macroscopically the same adenoma-carcinoma sequence which is 
characteristic for human intestinal carcinogenesis. In addition, I observed neoplastic lesions 
in young mice at the age of 4-8 weeks and low grade adenoma as well as high grade 
adenoma and invasive carcinoma in mice as early as 8 months of age.  
 
Figure 76: Nuclear β-catenin translocation in 
carcinoma. Translocation of β-catenin from the membrane 
into the nucleus could be observed in carcinoma from Mcl-
1∆IEC mice, suggesting activated Wnt/β-catenin signaling. 
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5.3.4 Genetic analysis of tumors by Sanger sequencing 
Due to the translocation of β-catenin in carcinoma of Mcl-1∆IEC mice, we expected to find 
mutations in the wnt pathway as described by Vogelstein and colleagues, because tumors 
evolving from benign to malignant lesions acquire a series of mutations over time, a 
sequence that has been particularly well studied in colorectal tumors [141]. For studying the 
presence of mutations and chromosomal instability in the Mcl-1∆IEC mouse model, we 
decided to analyze selected genes by Sanger sequencing. The protocols and work-flow was 
established together with Simone Büehler, who spent six months in lab of Prof. Achim Weber 
as a master student and helped in generating the sequencing results. 
Based on a literature research the following well-known oncogenes and tumor suppressor 
genes, which were described to accumulate driver mutations during intestinal tumorigenesis 
at specific hot-spots were selected: APC, β-catenin, Fbxw7, B-Raf, N-Ras, K-Ras, p53, 
PIK3CA,  Smad4 [141]. 
 
 
Figure 77: Mutational analysis of tumor and non-tumor tissue from Mcl-1∆IEC mice. Histology was 
examined and tumor lesions of different tumor quality defined and micro-dissected and gDNA for 
sequencing PCRS isolated from FFPE blocks.  
Neoplastic and non-neoplastic tissue from Mcl-1∆IEC mice and tissue from control mice was 
selected according to the tumor stage and gDNA was isolated from micro-needle punches 
obtained from paraffin blocks (Figure 77). gDNA was used to establish the PCR reaction for 
the genomic region of interest and the PCR products were sent to Microsynth/Balgach for 
Sanger sequencing and analyzed using the CLC Workbench software. 
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Mutations for Catenin-1β were found in exon 2 in three individual punches from intramucosal 
carcinoma derived from different animals. All mutations were heterozygote mutations (TC/TT) 
at Codon 33 (NM_007614.3:c.98C>T, p.Ser33Phe), which led to an amino acid substitution 
of serine with phenylalanine. Codon 33 is one of four evolutionary conserved 
serine/threonine residues at the amino-terminal region of β-catenin, which constitute the 
GSK-3 phosphorylation site. GSK-3 is a part of the β-catenin degradation complex. Hence, 
mutations in this recognition site lead to the accumulation of β-catenin and its translocation to 
the nucleus consistent with our observation on β-catenin translocation. In line, mutations in 
Codon 33, 37, 41 and 45 frequently occur in human colorectal cancer.  
In exon 1α of the Fbxw7 gene, one homozygous missense point mutation 
(NM_001177773.1:c 187A>G, p.Asn62Asp) led to an amino acid substitution of asparagine 
(AAC) with aspartate (GAC) and one homozygous silent point mutation 
(NM_001177773.1:c.342A>G, p.Glu114Glu) was detected in all samples as well as 
VillinCrenegative control samples, which is most probably the result of a spontaneous and 
silent germ-line mutation within the mouse strain compared to the C57BL/6 reference 
sequence in the database. This mutation is not described in the literature and control mice 
did not develope intestinal pathology or tumors. 
Analysis of p53 exon 5-8, Smad4 exon 5 & exon 6, Braf, APC exon 15, N-Ras exon 1 & exon 
2 and K-Ras exon 1 & exon 2 did not reveal mutations within the analyzed regions. However, 
it cannot be excluded that mutations in tumor tissue were missed due to biological or 
technical reasons. Due to technical limitations of the analyses performed by Microsynth, 
small (< 150bp) PCR products were not readable by the automated sequencer, thus 
sequences of N-Ras exon 1 (86bp), K-Ras exon 1 (98bp) could not be analyzed. Several 
attempts for the amplification of Apc exon 15A failed, most likely due to small molecular size 
of the isolated gDNA undergoing immense DNA fragmentation during formalin fixation when 
compared to native DNA.  
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Cancer, especially CRC, results from the accumulation of inherited and somatic mutations in 
oncogenes and tumor suppressor genes. These genes encode proteins that function in many 
regulatory pathways as summarized by Hanahan and Weinberg [41, 43]. These pathways 
also control genetic stability and chromosomal instability (CIN) is a feature of most human 
cancers [41, 43, 142]. To analyze genetic instability, I performed array comparative genomic 
hybridization analysis (aCGH) with gDNA isolated from intramucosal carcinoma, also used 
for mutational analysis by Sanger sequencing. Software based analysis performed by Dr. 
Kristian Unger (Helmholtz Zentrum/TU München) revealed chromosomal aberrations, with 
chromosomal gains and chromosomal losses being randomly distributed throughout the 
chromosomes and showing no recurrent pattern (Figure 78).  
 
 
 
Figure 78: Chromosomal aberration in tumors derived from Mcl-1∆IEC mice. Isolated gDNA from 
tumor tissue which was used for Sanger sequencing was also used to analyze chromosomal 
aberrations by aCGH analysis. A random pattern of chromosomal amplifications (indicated in blue) 
and deletions (indicated in red) were detected.  
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5.3.5 Characterization of intestinal inflammation in Mcl-1∆IEC mice  
The morphological analysis of 4-week-old Mcl-1∆IEC mice revealed besides the hyper-
apoptotic and hyper-plastic lesions also a strong inflammatory reaction throughout the 
intestinal tract. The inflammatory phenotype is consistent with observations in patients 
suffering from acute or chronic IBD, in which high levels of apoptosis are accompanied by 
inflamed lesions in the intestinal epithelium [117]. 
To characterize the inflammation in Mcl-1∆IEC mice in more detail and to better understand 
the pathophysiological mechanisms, I first analyzed immunohistochemical stainings for B- 
and T-cells and macrophages. I could observe inflammatory aggregates which were positive 
for the B-cell marker B220 and also an increase in numbers of CD3+ T-lymphocytes in the 
small intestine and the colon (Figure 79).  
 
Figure 79: Immunohistochemical analysis of inflamed colons of two-months-old Mcl-1∆IEC mice. 
Staining with B220 revealed B-lymphoyctes in inflammatory aggregates and an increased number of 
T-lymphocytes (CD3) and macrophages (F4/80).  
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Second, in collaboration with Dr. Lubor Borsig, we performed a flow cytometry analysis of 
immune cells isolated from the lamina propria of 8-week-old Mcl-1∆IEC mice. We observed a 
significantly increase in CD19-positive B-cells as well as increase of Ly6C-positive pro-
inflammatory monocytes and a Mac1-positive cell population of macrophages and 
neutrophils. Strikingly, we detected a significant decrease in CD3-positive T-cells, especially 
in the CD8-positive subset of T-cells (Figure 80). This was in contrast to our previous finding 
based on immunohistochemical analyses. Due to the experimental set-up chosen for the 
quantification of intraepithelial immune cells by flow cytometry, we calculated relative 
numbers of positive cells within the population of CD45-positive cell and due to the explosive 
increase of B-cells in inflamed intestines, all other analyzed cell types within the CD45-
positive cell populations were most likely artificially decreased and we used the data only 
carefully to draw any conclusions. 
 
 
Figure 80: Analysis of inflammatory cells by flow cytometry. Colonic immune cells were isolated 
from the lamina propria of two month-old Mcl-1∆IEC and control mice and an increase in CD19-positive 
B-lymphocytes, Ly6C-positive monocytes and Mac1-positive macrophages was observed. The 
percentage of CD3- and CD8-positive T-lymphocytes was reduced. 
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Due to the strong inflammatory phenotype of Mcl-1∆IEC mice and the potential role of immune 
cells and immune cell-derived cytokines in promoting intestinal tumorigenesis, I next wanted 
to address the role of B- and T-cells in mediating intestinal pathology and their contribution to 
tumorigenesis. Therefore, I decided to genetically deplete mature B- and T-cells by 
intercrossing Mcl-1∆IEC mice with RAG1-/- deficient mice. 
Interestingly, the Mcl-1∆IEC/RAG1-/- was very difficult to establish and the breeding did not 
give birth according to the expected Mendelian ratio. The number of expected Mcl-
1∆IEC/RAG1-/- mice was reduced and a substantial proportion of Mcl-1∆IEC/RAG1-/- mice was 
growth retarded and had to be euthanized quickly after weaning and the survival of Mcl-
1∆IEC/RAG1-/- mice was significantly reduced compared to Mcl-1∆IEC and wild-type mice 
(Figure 81). 
 
 
Figure 81: Body weight and survival of Mcl-1∆IEC/RAG1-/-. The body weight of female Mcl-
1∆IEC/RAG1-/- mice was reduced, compared to wild-type and Mcl-1∆IEC mice. Only females are shown 
due to the smal number of males obtained. The survival of Mcl-1∆IEC/RAG1-/- was significantly reduced 
compared to Mcl-1∆IEC mice and only ~20% of mice reached the age of 10 months. 
 
Histological analysis of intestinal sections derived from 4- and 8-week-old Mcl-1∆IEC/RAG1-/- 
mice revealed a similar histopathology as observed in Mcl-1∆IEC mice. With respect to the 
epithelial compartment, I found a histological spectrum including hyperplastic lesions, 
intraepithelial neoplasia and a loss of highly differentiated Paneth and Goblet cells. The 
patchy phenotype of affected and unaffected regions in the intestine was observed in Mcl-
1∆IEC/RAG1-/- mice and could potentially explain the survival of less affected Mcl-1∆IEC/RAG1-/- 
mice (Figure 82). 
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Figure 82: Histology of Mcl-1∆IEC/RAG1-/- mice. Histopathological signs of increased enterocyte cell 
death (black arrows), aberrant crypts and loss of tissue architecture were observed in the whole 
intestinal tract of Mcl-1∆IEC/RAG1-/- mice at the age of two months. 
 
As next step, I decided to analyze the cytokine expression in intestinal tissue to better 
understand the inflammatory reaction and to screen for a B- and T-lymphocyte independent 
cytokine to get an explanation for the unexpected phenotype in Mcl-1∆IEC/RAG1-/- mice.  
The expression analysis of S100A8/A9 showed increased levels in colons of Mcl-1∆IEC/RAG1-
/- mice compared to Mcl-1∆IEC mice and indicated a crucial role of calprotection-secreting 
granulocytes in the intestinal pathology and inflammatory phenotype of Mcl-1∆IEC/RAG1-/- 
mice (Figure 83). 
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 Figure 83: Expression of S100A8/A9 in Mcl-1∆IEC/RAG1-/- mice. Analysis of S100A8/A9 expression 
by qPCR revealed significantly increased levels in Mcl-1∆IEC/RAG1-/- mice compared to Mcl-1∆IEC mice. 
Elevated mRNA levels in RAG1-/- control mice suggest an altered immune cells composition in the 
colon due to the lack of B- and T-lymphocyte. 
 
Interestingly, the most important cytokines described to be relevant in IBD (e.g. IL-17, IL-22, 
IL-23) were not detectable on RNA level neither in RNA isolated from whole tissue lysates 
nor in intestinal epithelial scrapings (data not shown). Therefore, I established an ex vivo 
colon culture system initially developed in the lab of Richard Flavell [143]. Shortly, primary 
intestinal tissue was harvested, washed and chopped and cultured for up to 72h in specific 
cell culture medium. Released cytokines are enriched in the cell culture supernatant and I 
performed a multiplex ELISA to analyze the cytokine profile of intestinal tissue derived from 
Mcl-1∆IEC and Mcl-1∆IEC/RAG1-/- mice. 
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Figure 84: Ex vivo cytokine analysis in cell culture supernatant. The most relevant cytokines 
(IL17A, IL17F, IL22) for IBD were detected significantly enriched in cell culture supernatant from Mcl-
1∆IEC and Mcl-1∆IEC/RAG1-/- mice 48h after ex vivo incubation. 
 
Indeed, I could detect an enrichment of IBD-related cytokines in the cell culture supernatant. 
Besides the pro-inflammatory cytokines IL-1β, TNFα and IL-6, I found IL-22, IL-17F and IL-
17A (Figure 84). Especially IL-22 was of interest, as it is well-known to be released by TH17 
cells, is strongly linked to chronic inflammation in IBD and has a pro-proliferative stimulus on 
enterocytes to drive intestinal tissue regeneration [144]. TH17 cells were first defined by their 
expression of IL-17A, but have later been shown to also express IL-22, IL-17F and IL-21 
[143]. Also IL-23 is described to be crucial for TH17 cell differentiation and maintenance 
[145]. Taken together, the enhanced expression of these IBD-related cytokines confirmed the 
IBD phenotype of Mcl-1∆IEC mice. However, the increased expression of cytokines released 
by TH17 cells in intestinal tissue in Mcl-1∆IEC/RAG1-/- mice was contradictory and could not be 
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explained, because TH17 cells like all other B- and T-cells should be depleted in RAG1-/- 
mice due to the lack of the recombination activating gene 1 (RAG1) which is required for 
immunoglobulin V-D-J recombination. 
 
Therefore, I went back to the literature and searched for an explanation of a TH17 
expression profile in RAG1-/- mice and indeed found a paper, published at the same time by 
Prof. S. Leibundgut (ETH Zürich) dealing with an IL-17-dependent clearance of Candida 
albicans upon oral infection in RAG1-/- mice [146]. According to this paper, fungal clearance 
is not mediated via IL-17 released by conventional TH17 cells, but instead IL-17-dependent 
immunity is mediated by a non-conventional and IL-17-producing immune cell type called 
innate lymphoid cells (ILCs) and not by classical TH17 cells. 
ILCs lack rearranged antigen-specific receptors and the maturation of ILCs is therefore not 
affected by the deletion of Rag1 gene in mice [147]. As the role of ILCs is currently of high 
interest but first studies were only limited to pathogen-induced mouse models for intestinal 
inflammation [148], there was no study showing the causal relationship between ILC-
dependent inflammation and intestinal tumorigenesis. Consequently, I aimed to study the 
role ILCs in the Mcl-1∆IEC mouse models and depleted ILCs with an anti-Thy1 antibody in 
Mcl-1∆IEC mice. Because the Mcl-1 and the RORc gene locus were located on the same 
chromosome, a genetic knock-out of ILCs was not possible. But due to the strong 
inflammatory phenotype of Mcl-1∆IEC mice, I expected to see a potential effect early after 
antibody treatment.  
To study the role of ILCs in tumor initiation, I started to treat Mcl-1∆IEC mice at the age of one 
month for four weeks. In addition, to investigate the role of ILCs in tumor progression in old 
mice with established IBD, I additionally treated mice at the age of eleven months for four 
weeks. 
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 Figure 85: Histology of colons 4 weeks post anti-Thy1 treatment. Histological analysis of intestinal 
tissue revealed decreased inflammatory infiltrates, reduced tissue damage and intestinal tissue 
healing after 4 weeks of treatment in Mcl-1∆IEC mice at the age of 3 months. 
 
Interestingly, the anti-Thy1 treatment completely abolished the inflammatory phenotype in 
the small intestine as well as in the colon of Mcl-1∆IEC mice (Figure 85). Ex vivo cytokine 
analysis of anti-Thy1 treated mice showed a significantly reduced cytokine expression 
pattern in Mcl-1∆IEC and Mcl-1∆IEC/RAG1-/- mice. Especially the ILC-specific cytokines IL-17A, 
IL-17F and IL-22 were reduced to wild-type levels (Figure 86) and I could also detect a 
significant reduction of the cytokines IL-10, IL-1β and TNFα indicative of attenuated 
inflammation and tissue regeneration processes. In addition, histology confirmed the positive 
outcome of the anti-Thy1 treatment. Immunohistochemical stainings for CD3 confirmed the 
absence of T-cells and also B-cell infiltrates were eliminated (data not shown). Furthermore, 
morphological analysis showed mucosal healing and a restoration of the intestinal 
architecture (Figure 85). 
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Figure 86: Ex vivo cytokine analysis of anti-Thy1 treated mice. Four weeks treatment significantly 
reduced the amount of released cytokines from colon tissue of anti-Thy1 treated Mcl-1∆IEC mice and 
Mcl-1∆IEC/RAG1-/- mice compared to isotype control treated animals 
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5.3.6 Intestinal inflammation in Mcl-1∆IEC mice is promoted by the microbiota 
Next, I addressed why the inflammatory phenotype in Mcl-1∆IEC mice depends on ILCs and 
how inflammation is initiated in these mice. I hypothesized that the strong inflammatory 
reaction a) is due to a leaky intestinal barrier and that the inflammation is promoted by 
bacteria or their products and an elimination of the microbiota would reduce the inflammatory 
phenotype, and b) the inflammatory environment significantly accelerates tumor development 
and a depletion of inflammatory cells would also reduce tumorigenesis. First, I analyzed 
intestinal barrier dysfunction by performing a Limulus amebocyte lysate (LAL) assay and 
observed an increase of endotoxin levels in serum of in two-month-old Mcl-1∆IEC mice (Figure 
87A). Second, I orally administered FITC-labeled dextrane to two-month-old Mcl-1∆IEC and 
control mice and analyzed the amount of diffused dextran non-invasively 4h post 
administration in serum of mice. I detected significantly elevated levels of FITC-labeled 
dextrane in serum of Mcl-1∆IEC and therefore was able to confirm the leaky intestinal barrier 
(Figure 87B). 
 
A    B 
 
 
Figure 87: Intestinal barrier disruption in Mcl-1∆IEC mice. A) Analyzed endotoxin levels in sera were 
elevated by tendency and B) FITC-labeled dextran significantly elevated upon oral gavage of two-
month-old Mcl-1∆IEC mice (n=6) indicating a leaky intestinal barrier. 
 
Thus, Mcl-1∆IEC mice were embryo-transferred into the germ-free facility of Prof. Andrew 
Macpherson at the University of Berne to uncover the role of the microbiota in intestinal 
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inflammation and its contribution in tumorigenesis. Due to the time-consuming embryo-
transfer and difficulties in maintaining the mouse colony under germ-free conditions, we 
decided in addition to treat the Mcl-1∆IEC mice in our mouse facility with broad-spectrum 
antibiotics.  
 
 
Figure 88: Histology of Mcl-1∆IEC mice after four week under germ-free housing. Histological 
analysis of colonic tissue revealed reduced inflammation, intestinal tissue healing and restoration of 
intestinal tissue architecture in Mcl-1∆IEC mice. 
 
Germ-free housing as well as antibiotic treatment significantly improved and reduced 
inflammation and apoptosis in Mcl-1∆IEC mice at the age of 2 months (Figure 88). In addition, 
cytokine analyses showed a completely normal cytokine expression pattern (Figure 89). ILC-
specific cytokines as well as additional cytokines (e.g. IL-1β, TNFα, IL-6 and IL-10) were 
completely reverted to wild-type levels in supernatant of colonic and ileal tissue. These 
results clearly indicated that bacterial colonization and subsequent initiation of inflammatory 
processes - especially the activation of ILCs in the intestine - significantly contribute to the 
inflammatory phenotype of Mcl-1∆IEC mice.  
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 Figure 89: Cytokine analysis in serum of Mcl-1∆IEC mice.  Pro-inflammatory cytokines IL1β and 
TNFα as well as IL17A, IL17F and IL22 were significantly reduced in cell culture supernatant 48h post 
incubation of colonic tissue derived from Mcl-1∆IEC mice after four weeks under germ-free housing or 
antibiotic treatment, compared to mice under conventional housing. n= 4 - 8 mice were analyzed per 
group. 
To investigate the contribution of the bacterial colonization with respect to tumor 
 
112 
 
development in Mcl-1∆IEC mice, we collected organs from mice under germ-free housing and 
antibiotic-treatment at the age of 12 months. Due to the attenuated breeding of mice under 
germ-free conditions and the late starting-point of this experiment, these experiments are still 
under progress and organs of mice at the age of 12 months are periodically collected for 
future analysis. Until now, only two germ-free and six antibiotics-treated Mcl-1∆IEC mice could 
be collected at the late time-point and no macroscopic visible tumors or distinct carcinoma 
could be observed at morphological level. Due to the small number of mice and the 
phenotypically patchiness, this promising observation has to be considered carefully. 
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5.4 Discussion 
5.4.1 Mcl-1∆IEC mice recapitulate important aspects of human intestinal 
carcinogenesis 
The second project of my PhD thesis is focusing on the role of intestinal apoptosis and its 
impact on intestinal inflammation and carcinogenesis. By deleting the anti-apoptotic Mcl-1 in 
intestinal epithelial cells (Mcl-1∆IEC mice), I developed and characterized a novel mouse 
model for studying intestinal inflammation and carcinogenesis. 
So far, the gold standard for colorectal cancer research and the experimental basis for the 
Vogelstein adenoma-carcinoma-sequence are mice carrying an initially chemically-induced 
mutation in the APC gene [149, 150]. These mice develop multiple intestinal neoplasia 
(APCmin) in the small intestine and colon due to the genetic defect, but tumors do not 
spontaneously develop under inflammatory conditions as seen in IBD patients and 
recapitulated in Mcl-1∆IEC mice. APCmin mice actually resemble only a small spectrum of 
human colorectal cancer and are limited to human familial adenomatous polyposis (FAP) 
showing adenoma, nevertheless being still widely used. Until today, genetically modified 
versions of the APCmin mice are created and mice carrying different APC mutations e.g. 
APC1638N, APCΔ716 or conditional APCloxP are used for research [133, 151, 152]. 
In contrast to APCmin mice which develop phenotypically homogenous and non-invasive 
adenoma, tumors developing in Mcl-1∆IEC mice show invasive growth patterns and are 
genetically and histologically heterogeneous. Invasive carcinoma were randomly distributed 
in the small intestine and colon and were not limited to any specific site of the intestinal tract. 
Furthermore, as the germline-stable APC mutation was initially induced by chemical 
treatment of wild-type mice with ethylnitrosourea (Enu) to generate APCmin mice [150], 
mutations of oncogenes und tumor suppressor genes in carcinoma of Mcl-1∆IEC mice 
occurred spontaneously. However, I could not detect mutations in the APC gene in the 
analyzed exons of interest in tumor tissue of Mcl-1∆IEC mice by Sanger sequencing, but 
significantly decreased mRNA expression of Apc as well as β-catenin translocation are highly 
suggestive for APC dysfunction in tumors derived from Mcl-1∆IEC mice. Further mutational 
analyses of tumor tissue from Mcl-1∆IEC mice are needed for a better understanding of 
genetic changes during carcinogenesis. 
Although, one of the most important tumor suppressors FBXW7 in colorectal carcinogenesis 
is commonly mutated in human colorectal cancer, no mutations were detected in APCmin 
mice [153, 154]. Of note, carcinoma derived from Mcl-1∆IEC mice showed missense as well as 
silent point mutations for FBXW7 and therefore revealed the strong correlation between 
human colorectal carcinogenesis and carcinogenesis in the Mcl-1∆IEC mouse model on 
genetic level. 
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As mentioned before, adenoma in APCmin mice develop due to a specific genetic mutation 
and not on the background of chronic inflammation as known from IBD patients and as 
described in Mcl-1∆IEC mice. To study colorectal carcinogenesis under inflammatory 
conditions, the combined treatment with azoxymethane (AOM) and dextran sulfate sodium 
(DSS) is currently used as a common model of colitis-associated colorectal cancer in mice 
[155, 156]. The DSS/AOM approach is very prominent due to its high reproducibility, low 
costs, practicable handling and tumor development within 10 weeks, without intercrossing to 
a specific tumorigenic strain. In general, it is described as model for “inflammation-driven 
colorectal tumorigenesis” being somehow imprecise as the main driver of tumorigenesis is 
the genotoxic agent AOM and not DSS-induced inflammation. Therefore, the DSS/AOM 
approach is precisely a model for genotoxin-driven and inflammation-associated colorectal 
tumorigenesis. 
In contrast, tumors in Mcl-1∆IEC mice develop in the environment of constant intestinal tissue 
damage and regeneration without the artificial stimulus of genotoxic agents or DSS-mediated 
destruction of the full mucus layer. Adenoma are first detectable in 4 week or 8-week-old 
animals and carcinoma development in Mcl-1∆IEC mice are first detectable at eight months of 
age. Therefore, the Mcl-1∆IEC mouse model represents a more physiological model 
recapitulating the adenoma-carcinoma sequence, compared to the acute AOM/DSS-
dependent model.  
 
5.4.2 Inflammation-driven intestinal carcinogenesis  
IBD patients have an increased risk of colon cancer with cancer development and chronic 
inflammation often sharing the same molecular pathways [157]. However, the tumor-driving 
immune cells and cytokines are poorly understood. Grivennikov et al. recently published a 
milestone paper describing a key role of IL-23 in driving aberrant TH17 response and 
subsequent IL-17 and IL-22 cytokine production as main driver of tumor-elicited inflammation 
and tumor growth progression [133]. Furthermore, they describe that IL-23 is mainly 
produced by tumor-associated myeloid cells that are activated by penetrated microbial 
products into the tumor tissue due to intestinal barrier defects. Although it is hard to believe 
and unlikely that IL-23R deficiency or antibiotic treatment is able to rescue tumorigenesis in a 
mouse model for genetic mutation of the APC gene, their argumentation and data are 
conclusive and describe a novel microbiota dependent IL-23 and followed IL-17 cytokine 
expression as main tumor driving mechanism [133].  
Since we observed intestinal barrier disruption and deranged microbiotic colonization in Mcl-
1∆IEC mice early in the beginning of the project, we decided to house Mcl-1∆IEC mice under 
germ-free conditions. Indeed, in line with the Grivennikov paper, we also observed a 
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reduction of IL-23, IL-17 and especially IL-22 as main driver of epithelium proliferation in Mcl-
1∆IEC mice under germ-free housing or antibiotic treatment. In addition, we also observed a 
reduced tumor burden and mucosal healing reflecting advanced tissue regeneration, 
confirming the role the microbiota and the penetrance of microbial products into disrupted 
intestinal tissue as driver of tumor progression. Based on this observation, we aimed to 
identify not only the cytokines but rather the responsible immune cell type.  
Strikingly, the knock-out of conventional B and T-cells in the RAG1-/- intercrossing did not 
rescue the inflammatory phenotype in Mcl-1∆IEC mice and surprisingly but undoubtedly 
excluded TH17 immune cells as responsible cell type. Interestingly, the antibody-mediated 
depletion of an unconventional T-cell population called innate lymphoid cells (ILCs) rescued 
the inflammatory phenotype of Mcl-1∆IEC mice and also reduced the tumor burden, finally 
revealing an essential role of ILCs in the progression from colitis to intestinal cancer. 
At the same time a paper published in the lab of Prof. F. Powrie showed exactly the same 
causal relationship and the role of ILCs in promoting colon cancer in a different mouse 
model. They took advantage of an AOM mouse model and used Helicobacter hepaticus 
(Hh)-driven colitis in genetically susceptible 129SvEv.RAG-/- mice and induced tumorigenesis 
by AOM treatment. By antibody depleting experiments, they showed the strongest reduction 
in tumor development by depleting ILCs or inhibiting ILC-derived IL22, compared to less 
remarkable anti-IL17 or anti-IFNγ treatments [157]. 
The published data can be seen as confirmation of our own finding and furthermore 
approved the Mcl-1∆IEC mouse model as useful tool to study human colonic carcinogenesis, 
but also showed the disadvantage of time consuming breeding time of Mcl-1 mice compared 
to easy to handle and process of infectious models. On the other hand, the finding of 
identifying the responsible immune cell type driving colonic cancer and the meaning for the 
anti-inflammatory treatment of human patients was published in an acute and AOM-
dependent mouse model [157] and the exact role and function of ILCs in a chronic model are 
still poorly understood. 
Although the responsible immune cell type is now known, the question still remains elusive 
how ILCs are activated upon intestinal barrier disruption. A recent publication described a co-
stimulation by IL-23 and IL-1 essential for ILC activation and subsequent IL-17 secretion. Not 
only IL-23 but also IL-1 secretion is controlled by the Nod/Ripk2 pathway in activated 
dendritic cells and therefore controls colitis and colorectal carcinoma in this model [158]. In 
contrast, a second paper published at the same time described CX3CR1-positive 
mononuclear phagocytes in integrating microbial signals to regulate colonic ILC-mediated 
cytokine secretion and colitis in murine and human inflamed intestinal tissue. They explicitly 
show the importance of CX3CR1-positive mononuclear phagocytes compared to CD103-
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positive dendritic cells [159]. Both groups argue conclusively based on the data obtained 
from their mouse models. But exactly the difference in both models, spontaneous colitis in T-
bet-/-RAG2-/- mice [158] and C. rodentium infection of Cx3cr1DTR+ mice with a specific 
depletion of colonic lamina propria mononuclear cells [159] is most reasonable the 
explanation for slight differences in the phenotypically outcome and the different drawn 
scientific conclusion. Thus, more research has to be carried out to understand the cellular an 
molecular mechanism driving ILC activation and subsequent intestinal inflammation and 
carcinogenesis. 
 
5.4.3 Mcl-1 as key regulator of intestinal homeostasis and carcinogenesis 
First of all, Mcl-1 emerged as a key regulator of homeostasis and immunity in intestinal 
barrier tissue. Whereas many studies are focusing at the inhibition of Mcl-1 for potential 
tumor therapies especially in hematological malignancy such as acute myelogenous 
leukemia (AML) [160]. Here, I uncovered a novel function of Mcl-1 as tumor-suppressor for 
intestinal carcinogenesis.  
It is very well accepted that inhibition of cell death is essential for tumorigenesis and 
according to the Vogelstein adenoma-carcinoma sequence and the hallmarks of cancer, the 
loss of pro-apoptotic genes and overexpression of anti-apoptotic factors like Mcl-1 is very 
common during tumor progression [43, 161]. Abnormal expression of Mcl-1 as well as Bax 
and Bcl-xL has been described during colorectal cancer progression and overexpression of 
anti-apoptotic genes in colorectal cancer may suppress the activity of the pro-apoptotic 
molecules Bax and Bak, contributing to cancer progression [162, 163]. Especially the 
overexpression of Mcl-1 as the main apoptosis regulator at the outer mitochondrial 
membrane was shown to directly correlate with tumor grade, tumor stage and metastasis in 
human colorectal tumors [162, 164, 165].  
In contrast to the current knowledge described in the literature, I show a novel function of 
Mcl-1 in preventing tumorigenesis. Mcl-1 emerged as tumor-suppressor in the intestinal 
epithelium by suppressing epithelial cell death followed by a sequence of hyper-proliferation, 
malignant transformation and finally tumorigenesis without any further genotoxic stimulus.  
Actually, Mcl-1 as well as Bcl-xl are well known to be frequently amplified in a variety of 
human cancers. Multiple copies of the Mcl-1 gene are often present at genomic level in 
tumors and correlate with chromosomal amplification of the Mcl-1 gene locus and 
subsequent chemotherapeutic resistance [166-168]. Mcl-1 is one of nine genes in an 
amplification peak in cytoband 1q21.2 with amplifications observed in 10.9% of cancers 
across multiple tissue types [168].  
Thus, at the first glance it seems to be contradictory that the lack of Mcl-1 is promotes tumor 
 
117 
 
development. But by dissecting the phenotype of Mcl-1∆IEC mice in different parts, one could 
get an explanation for the tumor suppressing function and the new definition of Mcl-1 as 
environmental tumor suppressor in regenerating tissue. 
First, the Mcl-1 deletion leads to fulminant enterocyte apoptosis and therefore to a leaky 
intestinal barrier and followed by the influx of microbiotic components and pathogens. This 
means Mcl-1 is required for tissue homeostasis and tissue integrity.  
Second, leakiness is triggering a strong inflammatory response and a cytokine secretion. 
Thus, Mcl-1 also emerged as suppressor for intestinal inflammation by preventing intestinal 
barrier disruption. Significantly elevated cytokines found in Mcl-1∆IEC mice such as IL-22,IL-10 
and IL-6 are well known tumor-promoting cytokines by driving STAT3/NF-kB activation and 
aberrant epithelium hyper-proliferation [169, 170]. Hence, not Mcl-1 itself or a related 
intracellular function but rather the loss of enterocytes and the disruption of the mucosal 
integrity are associated with the pathogenesis.  
Third, the vicious circle of constant enterocyte apoptosis and regeneration promotes 
spontaneous genetic mutations, the accumulation of genetic defects and the malignant 
transformation [171]. Whereas hyper-proliferation was clearly observable in apoptotic 
intestinal tissue, genetic defect, exactly chromosomal aberrations and oncogene/tumor 
suppressor gene mutation were only detected in carcinoma and not in regenerative tissue. 
But due to technical limitations, for conventional Sanger sequencing as well as array-based 
comparative genomic hybridization (aCGH) this has to be analyzed in more detail on single 
cell level to gain better understanding.  
Aberrant apoptosis signaling represents a main mechanism through which cancer cells are 
enabled acquire apoptosis resistance to survive therapy, i.e. chemotherapy or irradiation- 
induced cell death. In more detail, Bcl-xL expression levels were significantly higher in 
cancer tissue than in surrounding non-malignant tissue on protein and RNA level. Whereas 
Mcl-1 mRNA expression was significantly lower in malignant tissues, the protein expression 
was significantly increased as analyzed by immunohistochemistry and immunoblotting of cell 
lines derived from primary tumor tissue [165]. In line with these findings, it was 
experimentally shown that the knock-down of Bcl-xl or Mcl-1 in cell lines of colorectal origin 
leads to increased sensitivity towards chemotherapeutically induced cell death as well as 
increased sensitivity towards death receptor induced cell death by agonistic CD95 antibody 
treatment [165]. 
The above mentioned studies clearly implicate the anti-apoptotic activity of Bcl-2 family 
members, such as Bcl-xL and Mcl-1 are important components of the treatment resistance of 
colorectal cancer cells and efforts are in progress to find specific inhibitors against Bcl2 
family members for anti-tumor therapy. Especially Mcl-1 and Bcl-xl are promising targets for 
future cancer therapies to treat chemotherapy resistant patients. Great efforts are in progress 
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to find small molecules and inhibitors to target Mcl-1 for cancer therapy. The first promising 
inhibitor on the market was developed by the Abbott Laboratories, ABT-737 is a small 
molecule Bcl-2 homology (BH)-3 domain mimetic that acts as a specific inhibitor of Bcl2,Bcl-
xl and Bcl-w [172]. ABT-737 treatments were successful to some extent to treat lymphoma 
and other blood cancer but ABT-737 failed in general because it did not inhibit the 
compensatory upregaulted Mcl-1. 
As described in the first part of this discussion, Mcl-1 is an essential protein for tissue 
homeostasis, especially in regenerative tissues like liver and intestine. The systemic 
depletion of Mcl-1 would have dramatic short term or long-term outcome and based on the 
published literature [173, 174] and my own experimental findings I would expect cardiac 
toxicity, liver damage and intestinal tissue disruption. 
In summary, I demonstrated Mcl-1 is a key regulator in the intestinal epithelium for 
homeostasis and preventing intestinal inflammation and tumor development and can be 
reported as environmental tumor suppressor in regenerating organs. 
 
5.4.4 Intestinal epithelial apoptosis and necroptosis drive colonopathy and 
tumorigenesis in mouse models  
Recently, proteins regulating intestinal cell death, apoptosis as well as necroptosis came into 
the focus of IBD research. First, a critical role was shown for Caspase 8 in regulating 
necroptosis of IECs. Mice with a conditional deletion of Caspase 8 in the intestinal epithelium 
developed a phenotype reminiscent of human Crohn’s disease showing terminal ileitis 
[129].It was shown that Caspase 8 deficient enterocytes spontaneously undergo TNFα-
dependent and RIPK3-mediated necroptosis. Due to the strong apoptotic and inflammatory 
phenotype and premature death of Casp8∆IEC mice, the long-term outcome of constant 
intestinal necroptosis related to tumor development is not shown in this mouse model. In 
addition, evidence for increased necroptosis in the terminal ileum of patients with Crohn’s 
disease was shown, suggesting a potential role of necroptosis in the pathogenesis of IBD 
[129]. This study described that necroptosis in the intestinal epithelium is crucial for intestinal 
tissue homeostasis and intestinal inflammation following epithelial cell death [129]. 
Interestingly, the same group published a second paper about the deletion Caspase 8 
inhibitor cFLIP in the intestinal epithelium. The knock-out of cFLIP leads to embryonic 
lethality and when cFLIP was deleted from the intestinal epithelium of adult mice using 
tamoxifen-inducible knock-out mice, the animals died within a few days from severe tissue 
destruction, epithelial cell death, and intestinal inflammation [175]. As expected, the knock-
out of the negative regulator of Caspase 8 leads to a strong Caspase 8 activation upon 
tamoxifen induction and a Caspase 8 dependent but RIPK3-independent cell death. 
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Conclusively, the anti-apoptotic cFLIP is required for intestinal tissue homeostasis by 
controlling Caspase 8 to promote survival of intestinal epithelial cells and prevent 
inflammation. Furthermore, it was show that under steady-state conditions, intestinal 
epithelial cells depend on constitutive signaling via Caspase 8 and activation of Caspase 8 is 
essential for epithelial homeostasis in the steady-state. But the degree of activation is tightly 
controlled by cFLIP to mediate survival of epithelial cells and intestinal immune homeostasis 
[175]. 
In line with this finding, mice with an IEC-specific knock-out of FADD developed intestinal 
epithelial cell necroptosis and IBD-like and MyD88- and microbiota dependent inflammation. 
The additional genetic knock-out of RIPK3 also prevented the development of intestinal 
inflammation in these mice, revealing the importance of RIPK3 mediated necroptosis in 
intestinal tissue homeostasis [130]. 
Most interestingly, two independent  studies by Dannappel et al. and Takahashi et al. 
recently showed the effects of constant apoptotic epithelial cell death on intestinal tissue 
homeostasis, inflammation and tumorgenesis [176, 177]. Here, they show that RIPK1 
suppresses epithelial cell apoptosis and necroptosis by preventing FADD/caspase-8-
mediated apoptosis and RIPK3-dependent necroptosis. These findings, together with 
additional experimental data about antibiotic treatment and ex vivo organoids, suggest that 
RIPK1 is a master regulator of epithelial cell survival, homeostasis and inflammation in the 
intestine. Moreover, by using knock-in mice expressing the kinase-inactive RIPK1 they show 
that as well as promoting cell death, RIPK1 has a paradoxical function in supporting the 
survival of mouse epithelial cells that is independent of its kinase function [176-178].  
Taken together what we learn from different mouse models for intestinal pathologies:. 
Caspase 8-independent and RIPK3 dependent necroptotic cell death as well as Caspase 8 
dependent and RIPK3-independent apoptotic epithelial cell death drive massive intestinal 
tissue disruption leading to intestinal barrier loss, inflammation and premature death of 
knock-out mice. Not only necroptosis of enterocytes as described before is able to drive 
intestinal colonopathies, also constant apoptotic cell death of enterocytes is able to disturb 
intestinal homeostasis and drive IBD-like and microbiota-dependent inflammation and tumor 
lesions as already seen in the Mcl-1∆IEC. 
The Mcl-1∆IEC model represents an additional model to investigate the consequences of 
apoptotic epithelial cell death. In this project, we did not focus on the mechanisms of cell 
death. Although we observed Caspase 8 positive apoptotic enterocytes and also the 
histological analysis revealed no signs of necroptosis, we have no experimental evidence for 
the role of RIPK3 and RIPK1-dependent necroptotic cell death. The analysis of necroptosis 
in this mouse model remains elusive to better understand the molecular mechanisms driving 
the inflammatory and tumor phenotype. 
 
120 
 
5.4.5 Position-effect variegation and environmental factors lead to phenotypical 
patchyness 
Interestingly, the organ site of interest showing the phenotype in the intestinal tract differs a 
lot between the different mouse models. Taken together, all groups used the same VillinCre 
deleter line, initially published in 2002 by Madison et al and they use lacZ and β-Gal reporter 
genes to show the expression of the VillinCre transgene in the entire intestinal epithelium of 
mice [139]. The same VillinCre delete line was used to establish the Mcl-1∆IEC in 2010. 
Thus, the question remains elusive why different sites of the whole intestinal tract are 
affected to such a variable degree in the various knock-out mouse models? 
Mice with a conditional deletion of Caspase 8 in the intestinal epithelium spontaneously 
develop inflammatory lesions in the terminal ileum and mice with a specific knockout of 
FADD spontaneously develop the inflammatory phenotype mostly in the colon [129, 130]. 
Mcl-1 ∆IEC showed knock-out lesions and tumor development equally distributed throughout 
the whole intestine and no difference in phenotype between small intestine and colon. In our 
model, we have performed a detailed genetic analysis of the recombination event and 
uncovered a patchy phenotype which strongly correlated with the phenotypical outcome of 
mice. By using scrapings from intestinal FFPE section or laser micro-dissected lesion, we 
uncovered observed an incomplete recombination event for the floxed genomic Mcl-1 locus 
in unaffected regions. In line, mice with a deletion of Mcl-1 nearly through the whole intestinal 
tract did not survived whereas mice with only very few knock-out lesions, roughly less than 
5% of the intestinal tract, did not show any pathological phenotype and showed a body 
weight and survival similar to wild-type mice.  
Therefore we can speculate about the same patchy phenotype due to incomplete genetic 
recombination in other published models, but there are no published data officially available, 
only informal statements at conferences confirmed the patchyness at least in the Casp8∆IEC 
model. 
Epigenetic silencing or spontaneous point mutations in the Cre transgene might limit the Cre 
expression and these modifications could be outbred during the last years in the different 
mouse cohorts. But one has not only to think about the VillinCre deleter line as source of 
patchy genetic phenotype. Also the exact genomic locus of the floxed gene of interest and 
the accessibility of the chromosomal region e.g. in heterochromatin or flanking regulatory 
sequences has to be taken into account. It is also known that genes in the tightly packed 
heterochromatin are poorly expressed and can lead to position-effect variegation [179] and 
are described knock-out mice generated with the Cre/loxP recombination system [180, 181]. 
Cre transgenic mouse strains are mostly generated by random integration of a DNA 
construct containing the cell or tissue specific promoter and the Cre cDNA into the host DNA. 
The random integration may lead to unspecified genetic interactions, e.g. transactivations at 
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the site of integration which lead to unspecific Cre expression in other cell types [180, 181]. 
Indeed, the Cre expression for the VillinCre deleter line was observed in the kidney by using 
the lacZ reporter mouse line [139]. Most likely, the random integration site of the VillinCre 
construct lead to position-effect variegation and to mosaic expression of the Cre-transgene. 
Interestingly, the integration site of the VillinCre transgene has never been analyzed or the 
mosaic expression published. 
In the Mcl-1∆IEC mouse model, mice which had to be sacrificed due to body weight loss and 
symptoms of diarrhea, showed affected areas with signs of apoptosis and tissue damage 
almost throughout the whole intestinal tract in contrast to almost unaffected mice which 
reached the age of 12 months and older. Altogether, the patchy phenotype had clear benefits 
because mice with a 100% knock-out of Mcl-1 most probably would not have survived and 
the phenotype would be most probably embryonic lethal. In addition, intestinal pathology with 
affected and unaffected areas is more similar to the pathology of humans. The genetic 
patchyness provided an experimental window to let the tumorigenic phenotype develop 
stepwise and finally recapitulate the whole spectrum of the adenoma-carcinoma sequence.  
Furthermore, due to the rescue of Mcl-1 ∆IEC under germ-free conditions or antibiotic 
treatment we can show in two independent experiments that the inflammatory reaction and 
ILC-driven enteritis in Mcl-1 ∆IEC depend on the microbiotic colonization and not exclusively on 
mouse genetics. Additionally, two different groups describing the same apoptotic and 
inflammatory phenotype of Ripk1∆IEC in the ileum and the colon show a different survival rate 
of mice and different success upon microbiota depletion experiments [176, 177]. But these 
phenotypical differences are most probably caused by the housing of mice in different mouse 
facilities and due to different colonization of the intestine. Therefore environmental factors 
substantially influence the phenotype of genetically-modified mice.  
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6 Material and Methods 
Human material: Formalin-fixed, paraffin-embedded normal or tumor tissue was retrieved 
from the archives of the Institute of Surgical Pathology, University Hospital Zürich. Snap-
frozen liver needle biopsies from the biobank were used to extract RNA and proteins for 
molecular analyses. A tissue microarray (TMA) with duplicates of 95 HCC and 58 non-
neoplastic liver samples was used for immunohistochemical analysis as described [17]. 
Follow-up data for all patients were available. The study was approved by the local ethics 
committee (“Kantonale Ethikkommission Zürich”, application number StV26/2005 and KEK-
ZH-Nr. 2013-0382).) as described. 
 
Human cohort studies: For evaluation of liver function tests as potential predictors of HCC 
development, HCV-positive patients with confirmed diagnosis of HCC and HCV positive 
patients with liver disease but without HCC were selected from the patient database as 
matched pairs according to MELD score for the given time point before the HCC diagnosis. 
The MELD score was chosen as the current international standard for assessment of 
severity of liver disease e.g. in liver transplant organ allocation and is based on laboratory 
values bilirubin, creatinine and INR. HCV-positive patients who underwent liver 
transplantation (Swiss Hepato-Pancreato-Biliary Center, UniversityHospital Zürich) due to 
liver tumors were chosen for the transplantation study and compared to HCV-positive which 
underwent liver transplantation but without liver tumors development. 
 
Mice: Animals were maintained under specific pathogen-free conditions and experiments 
were approved in accordance to the guidelines of the Swiss Animal Protection Law, 
Veterinary Office, Canton Zürich. Generation of hepatocyte specific Mcl-1 knock-out 
(homozygous: AlbCretg/+/Mcl-1flox/flox (Mcl-1∆hep), heterozygous AlbCretg/+/Mcl-1flox/wt) was 
described previously [55].  TNFR1-/- and TNFR1/2-/- mice were purchased from Jackson 
Laboratories and TNFR1-/- mice intercrossed to Mcl-1∆he mice and bred in house. Xiap−/−  and 
cFlip mice were kindly provided [182, 183]. Tak1∆hep, Casp8 ∆hep, Tak1/Casp8 ∆hep and 
Tak1∆hep/RIP3-/- were described previously [49]. Ikkβ∆hep mice [184], Ltβr∆hep mice and 
JNK1/2∆hep mice [generated by crossing of JNK1/2loxP/loxP [185] or LtβrloxP/loxP [186] with Alb-
Cre mice [187]] were bred in house. Ripk1-/-/Ripk3−/−/Casp8−/−, Ripk3−/−Casp8−/− and Ripk3−/− 
were kindly provided and have been described recently [188]. 
 
Animal experiments: Injections of Doxorubicin (Sigma) or vehicle (DMSO) were performed 
as previously described [189]. Shortly, intraperitoneally (15 mg/kg) on gender and age 
matched mice at 6-8 weeks of age. Mice were sacrificed 12 hr or 48h post injection and 
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littermates carrying the respective loxP-flanked alleles but lacking the Cre recombinase 
served as wild-type controls. The pan-Caspase inhibitor QVD-OPh (20mg/kg, Sigma) or the 
RIPK1 inhibitor Necrostatin1 (6 mg/kg, Sigma) were administered intraperitoneally 1h before 
doxorubicin injection and repeated after 24h. Induction of hepatocyte cell death was 
performed as described elsewhere [190]. Shortly, mice were injected i.p. with the liver-
specific transcriptional inhibitor d-(+)-galactosamine (800 mg/kg, Sigma), followed by i.v. 
injection with lipopolysaccharide (5mg/kg, Sigma). Eventually, mice were pre-treated 30min 
prior LPS/DGal injections with QVD-OPH or Nec1. For irradiation experiments, mice were 
irradiated with 100Rad (1Gy) and sacrificed 30min post irradiation. Two-third partial 
hepatectomy was performed with mice of 6 to 8 weeks previously described [191]. After 
surgery, mice were injected subcutaneously with buprenorphine (Temgesic; 0.1 µg/g body 
weight; Essex Chemie AG, Luzern, Switzerland) for analgesia. At different time points after 
surgery, mice were sacrificed and remaining liver tissue was harvested. Livers removed 
during surgery served as controls. All mice were sacrificed by CO2 inhalation. All animal 
experiments were approved by the Swiss Veterinary Office (134/2014, 217/2012, 63/2011 
Zürich, Switzerland) and performed according to federal and institutional guidelines. 
 
Germ free housing and antibiotic treatment: Mcl-1∆IEC mice were embryo transferred into 
the germ-free facility of Prof. Andrew Macpherson (University of Berne) and mice kept and 
bred under axenic conditions.  
Mcl-1∆IEC mice at the age of four weeks were given drinking water supplemented with 
antibiotics to deplete the complete microbiota under SPF housing. The mixture of antibiotics 
was described previously [133] and drinking water and cage bedding was changed three 
times per week. 
 
Table 2 Composition of antibiotics for supplemented drinking water 
Antibiotic dose efficiency 
Ciprofloxacin 200 mg/l   bactericide (gram-negative) 
Ampicillin 1 g/l bactericide (gram-positive) 
Metronidazole 1 g/l anaerobic bacteria 
Vancomycin 500 mg/l cocci 
 
Ex vivo colon culture: Murine intestinal tissue from Mcl-1∆IEC and control mice was 
incubated ex vivo in modified cell culture medium to collect and analyze secreted cytokines 
in cell culture supernatant [143]. Briefly, animals were sacrificed, small intestine and colon 
were excised, feces flushed out with ice-cold PBS. After that, payers patches removed, 
tissue was cut into 1 cm pieces, opened longitudinally and washed three times with PBS and 
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once with specific culture medium. At least one piece of tissue was incubated at 37°C and 
5% CO2 in freshly prepared 0.5 ml culture medium in a 24-well plate. After 48 hrs, medium 
was collected, centrifuged for 5 min at 1000g and the supernatant was directly used for 
ELISA. 
 
Table 3 Medium conditions for ex vivo culture of intestinal murine tissue 
 For 10 ml: Final concentration 
Click’s Medium   
FBS  1 ml 10% 
NEAA (100x) 100 µl 1x 
Gentamicin/Amphotericin (500x) 100 µl 5x 
Antibiotic/Antimicotic (100x) 200 µl 2x 
L-Glutamin (100x) 100 µl 1x 
NaHCO3 (0.5 M) 500 µl 25 mM 
Na Pyruvate (1 mM) 100 µl 0.01 mM 
 
Flow cytometry for intrahepatic immune cells: Livers were minced, digested in 0.05% 
Collagenase IV and hepatic lymphocytes were purified using a Ficoll gradient. Antibody 
staining was done in presence of Fc receptor blockade (monoclonal antibody to mouse 
CD16-CD32 (eBioscience) in flow cytometry buffer. A FACSCanto II or Fortessa (BD 
Biosciences) and FlowJo sofware (TreeStar) were used for acquisition and data analysis. 
LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen) was used for exclusion of dead cells. 
The following antibodies were used: CD45, CD3, B220, Ly6C (eBioscience) and CD11b, 
Ly6G (BD Bioscience). 
 
Flow cytometry for DNA damage:  Flow cytometry for the analysis of DNA damage in 
hepatocytes was performed as described previously (Forment JV Cytometry A. 2012). First, 
primary murine hepatocytes were isolated by the two-step collagenase perfusion method, 
purified by Percoll gradient and finally collected in RPMI 1640 medium for flow cytometry 
procedures. Next, hepatcytes were fixed and permeabilized, followed by incubation with 
antibodies against γH2AX (#9718; Cell Signaling Technology) and RPA (NA19L, 
Calbiochem) and suitable secondary antibodies. DNA was stained with 1 µg/ml DAPI. 
Samples were measured on a Cyan ADP flow cytometer (Beckman Coulter) and analyzed 
with Summit software v4.3 (Beckman Coulter). 
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Measurement of serum parameters: The analysis for aminotransferases (AST/ALT) and 
bilirubin was performed with mouse serum on a Roche Modular System (Roche Diagnostics) 
with a commercially available automated colorimetric system at the Institute of Clinical 
Chemistry at the University Hospital Zürich using a Hitachi P-Modul (Roche).  
 
RNA isolation: Total RNA from snap-frozen human liver biopsies or mouse livers was 
isolated using RNeasy Mini Kit (Qiagen) according to the manufactures protocol. The 
quantity and quality of the RNA was determined spectroscopically using a Nanodrop 
(Thermo Scientific).  
 
Real-time PCR: Total RNA (1 μg) was reversely transcribed into cDNA using Quantitect 
Reverse Transcription Kit (Qiagen) according to the manufacturer’s protocol. For mRNA 
expression analysis real-time PCR was performed (reactions in duplicates) using Fast Start 
SYBR Green Master Rox (Roche). Primers were custom made by Microsynth. Real-time 
PCR was performed on an ABI PRISM 7900 HT and VIIA7 Fast Real-Time PCR System 
(AB). Data were generated and analyzed using SDS 2.4 and RQ manager 1.2 software. For 
human samples, mRNA expression levels were normalized to the housekeeping gene HPRT 
and for murine samples to the housekeeping gene GAPDH. Expression profiling of murine 
liver tumors for a 16 gene array to cluster the tumors according to the proliferation or 
differentiation status was performed as described [59]. Primer sequences for oncogene and 
tumor-suppressor gene expression analysis were described before [46]. 
 
DNA extraction: DNA was isolated from unstained 2 µm sections of murine or human FFPE 
slides by scrapings or punching from paraffin blocks and tissue digested with Proteinase K 
overnight. After Proteinase K inactivation for 10min at 95°C the DNA concentration was 
determined spectroscopically using a Nanodrop (Thermo Scientific) and genomic DNA was 
directly used for PCR reactions in duplicates 
 
Taqman copy number analysis: Taqman copy number analysis was carried out as 
multiplex PCR in duplicates with 20 ng DNA per reaction and Ttert as internal reference 
according to the manufacturer’s protocol. Wwox, Spata22, Fhit were selected as described 
markers from common fragile sites in humans and Fgfr1 and Fgr were selected as genes of 
interest in previously published areas of genetic instability in Tak1∆hep mice [46]. Data 
analysis was performed using Copy Caller Software (Life Technologies).  
 
Fragment length analysis for allelic imbalance: For analysis of allelic imbalance the 
markers D3S1263 and D3S1289 at described common fragile sites were selected [53]. Four 
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distinct regions (non-inflamed) of interest per liver needle biopsy were identified by 
pathologists and gDNA isolated from 2 µm unstained consecutive sections. PCR products 
were separated by capillary electrophoresis using the ABI 3130XL Genetic Analyzer (Applied 
Biosystems) and results are analyzed with the help of GeneMapper software (Applied 
Biosystems). Allelic imbalance was identified by calculating the fluorescence ratios of 
heterozygous (informative) markers for each biopsy. The following primers were used: 
D3S1263-Fwd CTG TTG ACC CAT TGA TAC CC (FAM labeled), D3S1263-Rev TAA AAT 
CAC AGC AGG GGT TC, D3S1289-Fwd AAA GCA ACT TGT AAG AGA GCA (HEX 
labeled), D3S1289-Rev CTC CTA GAT ATA ATC ACT GGC A. 
 
Pulse field electrophoresis: Pulse field gel electrophoresis was performed as published 
previously [192, 193]. Briefly, snap-frozen liver tissue was directly put into 4% formaldehyde 
without thawing and incubated for 10min at 37°C. Tissue was mechanically dissociated 
(gentleMACS Dissociator, Miltenyi Biotec), filtered through a 70 um cell strainer (Falcon) and 
2.5 × 105 cell were embedded in a 0.8% agarose plus, digested in lysis buffer (100 mM 
EDTA, 1% [wt/vol] sodium lauryl sarcosyne, 0.2% [wt/vol] sodium deoxycholate, and 1 mg/ml 
proteinase K) at 37°C for 48 h, and washed in 10 mM Tris-HCl, pH 8.0, and 100 mM EDTA. 
Electrophoresis was performed at 14°C in 0.9% (wt/vol) Pulsed Field Certified Agarose (Bio-
Rad Laboratories) containing Tris-borate/EDTA buffer in a CHEF DR III apparatus (9 h, 120°, 
5.5 V/cm, 30–18 s switch time; 6 h, 117°, 4.5 V/cm, 18–9 s switch time; 6 h, 112°, 4 V/cm, 9–
5 s switch time; Bio-Rad Laboratories). The gel was stained with ethidium bromide and 
imaged on an Alpha Innotech Imager.  
 
Immunoblot analysis: Snap-frozen Liver tissue was dissociated (gentleMACS Dissociator, 
Miltenyi Biotec) and homogenates (10%) were prepared in RIPA buffer (50 mM Tris; 1% 
NP40; 0.25% Deoxycholic acid sodium salt; 150 mM NaCl; 1 mM EGTA) containing Halt 
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Quantification with a BCA 
protein assay kit (Thermo Scientific) according to the manufacturer’s manual was followed by 
denaturation of 80µg protein in Laemmli buffer containing 5% β-mercaptoethanol and 
separated by gel electrophoresis (Mini Protean Gels, Bio Rad) and blotted by semi-dry 
blotting (Trans-Blot Turbo Transfer, Bio Rad) onto nitrocellulose membranes (Bio Rad) and 
tained with Ponceau Red. Membranes were blocked in 5% milk/PBST for at least 1hr at RT. 
Primary antibodies against γH2AX, p-p53, GAPDH, PCNA, p-ATM, p-CHK1, p-CHK2, p-ATR, 
pBRCA, claved-Casp3, cleaved-Casp8, RIPK1 (all Cell Signaling) and total-Casp8 
(SantaCruz) were incubated at 4°C overnight under shaking conditions. Incubation with the 
secondary antibody (HRP-anti rabbit IgG, 1:5000; Promega) was performed under shaking 
conditions for 1 hr. Detection was achieved with Clarity Western ECL Substrate (Bio Rad) 
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using Stella 3200 imaging system (Raytech).  
 
Histology and immunohistochemistry: Histology and immune stainings were performed 
as described before [194] with antibodies against the following proteins: glutamine 
synthetase (GS), 1:800 dilution (abcam); b-Catenin, 1:25 dilution (6B3, Cell Signaling 
Technology); A6, 1:20 dilution, kindly provided by Valentina Factor. Ki67, 1:200 dilution (SP6, 
NeoMarkers / Lab Vision Corporation), γH2AX, 1:300 dilution (Novus Biologicals). Human 
tissues: Bcl2A1, 1:500 dilution (EP517Y, abcam); Tpx2, 1:500 dilution (18D5-1, abcam); 
Tinag, 1:250 dilution (ptglab); Plk1, 1:100 dilution (F-8, Santa Cruz); p-cJUN, 1:100 (Abcam); 
cleaved-Caspase 8, 1:500; p-CHK1, 1:50 and p-CHK2, 1:500 (Novus Biologicals) and p-JNK 
,1:500 dilution (Abcam). For virtual microscopy and archiving, histological and 
immunohistochemical images were digitalized using a Nano Zoomer C9600 Virtual Slide 
Light microscope scanner by Hamamatsu using NDP, View Software, version 1.2.36. TMA 
immuno scoring was performed on TMA spots. For statistical analysis of TMA staining, 
Fisher`s exact test was applied using SPSS software (IBM SPSS, Version 21). 
 
Bead-based multiplex elisa: The Bio-Plex® Multiplex System (BIO-RAD) was used to 
detect and quantify multiple cytokines and chemokines in serum of mice and cell culture 
supernatant according to the manufacturer’s protocol. 
 
RNA Microarray: An Agilent one-color microarray-based gene expression analysis (Mouse 
DNA Microarray 4x 44K) was performed according to the manufacturer’s protocol. 2- and 12-
month-old mice were analyzed. For 12 months, HCC and corresponding non-tumor tissue 
(n=3) from the same animal (n=5) as well as livers from Cre-negative littermates as controls 
(n=3) were analyzed. For 2 months, Mcl-1∆hep (AlbCre-Mcl-1flox/flox), hemizygous Albcre-Mcl-
1flox/wt and Cre-negative controls were analyzed. Gene expression was quantified using 
Agilent Feature Extraction Software Version 9.5.3.1. Gene Ontology microarray data 
analysis: Lists of significantly differentially expressed genes were investigated in respect to 
enrichment of Gene Ontology categories using the Gene Ontology Browser as implemented 
in GeneSpring 7.3. A Fisher’s exact test was used to show whether more genes belonging to 
a Gene Ontology category are found in the list under investigation than in a randomized gene 
list of the same size. 
 
GSEA: Gene sets from the biological process gene ontology for GSEA analysis were 
downloaded from the Molecular Signatures Database (http://www.broadinstitute.org) or 
integrated manually into the GSEA for human HCV-induced hepatitis gene expression sets 
[195] or alcohol-induced hepatitis [196]. GSEA tests whether genes sets were 
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overrepresented in microarray expression data were performed with standard settings as 
described before [197]. 
 
Cell lines and in vitro experiments: U2OS were grown in DMEM containing 10% FBS and 
1% penicillin/streptomycin. Cells were transfected with lentiviral particles for Caspase 8 
(Santa Cruz, sc-29930-V) or control particles (Santa Cruz, sc-108080) according to the 
manufacturer's protocol and cells stably expressing the shRNA were isolated by puromycin 
selection (Santa Cruz). Cells were treated as indicated with Doxorubicin (Sigma) and for 
inhibition experiments, cells were pretreated for 4h with 10 µM of the ATM inhibitor Ku-55933 
(Selleckchem) or pretreated with the JNK inhibitor (SP600125, Abcam) at 25 µM and 
Doxorubicin added and cells incubated for indicated time.  
 
Statistical analysis: Statistical analysis was performed using GraphPad Prism software 
(version 5.0) or SPSS. All data are presented as mean ± SEM and were analyzed by ANOVA 
with Bonferroni correction. Analysis of two samples was performed with Student t test, 
statistics for HCC incidence were calculated using Fisher’s Exact test. Statistical significance 
is indicated as follows: ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; n.s. not significant. 
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